0000912061-19-000082.txt : 20191105 0000912061-19-000082.hdr.sgml : 20191105 20191105170202 ACCESSION NUMBER: 0000912061-19-000082 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 61 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191105 DATE AS OF CHANGE: 20191105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NATURAL HEALTH TRENDS CORP CENTRAL INDEX KEY: 0000912061 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MISCELLANEOUS NONDURABLE GOODS [5190] IRS NUMBER: 592705336 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36849 FILM NUMBER: 191194141 BUSINESS ADDRESS: STREET 1: UNITS 1205-07, 12F, MIRA PLACE TOWER A STREET 2: 132 NATHAN ROAD, TSIMSHATSUI, KOWLOON CITY: HONG KONG STATE: K3 ZIP: 00000 BUSINESS PHONE: 852-3107-0800 MAIL ADDRESS: STREET 1: UNITS 1205-07, 12F, MIRA PLACE TOWER A STREET 2: 132 NATHAN ROAD, TSIMSHATSUI, KOWLOON CITY: HONG KONG STATE: K3 ZIP: 00000 10-Q 1 nhtc20190930_10q.htm 10-Q Document
false--12-31Q3201900009120610.020.131.900.400.240.0010.0015000000050000000129794141297941445000000.0010.00150000005000000000016033221459090 0000912061 2019-01-01 2019-09-30 0000912061 2019-11-01 0000912061 2019-09-30 0000912061 2018-12-31 0000912061 2018-07-01 2018-09-30 0000912061 2019-07-01 2019-09-30 0000912061 2018-01-01 2018-09-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000912061 us-gaap:CommonStockMember 2018-09-30 0000912061 us-gaap:PreferredStockMember 2018-03-31 0000912061 us-gaap:TreasuryStockMember 2017-12-31 0000912061 us-gaap:CommonStockMember 2018-06-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0000912061 us-gaap:TreasuryStockMember 2018-09-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0000912061 us-gaap:TreasuryStockMember 2018-06-30 0000912061 2018-04-01 2018-06-30 0000912061 us-gaap:PreferredStockMember 2018-06-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000912061 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000912061 us-gaap:RetainedEarningsMember 2018-03-31 0000912061 2018-01-01 2018-03-31 0000912061 us-gaap:PreferredStockMember 2017-12-31 0000912061 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0000912061 us-gaap:RetainedEarningsMember 2018-09-30 0000912061 2017-12-31 0000912061 us-gaap:TreasuryStockMember 2018-03-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0000912061 us-gaap:RetainedEarningsMember 2017-12-31 0000912061 us-gaap:CommonStockMember 2017-12-31 0000912061 2018-09-30 0000912061 us-gaap:PreferredStockMember 2018-09-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000912061 us-gaap:TreasuryStockMember 2018-01-01 2018-03-31 0000912061 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000912061 2018-03-31 0000912061 2018-06-30 0000912061 us-gaap:RetainedEarningsMember 2018-06-30 0000912061 us-gaap:CommonStockMember 2018-03-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000912061 us-gaap:CommonStockMember 2018-12-31 0000912061 us-gaap:RetainedEarningsMember 2019-06-30 0000912061 us-gaap:PreferredStockMember 2019-09-30 0000912061 us-gaap:RetainedEarningsMember 2019-03-31 0000912061 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0000912061 2019-04-01 2019-06-30 0000912061 us-gaap:CommonStockMember 2019-09-30 0000912061 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000912061 us-gaap:CommonStockMember 2019-06-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000912061 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000912061 2019-01-01 2019-03-31 0000912061 us-gaap:PreferredStockMember 2019-06-30 0000912061 us-gaap:TreasuryStockMember 2019-09-30 0000912061 us-gaap:CommonStockMember 2019-03-31 0000912061 us-gaap:PreferredStockMember 2018-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000912061 2019-03-31 0000912061 2019-06-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000912061 us-gaap:TreasuryStockMember 2019-03-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000912061 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000912061 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000912061 us-gaap:TreasuryStockMember 2019-06-30 0000912061 us-gaap:RetainedEarningsMember 2019-09-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000912061 us-gaap:RetainedEarningsMember 2018-12-31 0000912061 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000912061 us-gaap:TreasuryStockMember 2018-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000912061 us-gaap:PreferredStockMember 2019-03-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000912061 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000912061 us-gaap:ShippingAndHandlingMember 2019-07-01 2019-09-30 0000912061 us-gaap:ProductMember 2018-01-01 2018-09-30 0000912061 us-gaap:ProductMember 2018-07-01 2018-09-30 0000912061 us-gaap:ProductMember 2019-01-01 2019-09-30 0000912061 us-gaap:ShippingAndHandlingMember 2018-07-01 2018-09-30 0000912061 us-gaap:ShippingAndHandlingMember 2019-01-01 2019-09-30 0000912061 us-gaap:ProductMember 2019-07-01 2019-09-30 0000912061 us-gaap:ShippingAndHandlingMember 2018-01-01 2018-09-30 0000912061 srt:MaximumMember 2019-01-01 2019-09-30 0000912061 srt:MinimumMember 2019-01-01 2019-09-30 0000912061 country:JP 2019-01-01 2019-09-30 0000912061 srt:AmericasMember 2019-07-01 2019-09-30 0000912061 nhtc:RussiaandKazakhstanDomain 2019-07-01 2019-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 country:SG 2018-01-01 2018-09-30 0000912061 country:SG us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 country:KR 2018-01-01 2018-09-30 0000912061 country:HK 2019-07-01 2019-09-30 0000912061 srt:AmericasMember 2019-01-01 2019-09-30 0000912061 srt:AmericasMember 2018-01-01 2018-09-30 0000912061 country:TW us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 country:IN us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 country:KR us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 srt:EuropeMember 2018-01-01 2018-09-30 0000912061 nhtc:RussiaandKazakhstanDomain us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 nhtc:RussiaandKazakhstanDomain 2018-07-01 2018-09-30 0000912061 country:SG us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 country:TW 2019-01-01 2019-09-30 0000912061 country:MY us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 country:MY us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 country:IN 2019-01-01 2019-09-30 0000912061 country:CN 2019-07-01 2019-09-30 0000912061 country:SG us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 country:TW 2019-07-01 2019-09-30 0000912061 country:CN us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 country:HK us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 country:SG 2019-07-01 2019-09-30 0000912061 country:KR 2019-07-01 2019-09-30 0000912061 country:TW 2018-07-01 2018-09-30 0000912061 country:CN us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 country:HK us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 country:TW us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 srt:EuropeMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 nhtc:RussiaandKazakhstanDomain 2019-01-01 2019-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 country:MY us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 country:KR us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 nhtc:RussiaandKazakhstanDomain us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 srt:EuropeMember 2018-07-01 2018-09-30 0000912061 country:MY 2018-07-01 2018-09-30 0000912061 country:TW 2018-01-01 2018-09-30 0000912061 country:CN 2018-01-01 2018-09-30 0000912061 country:SG 2018-07-01 2018-09-30 0000912061 country:HK us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 srt:EuropeMember 2019-01-01 2019-09-30 0000912061 nhtc:RussiaandKazakhstanDomain us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 srt:EuropeMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 srt:EuropeMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 srt:EuropeMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 country:KR us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 country:HK 2018-07-01 2018-09-30 0000912061 country:SG us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 country:IN us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 country:TW us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 country:MY 2019-07-01 2019-09-30 0000912061 country:MY us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 country:HK us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 country:IN 2018-01-01 2018-09-30 0000912061 country:IN 2019-07-01 2019-09-30 0000912061 country:CN 2019-01-01 2019-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 country:JP 2018-07-01 2018-09-30 0000912061 nhtc:RussiaandKazakhstanDomain us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 country:IN us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 country:KR 2019-01-01 2019-09-30 0000912061 country:JP us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 country:JP 2019-07-01 2019-09-30 0000912061 country:JP us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 country:MY 2019-01-01 2019-09-30 0000912061 srt:EuropeMember 2019-07-01 2019-09-30 0000912061 country:CN us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 country:JP us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 country:CN 2018-07-01 2018-09-30 0000912061 country:HK 2019-01-01 2019-09-30 0000912061 country:IN us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 country:IN 2018-07-01 2018-09-30 0000912061 country:MY 2018-01-01 2018-09-30 0000912061 srt:AmericasMember 2018-07-01 2018-09-30 0000912061 country:SG 2019-01-01 2019-09-30 0000912061 country:JP 2018-01-01 2018-09-30 0000912061 country:KR us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 country:KR 2018-07-01 2018-09-30 0000912061 country:HK 2018-01-01 2018-09-30 0000912061 country:CN us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 nhtc:RussiaandKazakhstanDomain 2018-01-01 2018-09-30 0000912061 country:JP us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 country:TW us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 us-gaap:RestrictedStockMember 2019-07-01 2019-09-30 0000912061 us-gaap:RestrictedStockMember 2019-01-01 2019-09-30 0000912061 nhtc:UnshippedProductMember 2019-09-30 0000912061 nhtc:AutoShipAdvancesMember 2019-09-30 0000912061 nhtc:OtherRevenueMember 2019-09-30 0000912061 us-gaap:CashMember 2019-09-30 0000912061 nhtc:AutoShipAdvancesMember 2018-12-31 0000912061 nhtc:UnshippedProductMember 2018-12-31 0000912061 us-gaap:CashMember 2018-12-31 0000912061 us-gaap:CashEquivalentsMember 2019-09-30 0000912061 nhtc:OtherRevenueMember 2018-12-31 0000912061 us-gaap:CashEquivalentsMember 2018-12-31 0000912061 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2019-09-30 0000912061 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember 2019-09-30 0000912061 us-gaap:CashAndCashEquivalentsMember 2018-12-31 0000912061 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2019-09-30 0000912061 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2018-12-31 0000912061 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember 2018-12-31 0000912061 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000912061 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2019-09-30 0000912061 us-gaap:CashAndCashEquivalentsMember 2019-09-30 0000912061 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2018-12-31 0000912061 2019-03-15 2019-03-15 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-30 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-09-30 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-09-30 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-09-30 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2019-09-30 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2019-01-01 2019-09-30 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2018-12-31 0000912061 2019-08-01 2019-09-30 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2019-02-01 2019-02-01 0000912061 srt:DirectorMember 2019-05-16 0000912061 nhtc:EquityIncentive2016PlanMember us-gaap:CommonStockMember 2019-09-30 0000912061 2019-05-16 2019-05-31 0000912061 nhtc:EquityIncentive2016PlanMember us-gaap:CommonStockMember 2016-04-07 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2019-08-09 2019-08-09 0000912061 2016-01-12 0000912061 2015-07-28 0000912061 2019-05-16 0000912061 nhtc:MetuchenNewJerseyMember 2019-09-30 0000912061 country:CN 2019-09-30 0000912061 country:HK 2019-09-30 0000912061 nhtc:RollingHillsEstatesCaliforniaMember 2019-09-30 0000912061 nhtc:MontereyParkCaliforniaMember 2019-09-30 0000912061 nhtc:RichmondBritishColumbiaMember 2019-09-30 0000912061 us-gaap:ForeignCountryMember 2018-12-31 0000912061 srt:ExecutiveOfficerMember nhtc:SecuritiesClassActionMember 2019-01-08 2019-01-08 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:PresidentandHisWifeMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember 2019-09-30 0000912061 nhtc:BroadyHealthSciencesMember nhtc:ReStoreMember nhtc:RoyaltyAgreementandLicenseMember srt:AffiliatedEntityMember 2013-02-01 2013-02-28 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember 2019-09-30 0000912061 nhtc:BroadyHealthSciencesMember nhtc:ReStoreMember srt:DirectorMember nhtc:RoyaltyAgreementandLicenseMember srt:AffiliatedEntityMember 2019-09-30 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember 2019-03-31 0000912061 nhtc:BroadyHealthSciencesMember nhtc:ReStoreMember nhtc:RoyaltyAgreementandLicenseMember srt:AffiliatedEntityMember 2018-07-01 2018-09-30 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember 2019-01-01 2019-03-31 0000912061 nhtc:BroadyHealthSciencesMember nhtc:ReStoreMember nhtc:RoyaltyAgreementandLicenseMember srt:AffiliatedEntityMember 2019-01-01 2019-09-30 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember 2019-01-01 2019-09-30 0000912061 nhtc:TheGeorgeK.Broady2012IrrevocableTrustBroadyTrustMember srt:DirectorMember nhtc:StockRepurchaseAgreementMember srt:AffiliatedEntityMember 2019-05-17 2019-05-31 0000912061 nhtc:BroadyHealthSciencesMember nhtc:ReStoreMember nhtc:RoyaltyAgreementandLicenseMember srt:AffiliatedEntityMember 2018-01-01 2018-09-30 0000912061 nhtc:BroadyHealthSciencesMember nhtc:ReStoreMember nhtc:RoyaltyAgreementandLicenseMember srt:AffiliatedEntityMember 2019-07-01 2019-09-30 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:SharngHoldingsMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember 2019-09-30 0000912061 us-gaap:SubsequentEventMember 2019-10-29 2019-10-29 xbrli:pure nhtc:branch nhtc:defendant nhtc:order nhtc:service_station utreg:Rate xbrli:shares iso4217:USD iso4217:USD xbrli:shares utreg:sqft


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended September 30, 2019
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from ______ to _______
 
Commission File Number: 001-36849
NATURAL HEALTH TRENDS CORP.
(Exact name of registrant as specified in its charter)
Delaware
59-2705336
(State or other jurisdiction of
(I.R.S. Employer
incorporation or organization)
Identification No.)
Units 1205-07, 12F
Mira Place Tower A
132 Nathan Road, Tsimshatsui
Kowloon, Hong Kong
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: +852-3107-0800

Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
NHTC
The NASDAQ Stock Market LLC
 
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for shorter period that the registrant was required to submit such files). Yes þ No o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
o
 
Accelerated filer
þ
Non-accelerated filer
o
 
Smaller reporting company
 
 
 
Emerging growth company
 




If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No þ
 
At November 1, 2019, the number of shares outstanding of the registrant’s common stock was 11,520,324 shares.





NATURAL HEALTH TRENDS CORP.
Quarterly Report on Form 10-Q
September 30, 2019
 
INDEX 
 




FORWARD-LOOKING STATEMENTS
 
This Quarterly Report on Form 10-Q, in particular “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” includes “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). When used in this report, the words or phrases “will likely result,” “expect,” “intend,” “will continue,” “anticipate,” “estimate,” “project,” “believe” and similar expressions are intended to identify “forward-looking statements” within the meaning of the Exchange Act. These statements represent our expectations or beliefs concerning, among other things, future revenue, earnings, growth strategies, new products and initiatives, future operations and operating results, and future business and market opportunities.
 
Forward-looking statements in this report speak only as of the date hereof, and forward-looking statements in documents incorporated by reference speak only as of the date of those documents. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. We caution and advise readers that these statements are based on certain assumptions that may not be realized and involve risks and uncertainties that could cause actual results to differ materially from the expectations and beliefs contained herein.
 
For a summary of certain risks related to our business, see “Part I, Item 1A. Risk Factors” in our most recent Annual Report on Form 10-K, which includes the following:

We could be adversely affected by management changes or an inability to attract and retain key management, directors and consultants;
Because our Hong Kong operations account for a substantial portion of our overall business, and substantially all of our Hong Kong business is derived from the sale of products to members in China, any material adverse change in our business relating to either Hong Kong or China would likely have a material adverse impact on our overall business;
Our operations in China are subject to compliance with a myriad of applicable laws and regulations, and any actual or alleged violations of those laws or government actions otherwise directed at us could have a material adverse impact on our business and the value of our company;
Our failure to maintain and expand our member relationships could adversely affect our business;
We are currently involved in, and may in the future face, lawsuits, claims, and governmental proceedings and inquiries that could harm our business;
Although virtually all of our members are independent contractors, improper member actions that violate laws or regulations could harm our business;
Direct-selling laws and regulations may prohibit or severely restrict our direct sales efforts and cause our revenue and profitability to decline, and regulators could adopt new regulations that harm our business;
The high level of competition in our industry could adversely affect our business;
Challenges by third parties to the legality of our business operations could harm our business;
An increase in the amount of compensation paid to members would reduce profitability;
Currency exchange rate fluctuations could lower our revenue and net income;
Changes in tax or duty laws, and unanticipated tax or duty liabilities, could adversely affect our net income;
Transfer pricing regulations affect our business and results of operations;
Our products and related activities are subject to extensive government regulation, which could delay, limit or prevent the sale of some of our products in some markets;
Failure of new products to gain member and market acceptance could harm our business;
New regulations governing the marketing and sale of nutritional supplements could harm our business;
Regulations governing the production and marketing of our personal care products could harm our business;
If we are found not to be in compliance with good manufacturing practices our operations could be harmed;
Failure to comply with domestic and foreign laws and regulations governing product claims and advertising could harm our business;
Adverse publicity associated with our products, ingredients or network marketing program, or those of similar companies, could harm our financial condition and operating results;
We are subject to risks relating to product concentration and lack of revenue diversification;
We rely on a limited number of independent third parties to manufacture and supply our products;
Growth may be impeded by the political and economic risks of entering and operating in foreign markets;
We are subject to anti-bribery laws, including the U.S. Foreign Corrupt Practices Act;
Recently enacted tariffs, other potential changes to tariff and import/export regulations, and ongoing trade disputes between the United States and other jurisdictions, particularly China, may have a negative effect on global economic conditions and our business, financial results and financial condition;
We may be held responsible for certain taxes or assessments relating to the activities of our members and service providers, which could harm our financial condition and operating results;




We may be unable to protect or use our intellectual property rights;
We do not have a comprehensive product liability insurance program and product liability claims could hurt our business;
We identified a material weakness in our internal control over financial reporting. If we do not adequately address this material weakness or if other material weaknesses or significant deficiencies in our internal control over financial reporting are discovered, our financial statements could contain material misstatements and our business, operations and stock price may be adversely affected;
We rely on and are subject to risks associated with our reliance upon information technology systems;
System disruptions or failures, cybersecurity risks, and compromises of data could harm our business;
Our systems, software and data reside on third-party servers, exposing us to risks that disruption or intrusion of those servers could temporarily or permanently interrupt our access and damage our business;
Terrorist attacks, acts of war, epidemics or natural disasters may seriously harm our business;
We may experience negative cash flows, which may require that we seek debt or equity financing and could have a significant adverse effect on our business and threaten our solvency;
Disappointing quarterly revenue or operating results could cause the price of our common stock to fall;
Our common stock is particularly subject to volatility because of the industry in which we operate;
Our common stock continues to experience wide fluctuations in trading volumes and prices. This may make it more difficult for holders of our common stock to sell shares when they want and at prices they find attractive; and
Future sales by us or our existing stockholders could depress the market price of our common stock.

Additional factors that could cause actual results to differ materially from our forward-looking statements are set forth in this report, including under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and in our financial statements and the related notes.




PART I - FINANCIAL INFORMATION
Item 1. FINANCIAL STATEMENTS
  
NATURAL HEALTH TRENDS CORP.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data) 
 
September 30, 2019
 
December 31, 2018
 
(Unaudited)
 
 
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
101,113

 
$
132,653

Inventories
7,999

 
12,165

Other current assets
6,997

 
5,369

Total current assets
116,109

 
150,187

Property and equipment, net
821

 
934

Operating lease right-of-use assets
3,515



Goodwill
1,764

 
1,764

Restricted cash
2,881

 
2,998

Deferred tax asset
1,210

 
1,207

Other assets
807

 
831

Total assets
$
127,107

 
$
157,921

LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
627

 
$
1,631

Accrued commissions
3,798

 
12,502

Other accrued expenses
3,392

 
6,121

Deferred revenue
3,302

 
6,795

Amounts held in eWallets
13,090

 
14,611

Operating lease liabilities
1,689



Other current liabilities
1,188

 
1,424

Total current liabilities
27,086

 
43,084

Income taxes payable
15,365

 
16,982

Deferred tax liability
186

 
186

Long-term incentive

 
7,808

Operating lease liabilities
1,903



Total liabilities
44,540

 
68,060

Commitments and contingencies (Note 9)

 

Stockholders’ equity:
 
 
 
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding

 

Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at September 30, 2019 and December 31, 2018
13

 
13

Additional paid-in capital
86,102

 
86,415

Retained earnings
23,567

 
44,431

Accumulated other comprehensive loss
(1,764
)
 
(1,250
)
Treasury stock, at cost; 1,459,090 and 1,603,322 shares at September 30, 2019 and December 31, 2018, respectively
(25,351
)
 
(39,748
)
Total stockholders’ equity
82,567

 
89,861

Total liabilities and stockholders’ equity
$
127,107

 
$
157,921


See accompanying notes to consolidated financial statements.

1



NATURAL HEALTH TRENDS CORP. 
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(In thousands, except per share data)
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Net sales
$
17,023

 
$
47,043

 
$
59,779

 
$
150,320

Cost of sales
4,371

 
9,926

 
15,002

 
30,546

Gross profit
12,652

 
37,117

 
44,777

 
119,774

Operating expenses:
 
 
 
 
 
 
 
Commissions expense
7,362

 
22,001

 
28,258

 
67,291

Selling, general and administrative expenses
6,354

 
7,269

 
20,296

 
24,484

Total operating expenses
13,716

 
29,270

 
48,554

 
91,775

Income (loss) from operations
(1,064
)
 
7,847

 
(3,777
)
 
27,999

Other income, net
323

 
249

 
1,128

 
465

Income (loss) before income taxes
(741
)
 
8,096

 
(2,649
)
 
28,464

Income tax provision
502

 
467

 
120

 
2,988

Net income (loss)
$
(1,243
)
 
$
7,629

 
$
(2,769
)
 
$
25,476

Net income (loss) per common share:
 
 
 
 
 
 
 
Basic
$
(0.12
)
 
$
0.67

 
$
(0.25
)
 
$
2.25

Diluted
$
(0.12
)
 
$
0.67

 
$
(0.25
)
 
$
2.25

Weighted-average number of common shares outstanding:
 
 
 
 
 
 
 
Basic
10,623

 
11,309

 
11,010

 
11,298

Diluted
10,623

 
11,322

 
11,010

 
11,307

 
See accompanying notes to consolidated financial statements.
 

2



NATURAL HEALTH TRENDS CORP.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)
(In thousands)
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Net income (loss)
$
(1,243
)
 
$
7,629

 
$
(2,769
)
 
$
25,476

Other comprehensive income (loss), net of tax:
 
 
 
 
 
 
 
Foreign currency translation adjustment
(584
)
 
(433
)
 
(537
)
 
(798
)
Unrealized gains on available-for-sale securities
12

 
5

 
23

 
9

Comprehensive income (loss)
$
(1,815
)
 
$
7,201

 
$
(3,283
)
 
$
24,687

 
See accompanying notes to consolidated financial statements.
 

3



NATURAL HEALTH TRENDS CORP.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED)
(In Thousands, Except Share Data)

Nine months ended September 30, 2019
 
Preferred Stock
 
Common Stock
 
Additional
Paid-In
Capital
 
Retained Earnings
 
Accumulated
Other
Comprehensive
(Loss) Income
 
Treasury Stock
 
 
 
Shares
 
Amount
 
Shares
 
Amount
 
 
 
 
Shares
 
Amount
 
Total
BALANCE, December 31, 2018

 
$

 
12,979,414

 
$
13

 
$
86,415

 
$
44,431

 
$
(1,250
)
 
(1,603,322
)
 
$
(39,748
)
 
$
89,861

Net loss

 

 

 

 

 
(1,923
)
 

 

 

 
(1,923
)
Common stock issued

 

 

 

 
(166
)
 

 

 
22,603

 
543

 
377

Dividends declared, $0.24/share

 

 

 

 

 
(2,736
)
 

 

 

 
(2,736
)
Foreign currency translation adjustments

 

 

 

 

 

 
259

 

 

 
259

Unrealized gains on available-for-sale securities

 

 

 

 

 

 
17

 

 

 
17

BALANCE, March 31, 2019

 

 
12,979,414

 
13

 
86,249

 
39,772

 
(974
)
 
(1,580,719
)
 
(39,205
)
 
85,855

Net income

 

 

 

 

 
397

 

 

 

 
397

Repurchase of common stock

 

 

 

 

 

 

 
(612,729
)
 
(6,682
)
 
(6,682
)
Foreign currency translation adjustments

 

 

 

 

 

 
(212
)
 

 

 
(212
)
Unrealized losses on available-for-sale securities

 

 

 

 

 

 
(6
)
 

 

 
(6
)
BALANCE, June 30, 2019

 

 
12,979,414

 
13

 
86,249

 
40,169

 
(1,192
)
 
(2,193,448
)
 
(45,887
)
 
79,352

Net loss

 

 

 

 

 
(1,243
)
 

 

 

 
(1,243
)
Repurchase of common stock

 

 

 

 

 

 

 
(383,127
)
 
(2,882
)
 
(2,882
)
Common stock issued

 

 

 

 
(147
)
 
(15,359
)
 

 
1,117,485

 
23,418

 
7,912

Foreign currency translation adjustments

 

 

 

 

 

 
(584
)
 

 

 
(584
)
Unrealized gains on available-for-sale securities

 

 

 

 

 

 
12

 

 

 
12

BALANCE, September 30, 2019

 
$

 
12,979,414

 
$
13

 
$
86,102

 
$
23,567

 
$
(1,764
)
 
(1,459,090
)
 
$
(25,351
)
 
$
82,567


4




Nine months ended September 30, 2018
 
Preferred Stock
 
Common Stock
 
Additional
Paid-In
Capital
 
Retained Earnings
 
Accumulated
Other
Comprehensive
(Loss) Income
 
Treasury Stock
 
 
 
Shares
 
Amount
 
Shares
 
Amount
 
 
 
 
Shares
 
Amount
 
Total
BALANCE, December 31, 2017

 
$

 
12,979,414

 
$
13

 
$
86,683

 
$
44,908

 
$
(413
)
 
(1,637,524
)
 
$
(40,570
)
 
$
90,621

Net income

 

 

 

 

 
8,824

 

 

 

 
8,824

Common stock issued

 

 

 

 
(268
)
 

 

 
34,202

 
822

 
554

Dividends declared, $0.13/share

 

 

 

 

 
(1,479
)
 

 

 

 
(1,479
)
Foreign currency translation adjustments

 

 

 

 

 

 
397

 

 

 
397

Unrealized losses on available-for-sale securities

 

 

 

 

 

 
(11
)
 

 

 
(11
)
BALANCE, March 31, 2018

 

 
12,979,414

 
13

 
86,415

 
52,253

 
(27
)
 
(1,603,322
)
 
(39,748
)
 
98,906

Net income

 

 

 

 

 
9,023

 

 

 

 
9,023

Dividends declared, $1.90/share

 

 

 

 

 
(21,614
)
 

 

 

 
(21,614
)
Foreign currency translation adjustments

 

 

 

 

 

 
(762
)
 

 

 
(762
)
Unrealized gains on available-for-sale securities

 

 

 

 

 

 
15

 

 

 
15

BALANCE, June 30, 2018

 

 
12,979,414

 
13

 
86,415

 
39,662

 
(774
)
 
(1,603,322
)
 
(39,748
)
 
85,568

Net income

 

 

 

 

 
7,629

 

 

 

 
7,629

Dividends declared, $0.40/share

 

 

 

 

 
(4,551
)
 

 

 

 
(4,551
)
Foreign currency translation adjustments

 

 

 

 

 

 
(433
)
 

 

 
(433
)
Unrealized gains on available-for-sale securities

 

 

 

 

 

 
5

 

 

 
5

BALANCE, September 30, 2018

 
$

 
12,979,414

 
$
13

 
$
86,415

 
$
42,740

 
$
(1,202
)
 
(1,603,322
)
 
$
(39,748
)
 
$
88,218


See accompanying notes to consolidated financial statements.


5



NATURAL HEALTH TRENDS CORP.
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(In thousands)
 
 
Nine Months Ended September 30,
 
2019
 
2018
CASH FLOWS FROM OPERATING ACTIVITIES:
 
 
 
Net income (loss)
$
(2,769
)
 
$
25,476

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
 
 
 
Depreciation and amortization
290

 
332

Noncash lease expense
1,336



Deferred income taxes
(3
)
 

Changes in assets and liabilities:
 
 
 
Inventories
4,104

 
(2,828
)
Other current assets
(1,674
)
 
2,548

Other assets
2

 
(83
)
Accounts payable
(1,002
)
 
967

Accrued commissions
(8,683
)
 
2,003

Other accrued expenses
(1,779
)
 
314

Deferred revenue
(3,485
)
 
26

Amounts held in eWallets
(1,508
)
 
(930
)
Operating lease liabilities
(1,392
)


Income taxes payable
(1,617
)

(2,201
)
Other current liabilities
(235
)
 
438

Long-term incentive
(333
)
 
(800
)
Net cash provided by (used in) operating activities
(18,748
)
 
25,262

CASH FLOWS FROM INVESTING ACTIVITIES:
 
 
 
Purchases of property and equipment
(181
)
 
(176
)
Net cash used in investing activities
(181
)
 
(176
)
CASH FLOWS FROM FINANCING ACTIVITIES:
 
 
 
Repurchase of common stock
(9,564
)
 

Dividends paid
(2,736
)
 
(27,644
)
Net cash used in financing activities
(12,300
)
 
(27,644
)
Effect of exchange rates on cash, cash equivalents and restricted cash
(428
)
 
(711
)
Net decrease in cash, cash equivalents and restricted cash
(31,657
)
 
(3,269
)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period
135,651

 
138,478

CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period
$
103,994

 
$
135,209

SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:
 
 
 
Issuance of treasury stock for employee awards, net
$
8,289

 
$
554

Right-of-use assets obtained in exchange for operating lease liabilities
$
5,058


$

 
See accompanying notes to consolidated financial statements.

6



NATURAL HEALTH TRENDS CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION

Nature of Operations 
 
Natural Health Trends Corp., a Delaware corporation (whether or not including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.

The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia, Thailand and Vietnam; South Korea; Japan; India; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.

Basis of Presentation 
 
The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2018 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on April 26, 2019.

Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.

Reclassification

Certain prior year amounts in the balance sheet have been reclassified to conform to current year presentation.

Recent Accounting Pronouncements

In February 2016, the FASB established Topic 842, Leases, by issuing ASU No. 2016-02, which requires lessees to recognize the rights and obligations created by leases on the balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-11, Targeted Improvements, ASU No. 2018-10, Codification Improvements to Topic 842, and ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842. The new standard establishes a right-of-use (ROU) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. Effective January 1, 2019, the Company adopted the new standard using the effective date as its date of initial application. The new standard provided a number of optional practical expedients in transition. The Company elected the “package of practical expedients”, which permits entities not to reassess under the new lease standard prior conclusions about lease identification, lease classification and initial direct costs. Upon adoption, the Company recognized operating lease liabilities on its balance sheet for $4.5 million, with corresponding ROU assets of the same amount based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases. See Note 7 for additional information.

In August 2018, the SEC issued Release No. 33-10532 that amends and clarifies certain financial reporting requirements. The principal change to the Company’s financial reporting is the requirement to disclose in interim periods on Form 10-Q the changes in stockholder’s equity as prescribed by Rule 3-04 of Regulation S-X.


7



Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

2. REVENUE

Revenue Recognition

All revenue is recognized when the performance obligations under a contract are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.
 
Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 5% of sales.  Sales returns were 2% of sales for each of the nine months ended September 30, 2019 and 2018, respectively.  No material changes in estimates have been recognized during the periods presented. See Note 4 for additional information.
 
The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.

Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.

Deferred Revenue

The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are considered a contract liability and are recorded as deferred revenue. The decrease in deferred revenue for the three months ended September 30, 2019 is primarily due to $1.2 million of revenue recognized during the quarter that was included in deferred revenue as of June 30, 2019 offset by $1.1 million of cash payments received for unshipped product during the third quarter. See Note 4 for additional information.

Disaggregation of Revenue

The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through an engagement of a third-party service provider.


8



The following table sets forth revenue by market for the periods indicated (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Americas1
$
1,445

 
8.5
%
 
$
1,970

 
4.2
%
 
$
4,353

 
7.3
%
 
$
5,361

 
3.6
%
Hong Kong2
13,575

 
79.7

 
41,447

 
88.1

 
48,465

 
81.0

 
133,681

 
88.9

China
525

 
3.1

 
1,698

 
3.6

 
2,138

 
3.6

 
5,510

 
3.7

Taiwan
649

 
3.8

 
935

 
2.0

 
2,340

 
3.9

 
2,933

 
1.9

South Korea
98

 
0.6

 
133

 
0.3

 
288

 
0.5

 
392

 
0.3

Japan
47

 
0.3

 
51

 
0.1

 
141

 
0.2

 
160

 
0.1

Singapore
13

 
0.1

 
52

 
0.1

 
43

 
0.1

 
134

 
0.1

Malaysia
51

 
0.3

 
216

 
0.5

 
170

 
0.3

 
316

 
0.2

Russia and Kazakhstan
244

 
1.4

 
184

 
0.4

 
662

 
1.1

 
626

 
0.4

Europe
343

 
2.0

 
357

 
0.7

 
1,017

 
1.7

 
1,207

 
0.8

India
33

 
0.2

 

 

 
162

 
0.3

 

 

Total
$
17,023

 
100.0
%
 
$
47,043

 
100.0
%
 
$
59,779

 
100.0
%
 
$
150,320

 
100.0
%

1 United States, Canada, Mexico and Peru
2 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors” in this report and in our most recent Annual Report on Form 10-K.

The Company’s net sales by product and service are as follows (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Product sales
$
15,732

 
$
44,434

 
$
56,355

 
$
142,258

Freight and other
1,468

 
3,365

 
4,713

 
10,550

Less: sales returns
(177
)
 
(756
)
 
(1,289
)
 
(2,488
)
Total net sales
$
17,023

 
$
47,043

 
$
59,779

 
$
150,320



Concentration

No single market other than Hong Kong had net sales greater than 10% of total net sales. Sales are made to the Company’s members and no single customer accounted for 10% or more of net sales for the three and nine months ended September 30, 2019 and 2018. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.

Arrangements with Multiple Performance Obligations

The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.

Practical Expedients

The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded in commissions expense.

The Company does not provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of one year or less.


9



3. NET INCOME (LOSS) PER COMMON SHARE

Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized, if any, is assumed to be used to repurchase shares.

The following tables illustrate the computation of basic and diluted net income (loss) per common share for the periods indicated (in thousands, except per share data): 
 
Three Months Ended September 30,
 
2019
 
2018
 
Income (loss)
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
 
Income (loss)
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
Basic net income (loss) per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income (loss) available to common stockholders
$
(1,243
)
 
10,623

 
$
(0.12
)
 
$
7,629

 
11,309

 
$
0.67

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Non-vested restricted stock

 

 
 

 

 
13

 
 

Diluted net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
(1,243
)
 
10,623

 
$
(0.12
)
 
$
7,629

 
11,322

 
$
0.67

 
 
 
 
 
 
 
 
 
 
 
 
 
Nine Months Ended September 30,
 
2019
 
2018
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
Basic net income (loss) per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income (loss) available to common stockholders
$
(2,769
)
 
11,010

 
$
(0.25
)
 
$
25,476

 
11,298

 
$
2.25

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Non-vested restricted stock

 

 
 

 

 
9

 
 

Diluted net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income (loss) available to common stockholders plus assumed conversions
$
(2,769
)
 
11,010

 
$
(0.25
)
 
$
25,476

 
11,307

 
$
2.25



In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. As such, non-vested restricted stock totaling 672,231 and 263,289 shares were not included for the three and nine months ended September 30, 2019, respectively.


10



4. BALANCE SHEET COMPONENTS

The components of certain balance sheet amounts are as follows (in thousands):
 
September 30, 2019
 
December 31, 2018
Cash, cash equivalents and restricted cash:
 
 
 
Cash
$
17,711

 
$
47,323

Cash equivalents
83,402

 
85,330

 
101,113

 
132,653

Restricted cash
2,881

 
2,998

 
$
103,994

 
$
135,651

Inventories:
 
 
 
Finished goods
$
7,817

 
$
11,171

Raw materials
1,104

 
1,145

Reserve for obsolescence
(922
)
 
(151
)
 
$
7,999

 
$
12,165

Other accrued expenses:
 
 
 
Sales returns
$
290

 
$
801

Employee-related expense
1,998

 
4,051

Warehousing, inventory-related and other
1,104

 
1,269

 
$
3,392

 
$
6,121

Deferred revenue:
 
 
 
Unshipped product
$
1,171

 
$
4,574

Auto ship advances
1,983

 
1,876

Other
148

 
345

 
$
3,302

 
$
6,795



5. FAIR VALUE MEASUREMENTS

As of September 30, 2019, cash and cash equivalents include the Company’s investments in municipal and corporate debt securities, money market funds, and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with the FASB Accounting Standards Codification (“ASC”) 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at September 30, 2019 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs.

The carrying amounts of the Company’s financial instruments, including cash and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.
 
Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.


11



Investments by significant category included in cash equivalents at the end of each period were as follows (in thousands):
 
 
September 30, 2019
 
December 31, 2018
 
Fair Value Level1
Adjusted Cost
 
Gross Unrealized Losses
 
Fair Value
 
Adjusted Cost
 
Gross Unrealized Losses
 
Fair Value
Money market funds
Level 1
$
30,810

 
$

 
$
30,810

 
$
3,281

 
$

 
$
3,281

Time deposits
Level 2
14,904

 

 
14,904

 
18,071

 

 
18,071

Municipal debt securities
Level 2
3,432

 
1

 
3,433

 
12,149

 
(7
)
 
12,142

Corporate debt securities
Level 2
34,266

 
(11
)
 
34,255

 
51,862

 
(26
)
 
51,836

Total investments
 
$
83,412

 
$
(10
)
 
$
83,402

 
$
85,363

 
$
(33
)
 
$
85,330

 
1 FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs that are not corroborated by market data.

6. STOCKHOLDERS’ EQUITY
 
Dividends

The following table summarizes the Company’s cash dividend activity for the nine months ended September 30, 2019 (in thousands, except per share data):
Declaration Date
 
Per Share
 
Amount
 
Record Date
 
Payment Date
January 27, 2019 (special)
 
0.08

 
$
912

 
March 5, 2019
 
March 15, 2019
January 27, 2019
 
0.16

 
$
1,824

 
March 5, 2019
 
March 15, 2019
 
 
$
0.24

 
$
2,736

 
 
 
 


Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.

Stock Repurchases

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued.

On May 16, 2019, the Company’s Board of Directors authorized the Company to proceed with the purchase of up to $8.0 million in shares of common stock under the foregoing stock repurchase program. In connection therewith, the Company was advised that George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding shares of common stock, would participate in the stock repurchase program on a basis roughly proportional to his family’s ownership interest. See Note 10.

During May 2019, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of $4.7 million in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. The open market repurchases were completed on May 31, 2019. The stock repurchases, which included both open market purchases and the purchase of shares from Mr. Broady, resulted in the Company purchasing a total of 612,729 shares of its common stock for an aggregate purchase price of $6.7 million, plus transaction costs.

12




On August 6, 2019, the Company’s Board of Directors authorized the Company to proceed with purchases under the foregoing stock repurchase program in the open market in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. During August and September 2019, the Company purchased a total of 383,127 shares of common stock in the open market for an aggregate purchase price of $2.9 million, plus transaction costs.

As of September 30, 2019, $22.4 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.

Restricted Stock

At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At September 30, 2019, 1,219,583 shares remained available for issuance under the 2016 Plan.

On February 1, 2019, the Company granted 22,603 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interests with those of its stockholders and settling fiscal 2018 performance incentives totaling $377,000. The shares vest on a quarterly basis over the next three years and are subject to forfeiture in the event of their termination of service to the Company under specified circumstances.

On August 9, 2019, the Company granted 1,117,485 shares of restricted stock under the 2016 Plan to certain employees for the purpose of further aligning their interests with those of its stockholders and settling unpaid cash incentives of $7.9 million under the 2014 Long-Term Incentive Plan with respect to performance periods that concluded on or prior to December 31, 2018.

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2018
45,486

 
$
21.61

Granted
1,140,088

 
7.27

Vested
(125,405
)
 
11.07

Nonvested at September 30, 2019
1,060,169

 
7.44



Accumulated Other Comprehensive Loss
 
The changes in accumulated other comprehensive loss by component for the first nine months of 2019 were as follows (in thousands):
 
Foreign Currency Translation Adjustment
 
Unrealized Gains/(Losses) on Available-For-Sale Investments
 
Total
Balance, December 31, 2018
$
(1,217
)
 
$
(33
)
 
$
(1,250
)
Other comprehensive income (loss)
(537
)
 
23

 
(514
)
Balance, September 30, 2019
$
(1,754
)
 
$
(10
)
 
$
(1,764
)


7. LEASES

The Company leases 9,600 square feet of office space in Hong Kong with a term expiring in February 2021. The Company leases 4,900 square feet of office space in Rolling Hills Estates, California with a term expiring in September 2025. To help further develop the market for its products in North America, the Company leases 2,400, 1,600 and 2,000 square feet of retail space in Monterey Park, California, Richmond, British Columbia, and Metuchen, New Jersey, respectively. The Monterey

13



Park, Richmond and Metuchen locations have terms expiring in August 2020, February 2021, and November 2022, respectively.

The Company leases nine branch offices throughout China, and additional office space in Peru, Japan, Taiwan, South Korea, Singapore, Malaysia, Vietnam, Indonesia, Thailand, India, and the Cayman Islands. The Company also leases a multi-purpose facility and factory in Zhongshan, China and 11 service stations throughout the city of Guangzhou, China that serve or will in the future serve the needs of its Chinese consumers. The Company contracts with third parties for fulfillment and distribution operations in all of its international markets. None of the Company’s third party logistics contracts contain a lease as the Company does not have the right to access the warehouses or move its inventories at will.

The components of lease cost for the three months and nine months ended September 30, 2019 were as follows (in thousands):
 
Three Months Ended September 30, 2019
 
Nine Months Ended September 30, 2019
Operating leases
$
512

 
$
1,544

Short-term leases
73

 
201

Total lease cost
$
585

 
$
1,745



Cash paid for amounts included in the measurement of operating leases liabilities was $459,000 and $1.5 million for the three months and nine months ended September 30, 2019, respectively.

The weighted-average remaining lease term and discount rate related to operating leases as of September 30, 2019 were as follows:
Weighted-average remaining lease term (in years)
3.2

Weighted-average discount rate
5.5
%


As most of our leases do not provide an implicit rate, the Company used its incremental borrowing rate, or the rate of each of its subsidiaries if available, based on the information available at the lease commencement date to determine the present value of lease payments.

The annual scheduled lease payments of our operating lease liabilities as of September 30, 2019 were as follows (in thousands):
Remainder of 2019
$
473

2020
1,717

2021
730

2022
427

2023
245

Thereafter
400

Total lease payments
$
3,992

Less: imputed interest
(400
)
Present value of lease liabilities
$
3,592



For all asset classes, the Company elected not to recognize assets or liabilities at the acquisition date for leases that, at the acquisition date, have a remaining lease term of 12 months or less. Additionally, for all asset classes, the Company choose not to separate nonlease components from lease components and instead account for the combined lease and nonlease components associated with that lease component as a single lease component.

8. INCOME TAXES

The effective income tax rate for the three and nine months ended September 30, 2019 was impacted by recording the effect of the Tax Cuts and Jobs Act (the “Tax Act”) enacted on December 22, 2017 by the U.S. government, which makes broad and complex changes to the Internal Revenue Code of 1986, as amended.


14



On December 22, 2017, the Securities and Exchange Commission staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provided a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740, Income Taxes. In accordance with the expiration of the SAB 118 measurement period, we completed the assessment of the income tax effect of the Tax Act for the year ended December 31, 2017 in the fourth quarter of tax year 2018. All adjustments recorded to the provisional amounts have been included as an adjustment to income tax expense.

As a result of the Tax Act, the Company could be subject to additional income tax expense due to the Global Intangible Low Taxed Income inclusion on current net income of greater than 10% owned controlled foreign corporations (“GILTI”). To determine the amount of GILTI inclusion, the Company must determine, in addition to other factors, the current earnings of controlled foreign corporations, as well as the amount of foreign taxes paid by the foreign entities. The law provides that corporate taxpayers may benefit from a 50% reduction in the GILTI inclusion which effectively reduces the 21% U.S. corporate tax rate on the foreign income to an effective rate of 10.5%. The 50% reduction, however, is limited if the U.S. shareholder has current domestic losses or is utilizing net operating losses. The GILTI inclusion further provides for a foreign tax credit in connection with the foreign taxes paid. The Company is not expected to have any GILTI inclusion for the year ended December 31, 2019.

As of September 30, 2019, the Company does not have a valuation allowance against its U.S. deferred tax assets. The Company analyzed all sources of available income and determined that they are more likely than not to realize the tax benefits of their deferred assets. As of September 30, 2019, any attributes generated from a U.S. federal net operating loss for the year ended December 31, 2019 are expected to be fully utilized.

As of September 30, 2019, the Company has a valuation allowance against certain foreign deferred tax assets. The Company is recording a valuation allowance in foreign jurisdictions with an overall net operating loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision. At December 31, 2018, the Company had foreign net operating loss carryforwards of approximately $1.2 million in various jurisdictions with various expirations.

As a result of capital return activities, the Company determined that a portion of its current undistributed foreign earnings is no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. For state income tax purposes, the Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable state corporate income tax rate. As of September 30, 2019, the Company has recorded a state deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods. Due to the Tax Act, repatriation from foreign subsidiaries will be offset with a dividends received deduction, resulting in little to no impact on federal tax expense. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of September 30, 2019. During 2019, a loan was issued by the Company to one of its controlled foreign corporations that exceeded 50% of current earnings. This transaction is tax-free for federal income tax purposes and the state tax impact is insignificant to the consolidated financial statements.

The Company and its subsidiaries file tax returns in the United States, California, New Jersey and Texas and various foreign jurisdictions. During the fourth quarter of 2018, the Company was notified that it was selected for audit of the 2016 tax year by the U.S. Internal Revenue Service. For purposes of this audit, fiscal years 2007 through 2016 are open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. No adjustments have been proposed at this time. The Company is no longer subject to state income tax examinations for years prior to 2014. No other jurisdictions are currently examining any income tax returns of the Company.


15



9. COMMITMENTS AND CONTINGENCIES

On January 8, 2019, the Company and its two executive officers were named in a putative securities class action filed in the United States District Court for the Central District of California, captioned Kauffman v. Natural Health Trends Corp., Case No. 2:19-cv-00163. The complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between April 27, 2016 and January 5, 2019, inclusive, under (i) Section 10(b) of the Securities Exchange Act of 1934 (“Exchange Act”) and Rule 10b-5 promulgated thereunder against the Company and Chris T. Sharng and Timothy S. Davidson (together, the “Individual Defendants”), and (ii) Section 20(a) of the Exchange Act against the Individual Defendants. The complaint alleges, in part, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multilevel marketing business. The complaint seeks an indeterminate amount of damages, plus interest and costs. On May 3, 2019, the court issued an order appointing Xia Yang as lead plaintiff and appointing The Rosen Law Firm, P. A. as lead counsel. On June 3, 2019, lead plaintiff filed an amended complaint. On June 27, 2019, the parties filed a joint stipulation seeking to postpone briefing on defendants’ motion to dismiss to allow the parties to continue ongoing discussions, which stipulation was entered by the court on July 1, 2019.  On September 6, 2019, Defendants filed a motion to dismiss the amended complaint, which plaintiff opposed on October 16, 2019.  Defendants’ reply in support of their motion to dismiss was filed on November 4, 2019, and a hearing on the motion is currently set for November 18, 2019.  Defendants believe that these claims are without merit and intend to vigorously defend against them.

Since August 2016, the SEC has been conducting a non-public investigation to determine whether there have been violations of the federal securities laws relating to the trading of the Company’s securities. The Company has fully cooperated with the SEC and has and continues to provide documents in response to subpoenas. The SEC has expressly stated that its document requests should not be construed as an indication that any violation of law has occurred, or as a reflection upon any person, entity, or security. The amount of time needed to resolve this matter is uncertain, and the Company cannot predict the outcome or whether it will face additional governmental inquiries or other actions.

10. RELATED PARTY TRANSACTIONS

In February 2013, the Company entered into a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called ReStor™. George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding common stock, is owner of BHS. Under the agreement, the Company agreed to pay BHS a royalty based on a price per unit in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States. Such royalties were $19,000 and $72,000 for the three months ended September 30, 2019 and 2018, respectively, and $75,000 and $248,000 for the nine months ended September 30, 2019 and 2018, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days’ notice or, under certain circumstances, with no notice. Otherwise, the agreement terminates March 31, 2020.

The Company procured in China and arranged for shipment to The Aberdeen Group, LLC (“Aberdeen”) one order of apparel products in the amount of $7,100 during the three months ended March 31, 2019.  Aberdeen is owned 40% by Sharng Holdings, which is wholly-owned by the Company’s president, Chris T. Sharng, and his wife, 40% by Mr. Broady, and 20% by an unrelated third party.  Aberdeen promptly paid the Company for the product and shipping cost incurred. Given the Company’s provision of such product sourcing service to Aberdeen, Aberdeen also paid the Company a market-based fee consistent with the provision of such service of $420. The Company analyzed the nature of the transaction with Aberdeen to determine whether it could be construed a violation under the guidelines of Section 402 of the Sarbanes-Oxley Act of 2002. The Company, through advice from its legal counsel, concluded that there is not a reasonable possibility that the transaction with Aberdeen would be deemed a violation of Section 402. This relationship between the Company and Aberdeen ceased following the completion of this transaction.

On May 17, 2019, the Company entered into a Stock Repurchase Agreement with The George K. Broady 2012 Irrevocable Trust (“Broady Trust”). Mr. Broady is the trustee and a beneficiary of the Broady Trust. The Stock Repurchase Agreement, which the Company and the Broady Trust entered into in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, provided for the Company’s purchase of common stock from the Broady Trust in off-the-market, private transactions at a rate of 0.4105 times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on May 16, 2019. The Company’s purchases from the Broady Trust concluded on May 31, 2019, were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in an aggregate purchase price of $1.9 million. See Note 6.


16



11. SUBSEQUENT EVENT

On October 29, 2019, the Board of Directors declared a special cash dividend of $0.40 on each share of common stock outstanding. Such dividends are payable on November 29, 2019 to stockholders of record on November 19, 2019. Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.


17



Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
Business Overview

We are an international direct-selling and e-commerce company. Subsidiaries controlled by us sell personal care, wellness, and “quality of life” products under the “NHT Global” brand. Our wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia, Thailand and Vietnam; South Korea; Japan; India; and Europe. We also operate in Russia and Kazakhstan through our engagement with a local service provider.

As of September 30, 2019, we were conducting business through 68,150 active members, compared to 78,280 three months ago and 97,160 a year ago. We consider a member “active” if they have placed at least one product order with us during the preceding year. Our priority is to focus our resources in our most promising markets, which we consider to be Greater China and countries where our existing members have the connections to recruit prospects and sell our products, such as Southeast Asia, India, South America and Europe.

We generate approximately 92% of our net sales from subsidiaries located outside the Americas, with sales of our Hong Kong subsidiary representing 80% of net sales in the latest fiscal quarter. Because of the size of our foreign operations, operating results can be impacted negatively or positively by factors such as foreign currency fluctuations, and economic, political and business conditions around the world. In addition, our business is subject to various laws and regulations, in particular, regulations related to direct selling activities that create uncertain risks for our business, including improper claims or activities by our members and potential inability to obtain necessary product registrations. We have identified certain matters of potential noncompliance and are working on a continuing basis to satisfactorily address such matters. For further information regarding some of the risks associated with the conduct of our business in China and Hong Kong, see generally in “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2018, and more specifically under the captions “Because our Hong Kong operations account for a substantial portion of our overall business...” and “Our operations in China are subject to compliance with a myriad of applicable laws and regulations...”; in addition, see “Item 1A. Risk Factors” in this report under the caption “Our Hong Kong operations are being adversely affected by recent political and social developments in Hong Kong...”

China has been and continues to be our most important business development project. We operate an e-commerce direct selling model in Hong Kong that generates revenue derived from the sale of products to members in Hong Kong and elsewhere, including China. Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. Through a separate Chinese entity, we operate an e-commerce retail platform in China. We believe that neither of these activities require a direct selling license in China, which we do not currently hold. We have previously sought to obtain a direct selling license, and in August 2015 initiated the process for submitting a new preliminary application for a direct selling license in China. If we are able to obtain a direct selling license in China, we believe that the incentives inherent in the direct selling model in China would incrementally benefit our existing business. We do not expect that any increased sales in China derived from obtaining a direct selling license would initially be material and, in any event may be partially offset by the higher fixed costs associated with the establishment and maintenance of required service centers, branch offices, manufacturing facilities, certification programs and other legal requirements. We are unable to predict whether and when we will be successful in obtaining a direct selling license to operate in China, and if we are successful, when we will be permitted to conduct direct selling operations and whether such operations would be profitable.

On January 8, 2019, the Chinese government announced a 100-day campaign focused on companies involved in the sale of food, equipment, daily necessities, small home electrical appliances and services that are claimed to promote health. The Chinese government ministries in charge of this campaign indicated that they are targeting illegal practices in the industry, particularly the manufacture and sale of counterfeit and substandard products, and false advertising and misleading claims as to the health benefits of products and services. It is understood that the campaign is specifically focused on the business practices of direct selling companies. During the campaign, we understand that the government will not issue any additional direct selling licenses, will cease issuing certifications of quality or other approvals of various healthcare products, will review its regulatory oversight of the industry, and will prohibit companies from conducting large distributor meetings. We believe that the campaign will continue to negatively impact our business in China in the short-term, but will benefit us and Chinese consumers in the long-term as purveyors of substandard products are driven from the market. Since it was implemented, the campaign and associated negative media coverage has had a significant impact on our business, as consumers have widely curtailed their purchases within the affected industries. We, like some of our peers, voluntarily decided in January 2019 to temporarily suspend our member activities, such as product roadshows, product trainings and larger company-sponsored

18



events, in China. We did this because we have learned that the 100-day campaign was announced in broad outlines by the central government, and the interpretation and enforcement of the campaign was delegated to the provincial and local governments. We consider it a top priority for our business to develop an understanding of and cooperate with all levels and jurisdictions of the government agencies, and did not want to run the risk of being inadvertently entangled in government enforcement actions as the provincial and local governments formulate and implement their interpretive guidance and rule-making. Although we understand the 100-day campaign was to expire on or about April 18, 2019, we are not aware of any information indicating that the campaign has formally concluded. On August 27, 2019, the Chinese government announced that it would conduct a review of the 100-day campaign commencing September 1, 2019. We understand that this review is expected to be concluded by the end of November 2019.

Recent political and social developments in Hong Kong are also adversely affecting our Hong Kong operations. Hong Kong has historically served as a key location for meetings and events for our members, but these developments recently led us to curtail the number and scope of such meetings and events. These recent developments in Hong Kong, along with our currently effective suspension of member activities in China, are negatively impacting our business.

To date, the recently enacted tariffs and the trade disputes between the United States and China have not materially impacted our business, although they may have negatively impacted the value of the Chinese yuan, which has in turn negatively affected our Hong Kong revenues because the prices at which our Chinese members can purchase our products have effectively increased. In the event the trade disputes between the United States and China continue or intensify, our business could be negatively impacted in the future. For more information, see “Item 1A. Risk Factors - Recently enacted tariffs, other potential changes to tariff and import/export regulations, and ongoing trade disputes between the United States and other jurisdictions, particularly China, may have a negative effect on global economic conditions and our business, financial results and financial condition” in our Annual Report on Form 10-K for the year ended December 31, 2018.

Our Hong Kong net sales (substantially all of which were derived from products shipped to members residing in China) for the first nine months of 2019 were substantially lower than the comparable period in 2018, and it’s likely that we will experience continued lower net sales for the foreseeable future. The substantial decline in net sales during the first nine months of 2019 resulted in a net loss for the nine-month period ended September 30, 2019, as well as negative cash flows and a decreasing cash balance. We anticipate that our financial performance will be adversely impacted for the foreseeable future.

Income Statement Presentation
 
We mainly derive revenue from sales of products. Substantially all of our product sales are to independent members at published wholesale prices. Product sales are recognized when the products are shipped and title passes to independent members, which generally is upon our delivery to the carrier that completes delivery to the members. We estimate and accrue a reserve for product returns based on our return policies and historical experience. We bill members for shipping charges and recognize the freight revenue in net sales. We have elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrue for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Event and training revenue is deferred and recognized as the event or training occurs.

Cost of sales consists primarily of products purchased from third-party manufacturers, freight cost for transporting products to our foreign subsidiaries and shipping products to members, import duties, packing materials, product royalties, costs of promotional materials sold to our members at or near cost, and provisions for slow moving or obsolete inventories. Cost of sales also includes purchasing costs, receiving costs, inspection costs and warehousing costs.

Member commissions are our most significant expense and are classified as an operating expense. Under our compensation plan, members are paid weekly commissions by our subsidiary in which they are enrolled, generally in their home country currency, for product purchases by their down-line member network across all geographic markets. Our China subsidiary maintains an e-commerce retail platform and does not pay commissions, although our Chinese members may participate in our compensation plan through our other subsidiaries. This “seamless” compensation plan enables a member located in one country to enroll other members located in other countries where we are authorized to conduct our business. Currently, there are basically two ways in which our members can earn income:

through commissions paid on the accumulated bonus volume from product purchases made by their down-line members and customers; and


19



through retail profits on sales of products purchased by members at wholesale prices and resold at retail prices (for purchasers in some of our smaller markets and purchasers from our China subsidiary, sales are for personal consumption only and income may not be earned through retail profits).

Each of our products is designated a specified number of bonus volume points. Commissions are based on total personal and group bonus volume points per weekly sales period. Bonus volume points are essentially a percentage of a product’s wholesale price. As the member’s business expands from successfully enrolling other members who in turn expand their own businesses by selling product to other members, the member receives higher commissions from purchases made by an expanding down-line network. In some of our markets, to be eligible to receive commissions, a member may be required to make nominal monthly or other periodic purchases of our products. Certain of our subsidiaries do not require these nominal purchases for a member to be eligible to receive commissions. In determining commissions, the number of levels of down-line members included within the member’s commissionable group increases as the number of memberships directly below the member increases.

Under our current compensation plan, certain of our commission payouts may be limited to a hard cap dollar amount per week or a specific percentage of total product sales. In some markets, commissions may be further limited. In some markets, we also pay certain bonuses on purchases by up to three generations of personally sponsored members, as well as bonuses on commissions earned by up to seven generations of personally sponsored members. Members can also earn additional income, trips and other prizes in specific time-limited promotions and contests we hold from time to time. Member commissions are dependent on the sales mix and, for the first nine months of 2019 and 2018, represented 47% and 45%, respectively, of net sales. Occasionally, we make modifications and enhancements to our compensation plan to help motivate members, which can have an impact on member commissions. We may also enter into performance-based agreements for business or market development, which can result in additional compensation to specific members.

Selling, general and administrative expenses consist of administrative compensation and benefits, travel, credit card fees and assessments, professional fees, certain occupancy costs, and other corporate administrative expenses (including stock-based compensation). In addition, this category includes selling, marketing, and promotion expenses (including the costs of member training events and conventions that are designed to increase both product awareness and member recruitment). Because our various member conventions are not always held at the same time each year, interim period comparisons will be impacted accordingly.

The functional currency of our international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates. The resulting translation adjustments are recorded directly into accumulated other comprehensive income.

Sales by our foreign subsidiaries are generally transacted in the respective local currencies and are translated into U.S. dollars using average rates of exchange for each monthly accounting period to which they relate. Most of our product purchases from third-party manufacturers are transacted in U.S. dollars. Consequently, our sales and net earnings are affected by changes in currency exchange rates, with sales and earnings generally increasing with a weakening U.S. dollar and decreasing with a strengthening U.S. dollar.


20



Results of Operations 
 
The following table sets forth our operating results as a percentage of net sales for the periods indicated.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Net sales
100.0
 %
 
100.0
%
 
100.0
 %
 
100.0
%
Cost of sales
25.7

 
21.1

 
25.1

 
20.3

Gross profit
74.3

 
78.9

 
74.9

 
79.7

Operating expenses:
 
 
 
 
 
 
 
Commissions expense
43.2

 
46.8

 
47.3

 
44.8

Selling, general and administrative expenses
37.3

 
15.4

 
34.0

 
16.3

Total operating expenses
80.5

 
62.2

 
81.3

 
61.1

Income (loss) from operations
(6.2
)
 
16.7

 
(6.4
)
 
18.6

Other income, net
1.9

 
0.5

 
1.9

 
0.3

Income (loss) before income taxes
(4.3
)
 
17.2

 
(4.5
)
 
18.9

Income tax provision
2.9

 
1.0

 
0.2

 
2.0

Net income (loss)
(7.2
)%
 
16.2
%
 
(4.7
)%
 
16.9
%

Net Sales
 
The following table sets forth revenue by market for the periods indicated (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Americas1
$
1,445

 
8.5
%
 
$
1,970

 
4.2
%
 
$
4,353

 
7.3
%
 
$
5,361

 
3.6
%
Hong Kong2
13,575

 
79.7

 
41,447

 
88.1

 
48,465

 
81.0

 
133,681

 
88.9

China
525

 
3.1

 
1,698

 
3.6

 
2,138

 
3.6

 
5,510

 
3.7

Taiwan
649

 
3.8

 
935

 
2.0

 
2,340

 
3.9

 
2,933

 
1.9

South Korea
98

 
0.6

 
133

 
0.3

 
288

 
0.5

 
392

 
0.3

Japan
47

 
0.3

 
51

 
0.1

 
141

 
0.2

 
160

 
0.1

Singapore
13

 
0.1

 
52

 
0.1

 
43

 
0.1

 
134

 
0.1

Malaysia
51

 
0.3

 
216

 
0.5

 
170

 
0.3

 
316

 
0.2

Russia and Kazakhstan
244

 
1.4

 
184

 
0.4

 
662

 
1.1

 
626

 
0.4

Europe
343

 
2.0

 
357

 
0.7

 
1,017

 
1.7

 
1,207

 
0.8

India
33


0.2






162


0.3





Total
$
17,023

 
100.0
%
 
$
47,043

 
100.0
%
 
$
59,779

 
100.0
%
 
$
150,320

 
100.0
%
1 United States, Canada, Mexico and Peru
2 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors” in this report and in our most recent Annual Report on Form 10-K.
 

21



Net sales were $17.0 million for the three months ended September 30, 2019 compared with $47.0 million for the comparable period a year ago, a decrease of $30.0 million, or 64%.  Hong Kong net sales, substantially all of which were shipped to members residing in China, decreased $27.9 million, or 67%, over the comparable period a year ago. Our revenue decrease resulted from the continued impact of the comprehensive 100-day campaign in China mentioned above, as we voluntarily decided in January 2019 to temporarily suspend our member activities, such as product roadshows, product trainings and larger company-sponsored events in China. While the 100-day period technically expired in mid-April, the operating environment in China remains restrictive and adversely impacted our performance during the third quarter as compared with the same period last year. Additionally, we believe that our decision to curtail the number and scope of meetings and other events for our members in Hong Kong, including shifting our semi-annual Global Ambassador Academy from the third quarter of last year in Hong Kong to the fourth quarter of this year in Macau contributed to reduced net sales. Consequently, net sales were $59.8 million for the nine months ended September 30, 2019 compared with $150.3 million for the comparable period a year ago, a decrease of $90.5 million, or 60%.  Hong Kong net sales decreased $85.2 million, or 64%, over the comparable period a year ago.

Outside of our Hong Kong business, net sales decreased $2.1 million, or 38%, over the comparable three month period a year ago, driven largely by a 69% decrease in our China e-commerce business, which was also indirectly impacted by the 100-day campaign and our temporary suspension of activities. Over the comparable nine month period a year ago, net sales outside of our Hong Kong business decreased $5.3 million, or 32%, driven largely by a 61% decrease in our China e-commerce business.

As of September 30, 2019, deferred revenue was $3.3 million, which primarily consisted of $1.2 million pertaining to unshipped product orders and $2.0 million pertaining to auto ship advances.
 
Gross Profit
 
Gross profit was 74.3% of net sales for the three months ended September 30, 2019 compared with 78.9% of net sales for the three months ended September 30, 2018, and 74.9% of net sales for the nine months ended September 30, 2019 compared with 79.7% of net sales for the nine months ended September 30, 2018. The gross profit margin percentage decrease for both the three and nine month periods ended September 30, 2019 was primarily attributable to higher logistics costs. The three month period decrease was further impacted by an increase in the obsolescence reserve, while the nine month period decrease was also due to product promotions, specifically an AquaPur Water Purifier promotion during the first quarter of 2019.

Commissions
 
Commissions were 43.2% of net sales for the three months ended September 30, 2019, compared with 46.8% of net sales for the three month period ended September 30, 2018, and 47.3% of net sales for the nine months ended September 30, 2019, compared with 44.8% for the comparable period a year ago. The decrease as a percentage of net sales for the three month period largely resulted from lower estimated costs for on-going cash and other incentive programs and cost savings on incentive trips that occurred during the third quarter of 2019, partially offset by the cost of a special incentive program. The increase as a percentage of net sales for the nine month period was largely due to multiple special incentive programs, partially offset by lower estimated costs for on-going cash and other incentive programs and cost savings on incentive trips that occurred during the third quarter of 2019.
 
Selling, General and Administrative Expenses
 
Selling, general and administrative expenses were $6.4 million for the three months ended September 30, 2019 compared with $7.3 million in the same period a year ago. For the nine months ended September 30, 2019, selling, general and administrative expenses were $20.3 million compared with $24.5 million for the comparable period a year ago. The decrease in selling, general and administrative expenses during the 2019 three-month period as compared to the 2018 period is primarily due to a decrease in event costs because, as mentioned above, our semi-annual Global Ambassador Academy event was held in the fourth quarter (October 2019) instead of the third quarter like last year. The decrease in selling, general and administrative expenses during the 2019 nine-month period as compared to the 2018 period is mainly due to a decrease in employee-related costs, credit card fees and event costs, partially offset by an increase in professional fees.


22



Income Taxes

An income tax provision of $502,000 and $467,000 was recognized during the three month periods ended September 30, 2019 and 2018, respectively. An income tax provision of $120,000 was recognized for the nine months ended September 30, 2019 compared with $3.0 million for the comparable period a year ago. The decrease for both periods is due primarily to a smaller forecasted operating profit in foreign jurisdictions during 2019. As a result, the Global Intangible Low-Tax Income (“GILTI”) inclusion, which subjects U.S. taxpayers owning at least 10% of a foreign controlled corporation to current taxation on the earnings and profits of the foreign corporation, decreased as compared to the same periods in 2018. Although a pre-tax net loss was incurred for the three and nine months ended September 30, 2019, income is projected in some foreign jurisdictions for 2019, resulting in an overall tax provision that is partially offset by U.S. federal and state tax benefits.

Liquidity and Capital Resources
 
At September 30, 2019, our cash and cash equivalents totaled $101.1 million. Total cash and cash equivalents decreased by $31.5 million from December 31, 2018 to September 30, 2019, primarily due to the net loss incurred, the payment of prior year accrued commissions, stock repurchases and dividends paid during the year. We consider all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. As of September 30, 2019, we had $83.4 million in available-for-sale investments classified as cash equivalents. In addition, cash and cash equivalents included $8.7 million held in banks located within China subject to foreign currency controls.

As of September 30, 2019, the ratio of current assets to current liabilities was 4.29 to 1.00 and we had $89.0 million of working capital. Working capital as of September 30, 2019 decreased $18.1 million compared to our working capital as of December 31, 2018, due primarily to the decrease in cash and cash equivalents during the nine months ended September 30, 2019 as stated above, as well as the $1.7 million of operating lease liabilities recognized on the balance sheet at September 30, 2019 due to the adoption of the new lease accounting standard effective January 1, 2019.
 
Cash used in operations was $18.7 million for the first nine months of 2019 compared with $25.3 million cash provided by operations in the comparable period of 2018. The decrease in operating cash flows resulted primarily from the net loss incurred and the decrease in accrued commissions.
 
Cash flows used in investing activities totaled $181,000 and $176,000 during the first nine months of 2019 and 2018, respectively.
 
Cash flows used in financing activities during the first nine months of 2019 totaled $12.3 million. On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and are made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued.

On May 16, 2019, the Company’s Board of Directors authorized the Company to proceed with the purchase of up to $8.0 million in shares of common stock under the foregoing stock repurchase program. In connection therewith, the Company was advised that George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding shares of common stock, would participate in the stock repurchase program on a basis roughly proportional to his family’s ownership interest. During May 2019, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market. The stock repurchases, which included both open market purchases and the purchase of shares from Mr. Broady, resulted in the Company purchasing a total of 612,729 shares of its common stock for an aggregate purchase price of $6.7 million, plus transaction costs. On August 6, 2019, the Company’s Board of Directors authorized the Company to proceed with further purchases under the foregoing stock repurchase program. During August and September 2019, the Company purchased a total of 383,127 shares of common stock in the open market for an aggregate purchase price of $2.9 million, plus transaction costs. As of September 30, 2019, $22.4 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.

Cash flows used in financing activities during the first nine months of 2019 also included the following dividend payments (in thousands, except per share amounts):


23



Declaration Date
 
Per Share
 
Amount
 
Record Date
 
Payment Date
January 27, 2019 (special)
 
0.08

 
$
912

 
March 5, 2019
 
March 15, 2019
January 27, 2019
 
0.16

 
$
1,824

 
March 5, 2019
 
March 15, 2019
 
 
$
0.24

 
$
2,736

 
 
 
 

On August 9, 2019, the Company granted 1,117,485 shares of restricted stock under the 2016 Plan to certain employees for the purpose of further aligning their interests with those of its stockholders and settling unpaid cash incentives of $7.9 million under the 2014 Long-Term Incentive Plan with respect to performance periods that concluded on or prior to December 31, 2018.

Subsequent to September 30, 2019, on October 29, 2019, the Board of Directors declared a special cash dividend of $0.40 on each share of common stock outstanding. Such dividends are payable on November 29, 2019 to stockholders of record on November 19, 2019. Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.

Cash flows used in financing activities during the first nine months of 2018 consisted solely of dividend payments totaling $27.6 million.

We believe that our existing internal liquidity, supported by cash on hand and cash flows from operations should be adequate to fund normal business operations and address our financial commitments for the foreseeable future.
 
We do not have any significant unused sources of liquid assets. If necessary, we may attempt to generate more funding from the capital markets, but currently we do not believe that will be necessary.

Our priority is to focus our resources on investing in our most important markets, which we consider to be Greater China and countries where our existing members may have the connections to recruit prospects and sell our products, such as Southeast Asia, India, South America and Europe. We will continue to invest in our Mainland China entity for such purposes as establishing China-based manufacturing capabilities, increasing public awareness of our brand and our products, sourcing more Chinese-made products, building a chain of service stations, opening additional Healthy Lifestyle Centers or branch offices, adding local staffing and other requirements for a China direct selling license application.
 
Critical Accounting Policies and Estimates 
 
A summary of our significant accounting policies is provided in Note 1 of the Notes to Consolidated Financial Statements in “Item 8. Financial Statements and Supplementary Data” of our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on April 26, 2019. The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.
 
Critical accounting policies and estimates are defined as both those that are material to the portrayal of our financial condition and results of operations and as those that require management’s most subjective judgments.  Management believes our critical accounting policies and estimates are those related to revenue recognition, as well as those used in the determination of liabilities related to member commissions and income taxes.
 
Revenue Recognition. All revenue is recognized when the performance obligations under a contract are satisfied. Product sales are recorded when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon our delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” We primarily receive payment by credit card at the time members place orders. Our sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. Amounts received for unshipped product are recorded as deferred revenue. Such amounts totaled $1.2 million and $4.6 million at September 30, 2019 and December 31, 2018, respectively. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs.

24




Additionally, deferred revenue includes advances for auto ship orders. In certain markets, when a member’s cumulative commission income reaches a certain threshold, a percentage of the member’s weekly commission is held back as an advance and applied to an auto ship order once the accumulated amount of the advances is sufficient to pay for the pre-selected auto ship package of the member.  Such advances were $2.0 million and $1.9 million at September 30, 2019 and December 31, 2018, respectively.
 
Commissions. Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of our products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  We accrue commissions when earned and as the related revenue is recognized and pay commissions on product sales generally two weeks following the end of the weekly sales period.
 
Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  For each individual incentive, we estimate the total number of qualifiers as well as the expected per qualifier cost and accrue all costs associated with incentives throughout the qualification period. We regularly review and update, if necessary, the estimates of both qualifiers and cost as more information is obtained during the qualification period. Any resulting change in total cost is recognized over the remaining qualification period. Long-term promotions and incentives (lasting up to one year) can, in particular, result in uncertain ultimate cost. Accrued commissions, including the estimated cost of our international recognition incentive program and other supplemental programs, totaled $3.8 million and $12.5 million at September 30, 2019 and December 31, 2018, respectively.
 
Income Taxes.  Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory rates for the years in which the temporary differences are expected to be recovered or settled. We evaluate the probability of realizing the future benefits of any of our deferred tax assets and record a valuation allowance when we believe a portion or all of our deferred tax assets may not be realized. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Based on the technical merits of our tax position, tax benefits may be recognized if we determine it is more likely than not that our position will be sustained on examination by tax authorities. The complex nature of these estimates requires us to anticipate the likely application of tax law and make judgments on the largest benefit that has a greater than fifty percent likelihood of being realized prior to the completion and filing of tax returns for such periods. As of September 30, 2019, we do not have a valuation allowance against our U.S. deferred tax assets. We maintain a valuation allowance in certain foreign jurisdictions with an overall tax loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.

Provision for income taxes depends on the statutory tax rates in each of the jurisdictions in which we operate. As a result of capital return activities, we determined that a portion of our current undistributed foreign earnings are no longer deemed reinvested indefinitely by our non-U.S. subsidiaries. For state income tax purposes, we will continue to periodically reassess the needs of our foreign subsidiaries and update our indefinite reinvestment assertion as necessary. The Tax Act, enacted on December 22, 2017 by the U.S. government, required a one-time repatriation tax on certain un-repatriated earnings of foreign subsidiaries at a rate of 15.5% tax on post-1986 foreign earnings held in cash and an 8% rate on all other post-1986 earnings. Due to the adoption of a territorial tax regime, any foreign source portion of a qualified dividend received by a 10% U.S. corporate shareholder is exempt from U.S. federal tax, therefore resulting in any future repatriation having a minimal effect on our effective tax rate. To the extent that additional foreign earnings are not deemed permanently reinvested, we expect to recognize additional income tax provision at the applicable U.S. state corporate tax rate(s). As of September 30, 2019, we have accrued tax liabilities for earnings that we plan to repatriate out of accumulated earnings in future periods for state tax purposes only. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of September 30, 2019. During 2019, a loan was issued by the Company to one of its controlled foreign corporations that exceeded 50% of current earnings. This transaction is tax-free for federal income tax purposes and the state tax impact is insignificant to the consolidated financial statements.

We estimate what our effective tax rate will be for the full fiscal year at each interim reporting period and record a quarterly tax provision based on that estimated effective tax rate. Throughout the year that estimated rate may change based on variations in our business, changes in our corporate structure, changes in the geographic mix and amount of income, applicable tax laws and regulations, communications with tax authorities, as well as our estimated and actual level of annual pre-tax income. We adjust our income tax provision in the reporting period in which the change in our estimated rate occurs so that the year-to-date provision is consistent with the anticipated annual tax rate.


25



Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
Not applicable under smaller reporting company disclosure rules.

Item 4. CONTROLS AND PROCEDURES
 
Disclosure Controls and Procedures

Management, with the participation of the Company’s principal executive officer and principal financial officer, evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of September 30, 2019. The Company’s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to management, including the Company’s principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, the principal executive officer and principal financial officer concluded that, due to a material weakness in internal control over financial reporting described in Part II, Item 9A of our Annual Report on Form 10-K for the year ended December 31, 2018, our disclosure controls and procedures were not effective as of September 30, 2019.

Changes in Internal Control over Financial Reporting

Other than with respect to the remediation efforts discussed below, there were no changes in internal control over financial reporting that occurred during the fiscal quarter ended September 30, 2019 that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

Remediation Efforts to Address Material Weakness

Management, with oversight from the Audit Committee, implemented a plan intended to remediate the material weakness identified as of December 31, 2018 related to the Company’s review of shipment documentation provided by its third-party logistics (“3PL”) facilities. Amongst other enhancements of controls, the remediation plan included the following:

Obtaining and documenting a sufficient sample of product orders during each quarterly period and ensuring that the underlying shipment documentation agrees with the shipment date as provided by the 3PLs; and

Review of monthly deferred revenue reports by logistics staff to ensure unshipped items are validated.

During the third quarter of 2019, we completed testing of these and other controls related to the control environment which led to the material weakness, and we are currently evaluating the results of our testing. We expect that the remediation of this material weakness will be fully complete during the fourth quarter of 2019.


26



PART II — OTHER INFORMATION
 
Item 1. LEGAL PROCEEDINGS

Securities Class Action

On January 8, 2019, the Company and its two executive officers were named in a putative securities class action filed in the United States District Court for the Central District of California, captioned Kauffman v. Natural Health Trends Corp., Case No. 2:19-cv-00163.  The complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between April 27, 2016 and January 5, 2019, inclusive, under (i) Section 10(b) of the Securities Exchange Act of 1934 (“Exchange Act”) and Rule 10b-5 promulgated thereunder against the Company and Chris T. Sharng and Timothy S. Davidson (together, the “Individual Defendants”), and (ii) Section 20(a) of the Exchange Act against the Individual Defendants. The complaint alleges, in part, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multilevel marketing business.  The complaint seeks an indeterminate amount of damages, plus interest and costs. On May 3, 2019, the court issued an order appointing Xia Yang as lead plaintiff and appointing The Rosen Law Firm, P. A. as lead counsel. On June 3, 2019, lead plaintiff filed an amended complaint. On June 27, 2019, the parties filed a joint stipulation seeking to postpone briefing on defendants’ motion to dismiss to allow the parties to continue ongoing discussions, which stipulation was entered by the court on July 1, 2019.  On September 6, 2019, Defendants filed a motion to dismiss the amended complaint, which plaintiff opposed on October 16, 2019.  Defendants’ reply in support of their motion to dismiss was filed on November 4, 2019, and a hearing on the motion is currently set for November 18, 2019.  Defendants believe that these claims are without merit and intend to vigorously defend against them.

Item 1A. RISK FACTORS
 
Our operations and financial results are subject to various risks and uncertainties, including those described in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2018, which could adversely affect our business, financial condition, results of operations, cash flows, and the trading price of our common stock. There have been no material changes to our risk factors since our Annual Report on Form 10-K for the year ended December 31, 2018, except that we are now adding the following risk factor:

Our Hong Kong operations are being adversely affected by recent political and social developments in Hong Kong, and the negative impact on our operations and financial performance could continue or intensify.

Our headquarters and a majority of our employees are based in Hong Kong, and our Hong Kong subsidiary generates a substantial portion of our overall business. Hong Kong has recently experienced significant political unrest and social strife, including a series of large-scale protests. Hong Kong has historically served as a key location for meetings and events for our members, but these developments recently led us to curtail the number and scope of such meetings and events. These meetings and events are an important component of our product marketing and distribution efforts and we believe that this curtailment has negatively affected our operations and financial performance. If current conditions continue or further deteriorate, we anticipate that our business, financial condition and results of operations will be adversely affected.


27



Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

(c)   Purchases of Equity Securities by the Issuer and Affiliated Purchasers
 
A summary of the Company’s purchases of shares of its common stock during the three months ended September 30, 2019 is as follows:
Period
 
Total Number of Shares Purchased (a)
 
Average Price Paid Per Share
 
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (b)
 
Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs (c)
(in thousands)
July 1-31, 2019
 

 
$

 

 
$
29,640

August 1-31, 2019
 
232,489

 
$
7.40

 
232,489

 
$
27,920

September 1-30, 2019
 
150,638

 
$
7.68

 
150,638

 
$
26,762

 
(a)
The shares were purchased in both open market transactions and directly from George K. Broady, a director and beneficial owner of more than 5% of the Company’s outstanding shares of common stock.

(b)
On January 12, 2016, the Board of Directors authorized an increase to our stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that our earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, we may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require us to acquire a specific number of shares, and may be suspended from time to time or discontinued. On May 16, 2019, the Board of Directors authorized the Company to proceed with the purchase of up to $8.0 million in shares of common stock under the foregoing stock repurchase program. During May 2019, we purchased a total of 612,729 shares of our common stock for an aggregate purchase price of $6.7 million, plus transaction costs, under the stock repurchase program. On August 6, 2019, the Company’s Board of Directors authorized the Company to proceed with purchases under the foregoing stock repurchase program. During August and September 2019, the Company purchased a total of 383,127 shares of common stock for an aggregate purchase price of $2.9 million, plus transaction costs
 
(c)
As of September 30, 2019, $26.8 million of the $70.0 million stock repurchase program first approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases. The after-tax equivalent remaining available is $22.4 million (see Note 6 to the consolidated financial statements).

Item 3. DEFAULTS UPON SENIOR SECURITIES
 
None.
 
Item 4. MINE SAFETY DISCLOSURES
 
Not applicable.
 
Item 5. OTHER INFORMATION
 
None.
 

28



Item 6. EXHIBITS
 
Exhibit
Number
 
 
Exhibit Description
 
 
 
10.1
 
31.1
 
31.2
 
32.1
 
101.INS
 
Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH
 
XBRL Taxonomy Extension Schema
101.CAL
 
XBRL Taxonomy Extension Calculation
101.DEF
 
XBRL Taxonomy Extension Definition
101.LAB
 
XBRL Taxonomy Extension Labels
101.PRE
 
XBRL Taxonomy Extension Presentation

29



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
NATURAL HEALTH TRENDS CORP.
 
 
 
 
Date: November 5, 2019
/s/ Timothy S. Davidson
 
 
Timothy S. Davidson
 
 
Senior Vice President and Chief Financial Officer
 
 
(Principal Financial Officer)
 

30



EXHIBIT INDEX
 
Exhibit
Number
 
Exhibit Description
 
 
 
10.1
 
31.1
 
31.2
 
32.1
 
101.INS
 
Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH
 
XBRL Taxonomy Extension Schema
101.CAL
 
XBRL Taxonomy Extension Calculation
101.DEF
 
XBRL Taxonomy Extension Definition
101.LAB
 
XBRL Taxonomy Extension Labels
101.PRE
 
XBRL Taxonomy Extension Presentation

31
EX-31.1 2 ex31-1.htm EXHIBIT 31.1 Exhibit


EXHIBIT 31.1
 
CERTIFICATION
 
I, Chris T. Sharng, certify that:
 
1. I have reviewed this Quarterly Report on Form 10-Q of Natural Health Trends Corp.;
 
2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.  The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
 
5.  The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: November 5, 2019
/s/ Chris T. Sharng
 
 
Chris T. Sharng
 
 
President
 
 
(Principal Executive Officer)
 


EX-31.2 3 ex31-2.htm EXHIBIT 31.2 Exhibit


EXHIBIT 31.2
 
CERTIFICATION
 
I, Timothy S. Davidson, certify that:
 
1. I have reviewed this Quarterly Report on Form 10-Q of Natural Health Trends Corp.;
 
2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.  The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
 
5.  The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: November 5, 2019
/s/ Timothy S. Davidson
 
 
Timothy S. Davidson
 
 
Senior Vice President and Chief Financial Officer
 
 
(Principal Financial Officer)
 


EX-32.1 4 ex32-1.htm EXHIBIT 32.1 Exhibit


EXHIBIT 32.1
 

CERTIFICATIONS PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of Natural Health Trends Corp. (the “Company”) on Form 10-Q for the period ended September 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Chris T. Sharng, the Principal Executive Officer, and Timothy S. Davidson, the Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
 
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: November 5, 2019
/s/ Chris T. Sharng
 
 
Chris T. Sharng
 
 
President
 
 
(Principal Executive Officer)
 
 
 
 
 
 
 
Date: November 5, 2019
/s/ Timothy S. Davidson
 
 
Timothy S. Davidson
 
 
Senior Vice President and Chief Financial Officer
 
 
(Principal Financial Officer)
 
 
The foregoing certifications are not deemed filed with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.


EX-101.SCH 5 nhtc-20190930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2104100 - Disclosure - BALANCE SHEET COMPONENTS link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - BALANCE SHEET COMPONENTS (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - BALANCE SHEET COMPONENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2409401 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1004501 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover page link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - FAIR VALUE MEASUREMENTS - Available-for-Sale Investments Included in Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 2407405 - Disclosure - LEASES - Annual Scheduled Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2407405 - Disclosure - LEASES - Annual Scheduled Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - LEASES - Components of Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - LEASES - Weighted-average Remaining Lease Term and Discount Rate (Details) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION (Policies) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - REVENUE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - REVENUE - Net Sales by Product and Service (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - REVENUE - Revenue by Market (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - STOCKHOLDERS' EQUITY - Cash Dividend Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - STOCKHOLDERS' EQUITY - Changes in Accumulated Other Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - SUBSEQUENT EVENT link:presentationLink link:calculationLink link:definitionLink 2411401 - Disclosure - SUBSEQUENT EVENT (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 nhtc-20190930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 nhtc-20190930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 nhtc-20190930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Balance Sheet Components [Abstract] Balance Sheet Components [Abstract] BALANCE SHEET COMPONENTS Supplemental Balance Sheet Disclosures [Text Block] Equity [Abstract] Schedule of Company's Cash Dividend Activity Dividends Declared [Table Text Block] Schedule of Company's Restricted Stock Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Schedule of Changes in Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Statement of Comprehensive Income [Abstract] Net income (loss) Net Income (Loss) Attributable to Parent Other comprehensive income (loss), net of tax: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Unrealized gains on available-for-sale securities Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Additional Balance Sheet Components Schedule of Additional Balance Sheet Components [Table Text Block] Schedule of Additional Balance Sheet Components [Table Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Title of Individual [Axis] Title of Individual [Axis] Title of Individual [Domain] Title of Individual [Domain] Director Director [Member] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Restricted Stock Restricted Stock [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2016 Plan Equity Incentive 2016 Plan [Member] Equity Incentive 2016 Plan Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock repurchase program, amount authorized Stock Repurchase Program, Authorized Amount Percentage of common stock outstanding (more than) Common Stock, Percentage of Beneficial Stock Outstanding Common Stock, Percentage of Beneficial Stock Outstanding Total purchase price of common stock repurchased Treasury Stock, Value, Acquired, Cost Method Repurchase of common stock (in shares) Treasury Stock, Shares, Acquired Aggregate price of common stock repurchased Payments for Repurchase of Common Stock Stock repurchase program, amount available for future purchases Stock Repurchase Program, Remaining Authorized Repurchase Amount Number of shares authorized under the plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of shares available for issuance under the plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Number of shares granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Total settling fiscal performance incentive Stock Issued During Period, Value, Restricted Stock Award, Gross Award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Inventories Inventory, Net Other current assets Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Goodwill Goodwill Restricted cash Restricted Cash, Noncurrent Deferred tax asset Deferred Income Tax Assets, Net Other assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued commissions Accrued Liabilities, Current Other accrued expenses Other Accrued Liabilities, Current Deferred revenue Contract with Customer, Liability, Current Amounts held in eWallets Capitalized Contract Costs, Liability, Current Capitalized Contract Costs, Liability, Current Operating lease liabilities Operating Lease, Liability, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Income taxes payable Accrued Income Taxes, Noncurrent Deferred tax liability Deferred Income Tax Liabilities, Net Long-term incentive Deferred Compensation Cash-based Arrangements, Liability, Classified, Noncurrent Operating lease liabilities Operating Lease, Liability, Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 9) Commitments and Contingencies Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding Preferred Stock, Value, Issued Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at September 30, 2019 and December 31, 2018 Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Retained earnings Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Treasury stock, at cost; 1,459,090 and 1,603,322 shares at September 30, 2019 and December 31, 2018, respectively Treasury Stock, Value Total stockholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ equity Liabilities and Equity Leases [Abstract] Remainder of 2019 Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2020 Lessee, Operating Lease, Liability, Payments, Due Year Two 2021 Lessee, Operating Lease, Liability, Payments, Due Year Three 2022 Lessee, Operating Lease, Liability, Payments, Due Year Four 2023 Lessee, Operating Lease, Liability, Payments, Due Year Five Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total lease payments Lessee, Operating Lease, Liability, Payments, Due Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Present value of lease liabilities Operating Lease, Liability Weighted-average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Statement of Stockholders' Equity [Abstract] Dividends declared (in dollars per share) Common Stock, Dividends, Per Share, Declared Revenue Recognition [Abstract] Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] Americas Americas [Member] Hong Kong HONG KONG China CHINA Taiwan TAIWAN, PROVINCE OF CHINA South Korea KOREA, REPUBLIC OF Japan JAPAN Singapore SINGAPORE Malaysia MALAYSIA Russia and Kazakhstan Russia and Kazakhstan [Domain] Russia and Kazakhstan [Domain] Europe Europe [Member] India INDIA Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Sales Revenue, Net Revenue Benchmark [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Geographic Concentration Risk Geographic Concentration Risk [Member] Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Net sales Revenue from Contract with Customer, Excluding Assessed Tax Percentage Concentration Risk, Percentage Income Tax Disclosure [Abstract] Tax Credit Carryforward [Table] Tax Credit Carryforward [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Foreign Tax Authority Foreign Tax Authority [Member] Tax Credit Carryforward [Line Items] Tax Credit Carryforward [Line Items] Net operating loss carryforwards Operating Loss Carryforwards Organization, Consolidation and Presentation of Financial Statements [Abstract] NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION Business Description and Basis of Presentation [Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Rolling Hills Estates, California Rolling Hills Estates, California [Member] Rolling Hills Estates, California Monterey Park, California Monterey Park, California [Member] Monterey Park, California Richmond, British Columbia Richmond, British Columbia [Member] Richmond, British Columbia Metuchen, New Jersey Metuchen, New Jersey [Member] Metuchen, New Jersey Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Leased area (sq ft) Lessee, Leased Area Lessee, Leased Area Number of leased branches Lessee, Number of Branches Lessee, Number of Branches Number of leased service stations Lessee, Number of Service Stations Lessee, Number of Service Stations Cash paid for amounts included in the measurement of operating leases liabilities Operating Lease, Payments Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Foreign Currency Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Unrealized Gains/(Losses) on Available-For-Sale Investments AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Total AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Balance, December 31, 2018 Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Balance, September 30, 2019 Fair Value Disclosures [Abstract] Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents Cash and Cash Equivalents [Member] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Money market funds Money Market Funds [Member] Time deposits Bank Time Deposits [Member] Municipal debt securities Municipal Bonds [Member] Corporate debt securities Corporate Debt Securities [Member] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Adjusted Cost Available-for-sale Securities, Amortized Cost Basis Gross Unrealized Losses Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax Fair Value Available-for-sale Securities Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation Noncash lease expense Lessee, Non-Cash Lease Expense Lessee, Non-Cash Lease Expense Deferred income taxes Deferred Income Tax Expense (Benefit), Excluding Effects of Foreign Exchange Deferred Income Tax Expense (Benefit), Excluding Effects of Foreign Exchange Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Inventories Increase (Decrease) in Inventories Other current assets Increase (Decrease) in Other Current Assets Other assets Increase (Decrease) in Other Noncurrent Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued commissions Increase (Decrease) in Accrued Liabilities Other accrued expenses Increase (Decrease) in Other Accrued Liabilities Deferred revenue Increase (Decrease) in Contract with Customer, Liability Amounts held in eWallets Increase (Decrease) in Capitalized Contract Cost Liability Increase (Decrease) in Capitalized Contract Cost Liability Operating lease liabilities Increase (Decrease) in Operating Lease Liabilities Increase (Decrease) in Operating Lease Liabilities Income taxes payable Increase (Decrease) in Income Taxes Payable Other current liabilities Increase (Decrease) in Other Current Liabilities Long-term incentive Increase (Decrease) in Deferred Compensation Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Repurchase of common stock Dividends paid Payments of Dividends Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rates on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION: Noncash Investing and Financing Items [Abstract] Issuance of treasury stock for employee awards, net Stock Issued Right-of-use assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Special cash dividend declared (in dollars per share) Common Stock, Special Dividends, Per Share, Declared Common Stock, Special Dividends, Per Share, Declared Related Party Transactions [Abstract] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] BHS Broady Health Sciences [Member] Represents Broady Health Sciences. Aberdeen The Aberdeen Group, LLC [Member] The Aberdeen Group, LLC Broady Trust The George K. Broady 2012 Irrevocable Trust (“Broady Trust”) [Member] The George K. Broady 2012 Irrevocable Trust (“Broady Trust”) Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Affiliated Entity Affiliated Entity [Member] Ownership [Axis] Ownership [Axis] Ownership [Domain] Ownership [Domain] Sharng Holdings Sharng Holdings [Member] Sharng Holdings Related Party Transaction [Axis] Related Party Transaction [Axis] Related Party Transaction [Domain] Related Party Transaction [Domain] Royalty Agreement and License Royalty Agreement and License [Member] Royalty Agreement and License Shipment of Apparel Products Shipment of Apparel Products [Member] Shipment of Apparel Products Stock Repurchase Agreement Stock Repurchase Agreement [Member] Stock Repurchase Agreement President and His Wife President and His Wife [Member] President and His Wife Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] ReStor ReStore [Member] Represents a product called ReStore™. Related Party Transaction [Line Items] Related Party Transaction [Line Items] Royalty expense Royalty Expense Number of days for termination notice Number Of Days Termination Notice Represents number of days termination notice. Number of product orders Number of Product Orders Number of Product Orders Amount of transaction with related party Related Party Transaction, Amounts of Transaction Ownership percentage by parent Noncontrolling Interest, Ownership Percentage by Parent Ownership percentage by unrelated third party Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Market-based fees paid Related Party Transaction, Other Revenues from Transactions with Related Party Ratio of number of common stock shares to be repurchased in off-the-market private transaction Stock Repurchase Program, Ratio of Number Shares Authorized To Be Repurchased In Private Transaction Stock Repurchase Program, Ratio of Number Shares Authorized To Be Repurchased In Private Transaction Earnings Per Share [Abstract] NET INCOME (LOSS) PER COMMON SHARE Earnings Per Share [Text Block] Condensed Balance Sheet Statement [Table] Condensed Balance Sheet Statement [Table] Cash Cash [Member] Cash equivalents Cash Equivalents [Member] Contract with Customer, Arrangement Type [Axis] Contract with Customer, Arrangement Type [Axis] Contract with Customer, Arrangement Type Contract with Customer, Arrangement Type [Domain] Contract with Customer, Arrangement Type [Domain] [Domain] for Contract with Customer, Arrangement Type Unshipped product Unshipped Product [Member] Represents unshipped product. Auto ship advances Auto Ship Advances [Member] Represents Auto Ship advances. Other Other Revenue [Member] Other Revenue Condensed Balance Sheet Statements, Captions [Line Items] Condensed Balance Sheet Statements, Captions [Line Items] Cash, cash equivalents and restricted cash: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract] Cash, cash equivalents and restricted cash Inventories: Inventory, Net [Abstract] Finished goods Inventory, Finished Goods, Gross Raw materials Inventory, Raw Materials and Supplies, Gross Reserve for obsolescence Inventory Valuation Reserves Inventories, net Other accrued expenses: Accrued Liabilities and Other Liabilities [Abstract] Sales returns Accrued Sales Returns Accrued Sales Returns Employee-related expense Accrued Employee Benefits, Current Warehousing, inventory-related and other Accrued Warehousing And Inventory Related Expense Accrued Warehousing And Inventory Related Expense Other accrued expenses Deferred revenue: Contract with Customer, Liability [Abstract] Deferred revenue Operating leases Operating Lease, Cost Short-term leases Short-term Lease, Cost Total lease cost Lease, Cost RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Special cash dividends paid, per share (in dollars per share) Common Stock, Special Dividends, Per Share, Cash Paid Common Stock, Special Dividends, Per Share, Cash Paid Cash dividends paid, per share (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid Special cash dividend paid Special Dividends, Common Stock, Cash Special Dividends, Common Stock, Cash Cash dividend paid Dividends, Cash Basic net income (loss) per common share: Earnings Per Share, Basic [Abstract] Net income (loss) available to common stockholders, Income (loss) (Numerator) Net Income (Loss) Available to Common Stockholders, Basic Net income (loss) available to common stockholders, Shares (Denominator) (in shares) Weighted Average Number of Shares Outstanding, Basic Net income (loss) available to common stockholders, Per Share Amount (in dollars per share) Earnings Per Share, Basic Effect of dilutive securities: Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract] Non-vested restricted stock, Shares (Denominator) (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Diluted net income per common share: Earnings Per Share, Diluted [Abstract] Net income (loss) available to common stockholders plus assumed conversions, Income (loss) (Numerator) Net Income (Loss) Available to Common Stockholders, Diluted Net income (loss) available to common stockholders plus assumed conversions, Shares (Denominator) (in shares) Weighted Average Number of Shares Outstanding, Diluted Net income (loss) available to common stockholders plus assumed conversions, Per Share Amount (in dollars per share) Earnings Per Share, Diluted Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive shares excluded from calculation of earnings per share in periods when losses are reported (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Revenue from Contract with Customer [Abstract] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Sales returns policy term Revenue From Contract With Customer, Sales Returns Policy Term Revenue From Contract With Customer, Sales Returns Policy Term Historical sales returns rates Revenue From Contract With Customers, Historical Sales Returns Percentage Revenue From Contract With Customers, Historical Sales Returns Percentage Actual sales returns rates Revenue From Contract With Customers, Sales Returns Percentage Revenue From Contract With Customers, Sales Returns Percentage Decrease in deferred revenue, revenue recognized Contract with Customer, Liability, Revenue Recognized Increase in deferred revenue from cash payments received Contract With Customer, Liability, Increase From Cash Receipts Contract With Customer, Liability, Increase From Cash Receipts STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] Product sales Product [Member] Freight and other Shipping and Handling [Member] Net sales Less: sales returns Contract with Customer, Refund Liability, Sales Returns Contract with Customer, Refund Liability, Sales Returns Schedule of Investments by Significant Category Included in Cash Equivalents Available-for-sale Securities [Table Text Block] Schedule of Components of Lease Cost, Weighted-average Remaining Lease Term and Discount Rate Lease, Cost [Table Text Block] Schedule of Annual Scheduled Operating Lease Payments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Reclassification Reclassification, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Concentration Concentration Risk, Credit Risk, Policy [Policy Text Block] Net Income (Loss) Per Share Earnings Per Share, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] ASU 2016-02 Accounting Standards Update 2016-02 [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] ROU assets INCOME TAXES Income Tax Disclosure [Text Block] Schedule of Revenue by Market Revenue from External Customers by Geographic Areas [Table Text Block] Schedule of Net Sales by Product and Service Revenue from External Customers by Products and Services [Table Text Block] Cover page. Document Type Document Type Document Quarterly Report Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, Country Entity Address, Country City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag LEASES Lessee, Operating Leases [Text Block] Commitments and Contingencies Disclosure [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Securities Class Action Securities Class Action [Member] Securities Class Action [Member] Executive Officers Executive Officer [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Number of defendants Loss Contingency, Number of Defendants Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Treasury stock, shares (in shares) Treasury Stock, Shares REVENUE Revenue from Contract with Customer [Text Block] Statement [Table] Statement [Table] Preferred Stock Preferred Stock [Member] Additional Paid-In Capital Additional Paid-in Capital [Member] Retained Earnings Retained Earnings [Member] Accumulated Other Comprehensive (Loss) Income Treasury Stock Treasury Stock [Member] Statement [Line Items] Statement [Line Items] Preferred stock, beginning balance (in shares) Common stock, beginning balance (in shares) Treasury stock, beginning balance (in shares) Stockholders' equity, beginning balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Common stock issued Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture Common stock issued (in shares) Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture Dividends declared Dividends Repurchase of common stock (in shares) Repurchase of common stock Preferred stock, ending balance (in shares) Common stock, ending balance (in shares) Treasury stock, ending balance (in shares) Stockholders' equity, ending balance COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Income Statement [Abstract] Cost of sales Cost of Goods and Services Sold Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Commissions expense Sales Commissions and Fees Selling, general and administrative expenses Selling, General and Administrative Expense Total operating expenses Operating Expenses Income (loss) from operations Operating Income (Loss) Other income, net Other Nonoperating Income (Expense) Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income tax provision Income Tax Expense (Benefit) Net income (loss) Net income (loss) per common share: Basic (in dollars per share) Diluted (in dollars per share) Weighted-average number of common shares outstanding: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Basic (in shares) Diluted (in shares) FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Nonvested at December 31, 2018 (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (in shares) Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Nonvested at September 30, 2019 (in shares) Wtd. Avg. Price at Date of Issuance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Nonvested at December 31, 2018 (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Nonvested at September 30, 2019 (in dollars per share) SUBSEQUENT EVENT Subsequent Events [Text Block] Schedule of Computation of Basic and Diluted Net Income (Loss) Per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] EX-101.PRE 9 nhtc-20190930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R29.htm IDEA: XBRL DOCUMENT v3.19.3
REVENUE - Revenue by Market (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Revenue from External Customer [Line Items]        
Net sales $ 17,023 $ 47,043 $ 59,779 $ 150,320
Sales Revenue, Net | Geographic Concentration Risk        
Revenue from External Customer [Line Items]        
Percentage 100.00% 100.00% 100.00% 100.00%
Americas        
Revenue from External Customer [Line Items]        
Net sales $ 1,445 $ 1,970 $ 4,353 $ 5,361
Americas | Sales Revenue, Net | Geographic Concentration Risk        
Revenue from External Customer [Line Items]        
Percentage 8.50% 4.20% 7.30% 3.60%
Hong Kong        
Revenue from External Customer [Line Items]        
Net sales $ 13,575 $ 41,447 $ 48,465 $ 133,681
Hong Kong | Sales Revenue, Net | Geographic Concentration Risk        
Revenue from External Customer [Line Items]        
Percentage 79.70% 88.10% 81.00% 88.90%
China        
Revenue from External Customer [Line Items]        
Net sales $ 525 $ 1,698 $ 2,138 $ 5,510
China | Sales Revenue, Net | Geographic Concentration Risk        
Revenue from External Customer [Line Items]        
Percentage 3.10% 3.60% 3.60% 3.70%
Taiwan        
Revenue from External Customer [Line Items]        
Net sales $ 649 $ 935 $ 2,340 $ 2,933
Taiwan | Sales Revenue, Net | Geographic Concentration Risk        
Revenue from External Customer [Line Items]        
Percentage 3.80% 2.00% 3.90% 1.90%
South Korea        
Revenue from External Customer [Line Items]        
Net sales $ 98 $ 133 $ 288 $ 392
South Korea | Sales Revenue, Net | Geographic Concentration Risk        
Revenue from External Customer [Line Items]        
Percentage 0.60% 0.30% 0.50% 0.30%
Japan        
Revenue from External Customer [Line Items]        
Net sales $ 47 $ 51 $ 141 $ 160
Japan | Sales Revenue, Net | Geographic Concentration Risk        
Revenue from External Customer [Line Items]        
Percentage 0.30% 0.10% 0.20% 0.10%
Singapore        
Revenue from External Customer [Line Items]        
Net sales $ 13 $ 52 $ 43 $ 134
Singapore | Sales Revenue, Net | Geographic Concentration Risk        
Revenue from External Customer [Line Items]        
Percentage 0.10% 0.10% 0.10% 0.10%
Malaysia        
Revenue from External Customer [Line Items]        
Net sales $ 51 $ 216 $ 170 $ 316
Malaysia | Sales Revenue, Net | Geographic Concentration Risk        
Revenue from External Customer [Line Items]        
Percentage 0.30% 0.50% 0.30% 0.20%
Russia and Kazakhstan        
Revenue from External Customer [Line Items]        
Net sales $ 244 $ 184 $ 662 $ 626
Russia and Kazakhstan | Sales Revenue, Net | Geographic Concentration Risk        
Revenue from External Customer [Line Items]        
Percentage 1.40% 0.40% 1.10% 0.40%
Europe        
Revenue from External Customer [Line Items]        
Net sales $ 343 $ 357 $ 1,017 $ 1,207
Europe | Sales Revenue, Net | Geographic Concentration Risk        
Revenue from External Customer [Line Items]        
Percentage 2.00% 0.70% 1.70% 0.80%
India        
Revenue from External Customer [Line Items]        
Net sales $ 33 $ 0 $ 162 $ 0
India | Sales Revenue, Net | Geographic Concentration Risk        
Revenue from External Customer [Line Items]        
Percentage 0.20% 0.00% 0.30% 0.00%
XML 11 R25.htm IDEA: XBRL DOCUMENT v3.19.3
STOCKHOLDERS' EQUITY (Tables)
9 Months Ended
Sep. 30, 2019
Equity [Abstract]  
Schedule of Company's Cash Dividend Activity
The following table summarizes the Company’s cash dividend activity for the nine months ended September 30, 2019 (in thousands, except per share data):
Declaration Date
 
Per Share
 
Amount
 
Record Date
 
Payment Date
January 27, 2019 (special)
 
0.08

 
$
912

 
March 5, 2019
 
March 15, 2019
January 27, 2019
 
0.16

 
$
1,824

 
March 5, 2019
 
March 15, 2019
 
 
$
0.24

 
$
2,736

 
 
 
 

Schedule of Company's Restricted Stock Activity
The following table summarizes the Company’s restricted stock activity under the 2016 Plan:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2018
45,486

 
$
21.61

Granted
1,140,088

 
7.27

Vested
(125,405
)
 
11.07

Nonvested at September 30, 2019
1,060,169

 
7.44


Schedule of Changes in Accumulated Other Comprehensive Income (Loss)
The changes in accumulated other comprehensive loss by component for the first nine months of 2019 were as follows (in thousands):
 
Foreign Currency Translation Adjustment
 
Unrealized Gains/(Losses) on Available-For-Sale Investments
 
Total
Balance, December 31, 2018
$
(1,217
)
 
$
(33
)
 
$
(1,250
)
Other comprehensive income (loss)
(537
)
 
23

 
(514
)
Balance, September 30, 2019
$
(1,754
)
 
$
(10
)
 
$
(1,764
)

XML 12 R21.htm IDEA: XBRL DOCUMENT v3.19.3
REVENUE (Tables)
9 Months Ended
Sep. 30, 2019
Revenue Recognition [Abstract]  
Schedule of Revenue by Market
The following table sets forth revenue by market for the periods indicated (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Americas1
$
1,445

 
8.5
%
 
$
1,970

 
4.2
%
 
$
4,353

 
7.3
%
 
$
5,361

 
3.6
%
Hong Kong2
13,575

 
79.7

 
41,447

 
88.1

 
48,465

 
81.0

 
133,681

 
88.9

China
525

 
3.1

 
1,698

 
3.6

 
2,138

 
3.6

 
5,510

 
3.7

Taiwan
649

 
3.8

 
935

 
2.0

 
2,340

 
3.9

 
2,933

 
1.9

South Korea
98

 
0.6

 
133

 
0.3

 
288

 
0.5

 
392

 
0.3

Japan
47

 
0.3

 
51

 
0.1

 
141

 
0.2

 
160

 
0.1

Singapore
13

 
0.1

 
52

 
0.1

 
43

 
0.1

 
134

 
0.1

Malaysia
51

 
0.3

 
216

 
0.5

 
170

 
0.3

 
316

 
0.2

Russia and Kazakhstan
244

 
1.4

 
184

 
0.4

 
662

 
1.1

 
626

 
0.4

Europe
343

 
2.0

 
357

 
0.7

 
1,017

 
1.7

 
1,207

 
0.8

India
33

 
0.2

 

 

 
162

 
0.3

 

 

Total
$
17,023

 
100.0
%
 
$
47,043

 
100.0
%
 
$
59,779

 
100.0
%
 
$
150,320

 
100.0
%

1 United States, Canada, Mexico and Peru
2 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors” in this report and in our most recent Annual Report on Form 10-K.
Schedule of Net Sales by Product and Service
The Company’s net sales by product and service are as follows (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Product sales
$
15,732

 
$
44,434

 
$
56,355

 
$
142,258

Freight and other
1,468

 
3,365

 
4,713

 
10,550

Less: sales returns
(177
)
 
(756
)
 
(1,289
)
 
(2,488
)
Total net sales
$
17,023

 
$
47,043

 
$
59,779

 
$
150,320


XML 14 R40.htm IDEA: XBRL DOCUMENT v3.19.3
LEASES - Weighted-average Remaining Lease Term and Discount Rate (Details)
Sep. 30, 2019
Leases [Abstract]  
Weighted-average remaining lease term (in years) 3 years 2 months 12 days
Weighted-average discount rate 5.50%
XML 15 R44.htm IDEA: XBRL DOCUMENT v3.19.3
RELATED PARTY TRANSACTIONS (Details)
1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended
May 31, 2019
USD ($)
May 31, 2019
USD ($)
Feb. 28, 2013
Sep. 30, 2019
USD ($)
Sep. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
order
Sep. 30, 2018
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
May 16, 2019
Related Party Transaction [Line Items]                    
Aggregate price of common stock repurchased   $ 6,700,000   $ 2,900,000       $ 9,564,000 $ 0  
Director                    
Related Party Transaction [Line Items]                    
Percentage of common stock outstanding (more than)                   5.00%
BHS | Affiliated Entity | Royalty Agreement and License | ReStor                    
Related Party Transaction [Line Items]                    
Royalty expense         $ 19,000   $ 72,000 $ 75,000 $ 248,000  
Number of days for termination notice     120 days              
BHS | Affiliated Entity | Royalty Agreement and License | Director | ReStor                    
Related Party Transaction [Line Items]                    
Percentage of common stock outstanding (more than)       5.00% 5.00%     5.00%    
Aberdeen | Affiliated Entity | Shipment of Apparel Products                    
Related Party Transaction [Line Items]                    
Number of product orders | order           1        
Amount of transaction with related party           $ 7,100        
Ownership percentage by unrelated third party       20.00% 20.00%     20.00%    
Market-based fees paid               $ 420    
Aberdeen | Affiliated Entity | Shipment of Apparel Products | President and His Wife                    
Related Party Transaction [Line Items]                    
Ownership percentage by parent       40.00% 40.00%     40.00%    
Aberdeen | Affiliated Entity | Sharng Holdings | Shipment of Apparel Products                    
Related Party Transaction [Line Items]                    
Ownership percentage by parent       40.00% 40.00%     40.00%    
Broady Trust | Affiliated Entity | Stock Repurchase Agreement | Director                    
Related Party Transaction [Line Items]                    
Ratio of number of common stock shares to be repurchased in off-the-market private transaction 0.4105                  
Aggregate price of common stock repurchased $ 1,900,000                  
XML 17 R30.htm IDEA: XBRL DOCUMENT v3.19.3
REVENUE - Net Sales by Product and Service (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Disaggregation of Revenue [Line Items]        
Net sales $ 17,023 $ 47,043 $ 59,779 $ 150,320
Less: sales returns (177) (756) (1,289) (2,488)
Product sales        
Disaggregation of Revenue [Line Items]        
Net sales 15,732 44,434 56,355 142,258
Freight and other        
Disaggregation of Revenue [Line Items]        
Net sales $ 1,468 $ 3,365 $ 4,713 $ 10,550
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.19.3
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income (loss) $ (2,769) $ 25,476
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:    
Depreciation and amortization 290 332
Noncash lease expense 1,336 0
Deferred income taxes (3) 0
Changes in assets and liabilities:    
Inventories 4,104 (2,828)
Other current assets (1,674) 2,548
Other assets 2 (83)
Accounts payable (1,002) 967
Accrued commissions (8,683) 2,003
Other accrued expenses (1,779) 314
Deferred revenue (3,485) 26
Amounts held in eWallets (1,508) (930)
Operating lease liabilities (1,392)  
Income taxes payable (1,617) (2,201)
Other current liabilities (235) 438
Long-term incentive (333) (800)
Net cash provided by (used in) operating activities (18,748) 25,262
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property and equipment (181) (176)
Net cash used in investing activities (181) (176)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Repurchase of common stock (9,564) 0
Dividends paid (2,736) (27,644)
Net cash used in financing activities (12,300) (27,644)
Effect of exchange rates on cash, cash equivalents and restricted cash (428) (711)
Net decrease in cash, cash equivalents and restricted cash (31,657) (3,269)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period 135,651 138,478
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period 103,994 135,209
SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:    
Issuance of treasury stock for employee awards, net 8,289 $ 554
Right-of-use assets obtained in exchange for operating lease liabilities $ 5,058  
XML 19 R34.htm IDEA: XBRL DOCUMENT v3.19.3
STOCKHOLDERS' EQUITY - Cash Dividend Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
9 Months Ended
Mar. 15, 2019
Sep. 30, 2019
Equity [Abstract]    
Special cash dividends paid, per share (in dollars per share) $ 0.08  
Cash dividends paid, per share (in dollars per share) $ 0.16 $ 0.24
Special cash dividend paid $ 912  
Cash dividend paid $ 1,824 $ 2,736
XML 20 R38.htm IDEA: XBRL DOCUMENT v3.19.3
LEASES - Narrative (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
USD ($)
ft²
branch
service_station
Sep. 30, 2019
USD ($)
ft²
branch
service_station
Lessee, Lease, Description [Line Items]    
Cash paid for amounts included in the measurement of operating leases liabilities | $ $ 459 $ 1,500
Hong Kong    
Lessee, Lease, Description [Line Items]    
Leased area (sq ft) 9,600 9,600
Rolling Hills Estates, California    
Lessee, Lease, Description [Line Items]    
Leased area (sq ft) 4,900 4,900
Monterey Park, California    
Lessee, Lease, Description [Line Items]    
Leased area (sq ft) 2,400 2,400
Richmond, British Columbia    
Lessee, Lease, Description [Line Items]    
Leased area (sq ft) 1,600 1,600
Metuchen, New Jersey    
Lessee, Lease, Description [Line Items]    
Leased area (sq ft) 2,000 2,000
China    
Lessee, Lease, Description [Line Items]    
Number of leased branches | branch 9 9
Number of leased service stations | service_station 11 11
XML 21 R4.htm IDEA: XBRL DOCUMENT v3.19.3
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Income Statement [Abstract]        
Net sales $ 17,023 $ 47,043 $ 59,779 $ 150,320
Cost of sales 4,371 9,926 15,002 30,546
Gross profit 12,652 37,117 44,777 119,774
Operating expenses:        
Commissions expense 7,362 22,001 28,258 67,291
Selling, general and administrative expenses 6,354 7,269 20,296 24,484
Total operating expenses 13,716 29,270 48,554 91,775
Income (loss) from operations (1,064) 7,847 (3,777) 27,999
Other income, net 323 249 1,128 465
Income (loss) before income taxes (741) 8,096 (2,649) 28,464
Income tax provision 502 467 120 2,988
Net income (loss) $ (1,243) $ 7,629 $ (2,769) $ 25,476
Net income (loss) per common share:        
Basic (in dollars per share) $ (0.12) $ 0.67 $ (0.25) $ 2.25
Diluted (in dollars per share) $ (0.12) $ 0.67 $ (0.25) $ 2.25
Weighted-average number of common shares outstanding:        
Basic (in shares) 10,623 11,309 11,010 11,298
Diluted (in shares) 10,623 11,322 11,010 11,307
XML 22 R17.htm IDEA: XBRL DOCUMENT v3.19.3
COMMITMENTS AND CONTINGENCIES
9 Months Ended
Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES

On January 8, 2019, the Company and its two executive officers were named in a putative securities class action filed in the United States District Court for the Central District of California, captioned Kauffman v. Natural Health Trends Corp., Case No. 2:19-cv-00163. The complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between April 27, 2016 and January 5, 2019, inclusive, under (i) Section 10(b) of the Securities Exchange Act of 1934 (“Exchange Act”) and Rule 10b-5 promulgated thereunder against the Company and Chris T. Sharng and Timothy S. Davidson (together, the “Individual Defendants”), and (ii) Section 20(a) of the Exchange Act against the Individual Defendants. The complaint alleges, in part, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multilevel marketing business. The complaint seeks an indeterminate amount of damages, plus interest and costs. On May 3, 2019, the court issued an order appointing Xia Yang as lead plaintiff and appointing The Rosen Law Firm, P. A. as lead counsel. On June 3, 2019, lead plaintiff filed an amended complaint. On June 27, 2019, the parties filed a joint stipulation seeking to postpone briefing on defendants’ motion to dismiss to allow the parties to continue ongoing discussions, which stipulation was entered by the court on July 1, 2019.  On September 6, 2019, Defendants filed a motion to dismiss the amended complaint, which plaintiff opposed on October 16, 2019.  Defendants’ reply in support of their motion to dismiss was filed on November 4, 2019, and a hearing on the motion is currently set for November 18, 2019.  Defendants believe that these claims are without merit and intend to vigorously defend against them.

Since August 2016, the SEC has been conducting a non-public investigation to determine whether there have been violations of the federal securities laws relating to the trading of the Company’s securities. The Company has fully cooperated with the SEC and has and continues to provide documents in response to subpoenas. The SEC has expressly stated that its document requests should not be construed as an indication that any violation of law has occurred, or as a reflection upon any person, entity, or security. The amount of time needed to resolve this matter is uncertain, and the Company cannot predict the outcome or whether it will face additional governmental inquiries or other actions.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.19.3
FAIR VALUE MEASUREMENTS
9 Months Ended
Sep. 30, 2019
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS

As of September 30, 2019, cash and cash equivalents include the Company’s investments in municipal and corporate debt securities, money market funds, and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with the FASB Accounting Standards Codification (“ASC”) 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at September 30, 2019 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs.

The carrying amounts of the Company’s financial instruments, including cash and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.
 
Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.

Investments by significant category included in cash equivalents at the end of each period were as follows (in thousands):
 
 
September 30, 2019
 
December 31, 2018
 
Fair Value Level1
Adjusted Cost
 
Gross Unrealized Losses
 
Fair Value
 
Adjusted Cost
 
Gross Unrealized Losses
 
Fair Value
Money market funds
Level 1
$
30,810

 
$

 
$
30,810

 
$
3,281

 
$

 
$
3,281

Time deposits
Level 2
14,904

 

 
14,904

 
18,071

 

 
18,071

Municipal debt securities
Level 2
3,432

 
1

 
3,433

 
12,149

 
(7
)
 
12,142

Corporate debt securities
Level 2
34,266

 
(11
)
 
34,255

 
51,862

 
(26
)
 
51,836

Total investments
 
$
83,412

 
$
(10
)
 
$
83,402

 
$
85,363

 
$
(33
)
 
$
85,330

 
1 FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs that are not corroborated by market data.
XML 24 R1.htm IDEA: XBRL DOCUMENT v3.19.3
Cover page - shares
9 Months Ended
Sep. 30, 2019
Nov. 01, 2019
Cover page.    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2019  
Document Transition Report false  
Entity File Number 001-36849  
Entity Registrant Name NATURAL HEALTH TRENDS CORP.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 59-2705336  
Entity Address, Address Line One Units 1205-07, 12F  
Entity Address, Address Line Two Mira Place Tower A  
Entity Address, Address Line Three 132 Nathan Road  
Entity Address, City or Town Tsimshatsui  
Entity Address, Country HK  
City Area Code 852  
Local Phone Number 3107-0800  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol NHTC  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   11,520,324
Entity Central Index Key 0000912061  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2019  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 25 R39.htm IDEA: XBRL DOCUMENT v3.19.3
LEASES - Components of Lease Cost (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2019
Leases [Abstract]    
Operating leases $ 512 $ 1,544
Short-term leases 73 201
Total lease cost $ 585 $ 1,745
XML 26 R5.htm IDEA: XBRL DOCUMENT v3.19.3
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Statement of Comprehensive Income [Abstract]        
Net income (loss) $ (1,243) $ 7,629 $ (2,769) $ 25,476
Other comprehensive income (loss), net of tax:        
Foreign currency translation adjustment (584) (433) (537) (798)
Unrealized gains on available-for-sale securities 12 5 23 9
Comprehensive income (loss) $ (1,815) $ 7,201 $ (3,283) $ 24,687
XML 27 R31.htm IDEA: XBRL DOCUMENT v3.19.3
NET INCOME (LOSS) PER COMMON SHARE (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Basic net income (loss) per common share:        
Net income (loss) available to common stockholders, Income (loss) (Numerator) $ (1,243) $ 7,629 $ (2,769) $ 25,476
Net income (loss) available to common stockholders, Shares (Denominator) (in shares) 10,623,000 11,309,000 11,010,000 11,298,000
Net income (loss) available to common stockholders, Per Share Amount (in dollars per share) $ (0.12) $ 0.67 $ (0.25) $ 2.25
Effect of dilutive securities:        
Non-vested restricted stock, Shares (Denominator) (in shares) 0 13,000 0 9,000
Diluted net income per common share:        
Net income (loss) available to common stockholders plus assumed conversions, Income (loss) (Numerator) $ (1,243) $ 7,629 $ (2,769) $ 25,476
Net income (loss) available to common stockholders plus assumed conversions, Shares (Denominator) (in shares) 10,623,000 11,322,000 11,010,000 11,307,000
Net income (loss) available to common stockholders plus assumed conversions, Per Share Amount (in dollars per share) $ (0.12) $ 0.67 $ (0.25) $ 2.25
Restricted Stock        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive shares excluded from calculation of earnings per share in periods when losses are reported (in shares) 672,231   263,289  
XML 28 R9.htm IDEA: XBRL DOCUMENT v3.19.3
NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION
9 Months Ended
Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION

Nature of Operations 
 
Natural Health Trends Corp., a Delaware corporation (whether or not including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.

The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia, Thailand and Vietnam; South Korea; Japan; India; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.

Basis of Presentation 
 
The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2018 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on April 26, 2019.

Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.

Reclassification

Certain prior year amounts in the balance sheet have been reclassified to conform to current year presentation.

Recent Accounting Pronouncements

In February 2016, the FASB established Topic 842, Leases, by issuing ASU No. 2016-02, which requires lessees to recognize the rights and obligations created by leases on the balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-11, Targeted Improvements, ASU No. 2018-10, Codification Improvements to Topic 842, and ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842. The new standard establishes a right-of-use (ROU) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. Effective January 1, 2019, the Company adopted the new standard using the effective date as its date of initial application. The new standard provided a number of optional practical expedients in transition. The Company elected the “package of practical expedients”, which permits entities not to reassess under the new lease standard prior conclusions about lease identification, lease classification and initial direct costs. Upon adoption, the Company recognized operating lease liabilities on its balance sheet for $4.5 million, with corresponding ROU assets of the same amount based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases. See Note 7 for additional information.

In August 2018, the SEC issued Release No. 33-10532 that amends and clarifies certain financial reporting requirements. The principal change to the Company’s financial reporting is the requirement to disclose in interim periods on Form 10-Q the changes in stockholder’s equity as prescribed by Rule 3-04 of Regulation S-X.

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.
XML 29 R35.htm IDEA: XBRL DOCUMENT v3.19.3
STOCKHOLDERS' EQUITY - Narrative (Details) - USD ($)
1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended
Aug. 09, 2019
Feb. 01, 2019
May 31, 2019
Sep. 30, 2019
Sep. 30, 2019
Jun. 30, 2019
Sep. 30, 2019
Sep. 30, 2018
May 16, 2019
Apr. 07, 2016
Jan. 12, 2016
Jul. 28, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Stock repurchase program, amount authorized                 $ 8,000,000.0   $ 70,000,000.0 $ 15,000,000.0
Total purchase price of common stock repurchased     $ 4,700,000   $ 2,882,000 $ 6,682,000            
Repurchase of common stock (in shares)     612,729 383,127                
Aggregate price of common stock repurchased     $ 6,700,000 $ 2,900,000     $ 9,564,000 $ 0        
Stock repurchase program, amount available for future purchases       $ 22,400,000 $ 22,400,000   $ 22,400,000          
2016 Plan | Common Stock                        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Number of shares authorized under the plan (in shares)                   2,500,000    
Number of shares available for issuance under the plan (in shares)       1,219,583 1,219,583   1,219,583          
Restricted Stock | 2016 Plan                        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Number of shares granted (in shares) 1,117,485 22,603         1,140,088          
Total settling fiscal performance incentive $ 7,900,000 $ 377,000                    
Award vesting period   3 years                    
Director                        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Percentage of common stock outstanding (more than)                 5.00%      
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.19.3
INCOME TAXES
9 Months Ended
Sep. 30, 2019
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES

The effective income tax rate for the three and nine months ended September 30, 2019 was impacted by recording the effect of the Tax Cuts and Jobs Act (the “Tax Act”) enacted on December 22, 2017 by the U.S. government, which makes broad and complex changes to the Internal Revenue Code of 1986, as amended.

On December 22, 2017, the Securities and Exchange Commission staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provided a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740, Income Taxes. In accordance with the expiration of the SAB 118 measurement period, we completed the assessment of the income tax effect of the Tax Act for the year ended December 31, 2017 in the fourth quarter of tax year 2018. All adjustments recorded to the provisional amounts have been included as an adjustment to income tax expense.

As a result of the Tax Act, the Company could be subject to additional income tax expense due to the Global Intangible Low Taxed Income inclusion on current net income of greater than 10% owned controlled foreign corporations (“GILTI”). To determine the amount of GILTI inclusion, the Company must determine, in addition to other factors, the current earnings of controlled foreign corporations, as well as the amount of foreign taxes paid by the foreign entities. The law provides that corporate taxpayers may benefit from a 50% reduction in the GILTI inclusion which effectively reduces the 21% U.S. corporate tax rate on the foreign income to an effective rate of 10.5%. The 50% reduction, however, is limited if the U.S. shareholder has current domestic losses or is utilizing net operating losses. The GILTI inclusion further provides for a foreign tax credit in connection with the foreign taxes paid. The Company is not expected to have any GILTI inclusion for the year ended December 31, 2019.

As of September 30, 2019, the Company does not have a valuation allowance against its U.S. deferred tax assets. The Company analyzed all sources of available income and determined that they are more likely than not to realize the tax benefits of their deferred assets. As of September 30, 2019, any attributes generated from a U.S. federal net operating loss for the year ended December 31, 2019 are expected to be fully utilized.

As of September 30, 2019, the Company has a valuation allowance against certain foreign deferred tax assets. The Company is recording a valuation allowance in foreign jurisdictions with an overall net operating loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision. At December 31, 2018, the Company had foreign net operating loss carryforwards of approximately $1.2 million in various jurisdictions with various expirations.

As a result of capital return activities, the Company determined that a portion of its current undistributed foreign earnings is no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. For state income tax purposes, the Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable state corporate income tax rate. As of September 30, 2019, the Company has recorded a state deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods. Due to the Tax Act, repatriation from foreign subsidiaries will be offset with a dividends received deduction, resulting in little to no impact on federal tax expense. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of September 30, 2019. During 2019, a loan was issued by the Company to one of its controlled foreign corporations that exceeded 50% of current earnings. This transaction is tax-free for federal income tax purposes and the state tax impact is insignificant to the consolidated financial statements.

The Company and its subsidiaries file tax returns in the United States, California, New Jersey and Texas and various foreign jurisdictions. During the fourth quarter of 2018, the Company was notified that it was selected for audit of the 2016 tax year by the U.S. Internal Revenue Service. For purposes of this audit, fiscal years 2007 through 2016 are open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. No adjustments have been proposed at this time. The Company is no longer subject to state income tax examinations for years prior to 2014. No other jurisdictions are currently examining any income tax returns of the Company.
XML 31 R12.htm IDEA: XBRL DOCUMENT v3.19.3
BALANCE SHEET COMPONENTS
9 Months Ended
Sep. 30, 2019
Balance Sheet Components [Abstract]  
BALANCE SHEET COMPONENTS BALANCE SHEET COMPONENTS

The components of certain balance sheet amounts are as follows (in thousands):
 
September 30, 2019
 
December 31, 2018
Cash, cash equivalents and restricted cash:
 
 
 
Cash
$
17,711

 
$
47,323

Cash equivalents
83,402

 
85,330

 
101,113

 
132,653

Restricted cash
2,881

 
2,998

 
$
103,994

 
$
135,651

Inventories:
 
 
 
Finished goods
$
7,817

 
$
11,171

Raw materials
1,104

 
1,145

Reserve for obsolescence
(922
)
 
(151
)
 
$
7,999

 
$
12,165

Other accrued expenses:
 
 
 
Sales returns
$
290

 
$
801

Employee-related expense
1,998

 
4,051

Warehousing, inventory-related and other
1,104

 
1,269

 
$
3,392

 
$
6,121

Deferred revenue:
 
 
 
Unshipped product
$
1,171

 
$
4,574

Auto ship advances
1,983

 
1,876

Other
148

 
345

 
$
3,302

 
$
6,795


XML 32 R24.htm IDEA: XBRL DOCUMENT v3.19.3
FAIR VALUE MEASUREMENTS (Tables)
9 Months Ended
Sep. 30, 2019
Fair Value Disclosures [Abstract]  
Schedule of Investments by Significant Category Included in Cash Equivalents
Investments by significant category included in cash equivalents at the end of each period were as follows (in thousands):
 
 
September 30, 2019
 
December 31, 2018
 
Fair Value Level1
Adjusted Cost
 
Gross Unrealized Losses
 
Fair Value
 
Adjusted Cost
 
Gross Unrealized Losses
 
Fair Value
Money market funds
Level 1
$
30,810

 
$

 
$
30,810

 
$
3,281

 
$

 
$
3,281

Time deposits
Level 2
14,904

 

 
14,904

 
18,071

 

 
18,071

Municipal debt securities
Level 2
3,432

 
1

 
3,433

 
12,149

 
(7
)
 
12,142

Corporate debt securities
Level 2
34,266

 
(11
)
 
34,255

 
51,862

 
(26
)
 
51,836

Total investments
 
$
83,412

 
$
(10
)
 
$
83,402

 
$
85,363

 
$
(33
)
 
$
85,330

 
1 FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs that are not corroborated by market data.
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.19.3
NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION (Policies)
9 Months Ended
Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Basis of Presentation 
 
The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2018 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on April 26, 2019.

Principles of Consolidation
Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.
Reclassification
Reclassification

Certain prior year amounts in the balance sheet have been reclassified to conform to current year presentation.
Recent Accounting Pronouncements
Recent Accounting Pronouncements

In February 2016, the FASB established Topic 842, Leases, by issuing ASU No. 2016-02, which requires lessees to recognize the rights and obligations created by leases on the balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-11, Targeted Improvements, ASU No. 2018-10, Codification Improvements to Topic 842, and ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842. The new standard establishes a right-of-use (ROU) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. Effective January 1, 2019, the Company adopted the new standard using the effective date as its date of initial application. The new standard provided a number of optional practical expedients in transition. The Company elected the “package of practical expedients”, which permits entities not to reassess under the new lease standard prior conclusions about lease identification, lease classification and initial direct costs. Upon adoption, the Company recognized operating lease liabilities on its balance sheet for $4.5 million, with corresponding ROU assets of the same amount based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases. See Note 7 for additional information.

In August 2018, the SEC issued Release No. 33-10532 that amends and clarifies certain financial reporting requirements. The principal change to the Company’s financial reporting is the requirement to disclose in interim periods on Form 10-Q the changes in stockholder’s equity as prescribed by Rule 3-04 of Regulation S-X.

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.
Revenue Recognition

Revenue Recognition

All revenue is recognized when the performance obligations under a contract are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.
 
Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 5% of sales.  Sales returns were 2% of sales for each of the nine months ended September 30, 2019 and 2018, respectively.  No material changes in estimates have been recognized during the periods presented. See Note 4 for additional information.
 
The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.

Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.

Deferred Revenue

The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are considered a contract liability and are recorded as deferred revenue. The decrease in deferred revenue for the three months ended September 30, 2019 is primarily due to $1.2 million of revenue recognized during the quarter that was included in deferred revenue as of June 30, 2019 offset by $1.1 million of cash payments received for unshipped product during the third quarter. See Note 4 for additional information.

Disaggregation of Revenue

The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through an engagement of a third-party service provider.

Arrangements with Multiple Performance Obligations

The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.

Practical Expedients

The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded in commissions expense.

The Company does not provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of one year or less.
Concentration
Concentration

No single market other than Hong Kong had net sales greater than 10% of total net sales. Sales are made to the Company’s members and no single customer accounted for 10% or more of net sales for the three and nine months ended September 30, 2019 and 2018. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.
Net Income (Loss) Per Share

Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized, if any, is assumed to be used to repurchase shares.
Cash and Cash Equivalents

As of September 30, 2019, cash and cash equivalents include the Company’s investments in municipal and corporate debt securities, money market funds, and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with the FASB Accounting Standards Codification (“ASC”) 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at September 30, 2019 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs.
Fair Value of Financial Instruments FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs that are not corroborated by market data.
The carrying amounts of the Company’s financial instruments, including cash and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.
 
Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.

XML 34 R28.htm IDEA: XBRL DOCUMENT v3.19.3
REVENUE - Narrative (Details) - USD ($)
$ in Millions
9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Disaggregation of Revenue [Line Items]    
Actual sales returns rates 2.00% 2.00%
Decrease in deferred revenue, revenue recognized $ 1.2  
Increase in deferred revenue from cash payments received $ 1.1  
Minimum    
Disaggregation of Revenue [Line Items]    
Sales returns policy term 14 days  
Historical sales returns rates 1.00%  
Maximum    
Disaggregation of Revenue [Line Items]    
Sales returns policy term 1 year  
Historical sales returns rates 5.00%  
XML 35 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 36 R41.htm IDEA: XBRL DOCUMENT v3.19.3
LEASES - Annual Scheduled Lease Payments (Details)
$ in Thousands
Sep. 30, 2019
USD ($)
Leases [Abstract]  
Remainder of 2019 $ 473
2020 1,717
2021 730
2022 427
2023 245
Thereafter 400
Total lease payments 3,992
Less: imputed interest (400)
Present value of lease liabilities $ 3,592
XML 37 R45.htm IDEA: XBRL DOCUMENT v3.19.3
SUBSEQUENT EVENT (Details)
Oct. 29, 2019
$ / shares
Subsequent Event  
Subsequent Event [Line Items]  
Special cash dividend declared (in dollars per share) $ 0.40
ZIP 38 0000912061-19-000082-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000912061-19-000082-xbrl.zip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end XML 39 R18.htm IDEA: XBRL DOCUMENT v3.19.3
RELATED PARTY TRANSACTIONS
9 Months Ended
Sep. 30, 2019
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS

In February 2013, the Company entered into a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called ReStor™. George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding common stock, is owner of BHS. Under the agreement, the Company agreed to pay BHS a royalty based on a price per unit in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States. Such royalties were $19,000 and $72,000 for the three months ended September 30, 2019 and 2018, respectively, and $75,000 and $248,000 for the nine months ended September 30, 2019 and 2018, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days’ notice or, under certain circumstances, with no notice. Otherwise, the agreement terminates March 31, 2020.

The Company procured in China and arranged for shipment to The Aberdeen Group, LLC (“Aberdeen”) one order of apparel products in the amount of $7,100 during the three months ended March 31, 2019.  Aberdeen is owned 40% by Sharng Holdings, which is wholly-owned by the Company’s president, Chris T. Sharng, and his wife, 40% by Mr. Broady, and 20% by an unrelated third party.  Aberdeen promptly paid the Company for the product and shipping cost incurred. Given the Company’s provision of such product sourcing service to Aberdeen, Aberdeen also paid the Company a market-based fee consistent with the provision of such service of $420. The Company analyzed the nature of the transaction with Aberdeen to determine whether it could be construed a violation under the guidelines of Section 402 of the Sarbanes-Oxley Act of 2002. The Company, through advice from its legal counsel, concluded that there is not a reasonable possibility that the transaction with Aberdeen would be deemed a violation of Section 402. This relationship between the Company and Aberdeen ceased following the completion of this transaction.

On May 17, 2019, the Company entered into a Stock Repurchase Agreement with The George K. Broady 2012 Irrevocable Trust (“Broady Trust”). Mr. Broady is the trustee and a beneficiary of the Broady Trust. The Stock Repurchase Agreement, which the Company and the Broady Trust entered into in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, provided for the Company’s purchase of common stock from the Broady Trust in off-the-market, private transactions at a rate of 0.4105 times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on May 16, 2019. The Company’s purchases from the Broady Trust concluded on May 31, 2019, were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in an aggregate purchase price of $1.9 million. See Note 6.

XML 40 nhtc20190930_10q_htm.xml IDEA: XBRL DOCUMENT 0000912061 2019-01-01 2019-09-30 0000912061 2019-11-01 0000912061 2019-09-30 0000912061 2018-12-31 0000912061 2018-07-01 2018-09-30 0000912061 2019-07-01 2019-09-30 0000912061 2018-01-01 2018-09-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000912061 us-gaap:CommonStockMember 2018-09-30 0000912061 us-gaap:PreferredStockMember 2018-03-31 0000912061 us-gaap:TreasuryStockMember 2017-12-31 0000912061 us-gaap:CommonStockMember 2018-06-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0000912061 us-gaap:TreasuryStockMember 2018-09-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0000912061 us-gaap:TreasuryStockMember 2018-06-30 0000912061 2018-04-01 2018-06-30 0000912061 us-gaap:PreferredStockMember 2018-06-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000912061 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000912061 us-gaap:RetainedEarningsMember 2018-03-31 0000912061 2018-01-01 2018-03-31 0000912061 us-gaap:PreferredStockMember 2017-12-31 0000912061 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0000912061 us-gaap:RetainedEarningsMember 2018-09-30 0000912061 2017-12-31 0000912061 us-gaap:TreasuryStockMember 2018-03-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0000912061 us-gaap:RetainedEarningsMember 2017-12-31 0000912061 us-gaap:CommonStockMember 2017-12-31 0000912061 2018-09-30 0000912061 us-gaap:PreferredStockMember 2018-09-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000912061 us-gaap:TreasuryStockMember 2018-01-01 2018-03-31 0000912061 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000912061 2018-03-31 0000912061 2018-06-30 0000912061 us-gaap:RetainedEarningsMember 2018-06-30 0000912061 us-gaap:CommonStockMember 2018-03-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000912061 us-gaap:CommonStockMember 2018-12-31 0000912061 us-gaap:RetainedEarningsMember 2019-06-30 0000912061 us-gaap:PreferredStockMember 2019-09-30 0000912061 us-gaap:RetainedEarningsMember 2019-03-31 0000912061 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0000912061 2019-04-01 2019-06-30 0000912061 us-gaap:CommonStockMember 2019-09-30 0000912061 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000912061 us-gaap:CommonStockMember 2019-06-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000912061 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000912061 2019-01-01 2019-03-31 0000912061 us-gaap:PreferredStockMember 2019-06-30 0000912061 us-gaap:TreasuryStockMember 2019-09-30 0000912061 us-gaap:CommonStockMember 2019-03-31 0000912061 us-gaap:PreferredStockMember 2018-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000912061 2019-03-31 0000912061 2019-06-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000912061 us-gaap:TreasuryStockMember 2019-03-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000912061 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000912061 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000912061 us-gaap:TreasuryStockMember 2019-06-30 0000912061 us-gaap:RetainedEarningsMember 2019-09-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000912061 us-gaap:RetainedEarningsMember 2018-12-31 0000912061 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000912061 us-gaap:TreasuryStockMember 2018-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000912061 us-gaap:PreferredStockMember 2019-03-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000912061 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000912061 us-gaap:ShippingAndHandlingMember 2019-07-01 2019-09-30 0000912061 us-gaap:ProductMember 2018-01-01 2018-09-30 0000912061 us-gaap:ProductMember 2018-07-01 2018-09-30 0000912061 us-gaap:ProductMember 2019-01-01 2019-09-30 0000912061 us-gaap:ShippingAndHandlingMember 2018-07-01 2018-09-30 0000912061 us-gaap:ShippingAndHandlingMember 2019-01-01 2019-09-30 0000912061 us-gaap:ProductMember 2019-07-01 2019-09-30 0000912061 us-gaap:ShippingAndHandlingMember 2018-01-01 2018-09-30 0000912061 srt:MaximumMember 2019-01-01 2019-09-30 0000912061 srt:MinimumMember 2019-01-01 2019-09-30 0000912061 country:JP 2019-01-01 2019-09-30 0000912061 srt:AmericasMember 2019-07-01 2019-09-30 0000912061 nhtc:RussiaandKazakhstanDomain 2019-07-01 2019-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 country:SG 2018-01-01 2018-09-30 0000912061 country:SG us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 country:KR 2018-01-01 2018-09-30 0000912061 country:HK 2019-07-01 2019-09-30 0000912061 srt:AmericasMember 2019-01-01 2019-09-30 0000912061 srt:AmericasMember 2018-01-01 2018-09-30 0000912061 country:TW us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 country:IN us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 country:KR us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 srt:EuropeMember 2018-01-01 2018-09-30 0000912061 nhtc:RussiaandKazakhstanDomain us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 nhtc:RussiaandKazakhstanDomain 2018-07-01 2018-09-30 0000912061 country:SG us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 country:TW 2019-01-01 2019-09-30 0000912061 country:MY us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 country:MY us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 country:IN 2019-01-01 2019-09-30 0000912061 country:CN 2019-07-01 2019-09-30 0000912061 country:SG us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 country:TW 2019-07-01 2019-09-30 0000912061 country:CN us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 country:HK us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 country:SG 2019-07-01 2019-09-30 0000912061 country:KR 2019-07-01 2019-09-30 0000912061 country:TW 2018-07-01 2018-09-30 0000912061 country:CN us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 country:HK us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 country:TW us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 srt:EuropeMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 nhtc:RussiaandKazakhstanDomain 2019-01-01 2019-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 country:MY us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 country:KR us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 nhtc:RussiaandKazakhstanDomain us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 srt:EuropeMember 2018-07-01 2018-09-30 0000912061 country:MY 2018-07-01 2018-09-30 0000912061 country:TW 2018-01-01 2018-09-30 0000912061 country:CN 2018-01-01 2018-09-30 0000912061 country:SG 2018-07-01 2018-09-30 0000912061 country:HK us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 srt:EuropeMember 2019-01-01 2019-09-30 0000912061 nhtc:RussiaandKazakhstanDomain us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 srt:EuropeMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 srt:EuropeMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 srt:EuropeMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 country:KR us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 country:HK 2018-07-01 2018-09-30 0000912061 country:SG us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 country:IN us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 country:TW us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 country:MY 2019-07-01 2019-09-30 0000912061 country:MY us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 country:HK us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 country:IN 2018-01-01 2018-09-30 0000912061 country:IN 2019-07-01 2019-09-30 0000912061 country:CN 2019-01-01 2019-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 country:JP 2018-07-01 2018-09-30 0000912061 nhtc:RussiaandKazakhstanDomain us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 country:IN us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 country:KR 2019-01-01 2019-09-30 0000912061 country:JP us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 country:JP 2019-07-01 2019-09-30 0000912061 country:JP us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 country:MY 2019-01-01 2019-09-30 0000912061 srt:EuropeMember 2019-07-01 2019-09-30 0000912061 country:CN us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 country:JP us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 country:CN 2018-07-01 2018-09-30 0000912061 country:HK 2019-01-01 2019-09-30 0000912061 country:IN us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0000912061 country:IN 2018-07-01 2018-09-30 0000912061 country:MY 2018-01-01 2018-09-30 0000912061 srt:AmericasMember 2018-07-01 2018-09-30 0000912061 country:SG 2019-01-01 2019-09-30 0000912061 country:JP 2018-01-01 2018-09-30 0000912061 country:KR us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 country:KR 2018-07-01 2018-09-30 0000912061 country:HK 2018-01-01 2018-09-30 0000912061 country:CN us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 nhtc:RussiaandKazakhstanDomain 2018-01-01 2018-09-30 0000912061 country:JP us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 country:TW us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0000912061 us-gaap:RestrictedStockMember 2019-07-01 2019-09-30 0000912061 us-gaap:RestrictedStockMember 2019-01-01 2019-09-30 0000912061 nhtc:UnshippedProductMember 2019-09-30 0000912061 nhtc:AutoShipAdvancesMember 2019-09-30 0000912061 nhtc:OtherRevenueMember 2019-09-30 0000912061 us-gaap:CashMember 2019-09-30 0000912061 nhtc:AutoShipAdvancesMember 2018-12-31 0000912061 nhtc:UnshippedProductMember 2018-12-31 0000912061 us-gaap:CashMember 2018-12-31 0000912061 us-gaap:CashEquivalentsMember 2019-09-30 0000912061 nhtc:OtherRevenueMember 2018-12-31 0000912061 us-gaap:CashEquivalentsMember 2018-12-31 0000912061 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2019-09-30 0000912061 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember 2019-09-30 0000912061 us-gaap:CashAndCashEquivalentsMember 2018-12-31 0000912061 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2019-09-30 0000912061 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2018-12-31 0000912061 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember 2018-12-31 0000912061 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000912061 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2019-09-30 0000912061 us-gaap:CashAndCashEquivalentsMember 2019-09-30 0000912061 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2018-12-31 0000912061 2019-03-15 2019-03-15 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-30 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-09-30 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-09-30 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-09-30 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2019-09-30 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2019-01-01 2019-09-30 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2018-12-31 0000912061 2019-08-01 2019-09-30 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2019-02-01 2019-02-01 0000912061 srt:DirectorMember 2019-05-16 0000912061 nhtc:EquityIncentive2016PlanMember us-gaap:CommonStockMember 2019-09-30 0000912061 2019-05-16 2019-05-31 0000912061 nhtc:EquityIncentive2016PlanMember us-gaap:CommonStockMember 2016-04-07 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2019-08-09 2019-08-09 0000912061 2016-01-12 0000912061 2015-07-28 0000912061 2019-05-16 0000912061 nhtc:MetuchenNewJerseyMember 2019-09-30 0000912061 country:CN 2019-09-30 0000912061 country:HK 2019-09-30 0000912061 nhtc:RollingHillsEstatesCaliforniaMember 2019-09-30 0000912061 nhtc:MontereyParkCaliforniaMember 2019-09-30 0000912061 nhtc:RichmondBritishColumbiaMember 2019-09-30 0000912061 us-gaap:ForeignCountryMember 2018-12-31 0000912061 srt:ExecutiveOfficerMember nhtc:SecuritiesClassActionMember 2019-01-08 2019-01-08 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:PresidentandHisWifeMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember 2019-09-30 0000912061 nhtc:BroadyHealthSciencesMember nhtc:ReStoreMember nhtc:RoyaltyAgreementandLicenseMember srt:AffiliatedEntityMember 2013-02-01 2013-02-28 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember 2019-09-30 0000912061 nhtc:BroadyHealthSciencesMember nhtc:ReStoreMember srt:DirectorMember nhtc:RoyaltyAgreementandLicenseMember srt:AffiliatedEntityMember 2019-09-30 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember 2019-03-31 0000912061 nhtc:BroadyHealthSciencesMember nhtc:ReStoreMember nhtc:RoyaltyAgreementandLicenseMember srt:AffiliatedEntityMember 2018-07-01 2018-09-30 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember 2019-01-01 2019-03-31 0000912061 nhtc:BroadyHealthSciencesMember nhtc:ReStoreMember nhtc:RoyaltyAgreementandLicenseMember srt:AffiliatedEntityMember 2019-01-01 2019-09-30 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember 2019-01-01 2019-09-30 0000912061 nhtc:TheGeorgeK.Broady2012IrrevocableTrustBroadyTrustMember srt:DirectorMember nhtc:StockRepurchaseAgreementMember srt:AffiliatedEntityMember 2019-05-17 2019-05-31 0000912061 nhtc:BroadyHealthSciencesMember nhtc:ReStoreMember nhtc:RoyaltyAgreementandLicenseMember srt:AffiliatedEntityMember 2018-01-01 2018-09-30 0000912061 nhtc:BroadyHealthSciencesMember nhtc:ReStoreMember nhtc:RoyaltyAgreementandLicenseMember srt:AffiliatedEntityMember 2019-07-01 2019-09-30 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:SharngHoldingsMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember 2019-09-30 0000912061 us-gaap:SubsequentEventMember 2019-10-29 2019-10-29 pure nhtc:branch nhtc:defendant nhtc:order nhtc:service_station utreg:Rate shares iso4217:USD iso4217:USD shares utreg:sqft false --12-31 Q3 2019 0000912061 0.02 0.13 1.90 0.40 0.24 0.001 0.001 50000000 50000000 12979414 12979414 4500000 0.001 0.001 5000000 5000000 0 0 0 0 1603322 1459090 10-Q true 2019-09-30 false 001-36849 NATURAL HEALTH TRENDS CORP. DE 59-2705336 Units 1205-07, 12F Mira Place Tower A 132 Nathan Road Tsimshatsui HK 852 3107-0800 Common Stock, par value $0.001 per share NHTC NASDAQ Yes Yes Accelerated Filer true false false 11520324 101113000 132653000 7999000 12165000 6997000 5369000 116109000 150187000 821000 934000 3515000 1764000 1764000 2881000 2998000 1210000 1207000 807000 831000 127107000 157921000 627000 1631000 3798000 12502000 3392000 6121000 3302000 6795000 13090000 14611000 1689000 1188000 1424000 27086000 43084000 15365000 16982000 186000 186000 0 7808000 1903000 44540000 68060000 0 0 13000 13000 86102000 86415000 23567000 44431000 -1764000 -1250000 25351000 39748000 82567000 89861000 127107000 157921000 17023000 47043000 59779000 150320000 4371000 9926000 15002000 30546000 12652000 37117000 44777000 119774000 7362000 22001000 28258000 67291000 6354000 7269000 20296000 24484000 13716000 29270000 48554000 91775000 -1064000 7847000 -3777000 27999000 323000 249000 1128000 465000 -741000 8096000 -2649000 28464000 502000 467000 120000 2988000 -1243000 7629000 -2769000 25476000 -0.12 0.67 -0.25 2.25 -0.12 0.67 -0.25 2.25 10623000 11309000 11010000 11298000 10623000 11322000 11010000 11307000 -1243000 7629000 -2769000 25476000 -584000 -433000 -537000 -798000 12000 5000 23000 9000 -1815000 7201000 -3283000 24687000 0 0 12979414 13000 86415000 44431000 -1250000 1603322 -39748000 89861000 -1923000 -1923000 -166000 22603 543000 377000 2736000 2736000 259000 259000 17000 17000 0 0 12979414 13000 86249000 39772000 -974000 1580719 -39205000 85855000 397000 397000 612729 6682000 6682000 -212000 -212000 -6000 -6000 0 0 12979414 13000 86249000 40169000 -1192000 2193448 -45887000 79352000 -1243000 -1243000 383127 2882000 2882000 -147000 -15359000 1117485 23418000 7912000 -584000 -584000 12000 12000 0 0 12979414 13000 86102000 23567000 -1764000 1459090 -25351000 82567000 0 0 12979414 13000 86683000 44908000 -413000 1637524 -40570000 90621000 8824000 8824000 -268000 34202 822000 554000 1479000 1479000 397000 397000 -11000 -11000 0 0 12979414 13000 86415000 52253000 -27000 1603322 -39748000 98906000 9023000 9023000 21614000 21614000 -762000 -762000 15000 15000 0 0 12979414 13000 86415000 39662000 -774000 1603322 -39748000 85568000 7629000 7629000 4551000 4551000 -433000 -433000 5000 5000 0 0 12979414 13000 86415000 42740000 -1202000 1603322 -39748000 88218000 -2769000 25476000 290000 332000 1336000 0 -3000 0 -4104000 2828000 1674000 -2548000 -2000 83000 -1002000 967000 -8683000 2003000 -1779000 314000 -3485000 26000 -1508000 -930000 -1392000 -1617000 -2201000 -235000 438000 -333000 -800000 -18748000 25262000 181000 176000 -181000 -176000 9564000 0 2736000 27644000 -12300000 -27644000 -428000 -711000 -31657000 -3269000 135651000 138478000 103994000 135209000 8289000 554000 5058000 NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Nature of Operations</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Natural Health Trends Corp., a Delaware corporation (whether or not including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia, Thailand and Vietnam; South Korea; Japan; India; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2018 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on April 26, 2019.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of Consolidation</span></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassification</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain prior year amounts in the balance sheet have been reclassified to conform to current year presentation.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB established Topic 842, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">, by issuing ASU No. 2016-02, which requires lessees to recognize the rights and obligations created by leases on the balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-11,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Targeted Improvements, ASU No. 2018-10, Codification Improvements to Topic 842</span><span style="font-family:inherit;font-size:10pt;">, and ASU No. 2018-01, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Land Easement Practical Expedient for Transition to Topic 842</span><span style="font-family:inherit;font-size:10pt;">. The new standard establishes a right-of-use (ROU) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. Effective January 1, 2019, the Company adopted the new standard using the effective date as its date of initial application. The new standard provided a number of optional practical expedients in transition. The Company elected the “package of practical expedients”, which permits entities not to reassess under the new lease standard prior conclusions about lease identification, lease classification and initial direct costs. Upon adoption, the Company recognized operating lease liabilities on its balance sheet for </span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, with corresponding ROU assets of the same amount based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases. See Note 7 for additional information.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the SEC issued Release No. 33-10532 that amends and clarifies certain financial reporting requirements. The principal change to the Company’s financial reporting is the requirement to disclose in interim periods on Form 10-Q the changes in stockholder’s equity as prescribed by Rule 3-04 of Regulation S-X.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.</span></div> <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2018 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on April 26, 2019.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of Consolidation</span></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.</span></div> <div style="line-height:174%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassification</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain prior year amounts in the balance sheet have been reclassified to conform to current year presentation.</span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB established Topic 842, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">, by issuing ASU No. 2016-02, which requires lessees to recognize the rights and obligations created by leases on the balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-11,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Targeted Improvements, ASU No. 2018-10, Codification Improvements to Topic 842</span><span style="font-family:inherit;font-size:10pt;">, and ASU No. 2018-01, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Land Easement Practical Expedient for Transition to Topic 842</span><span style="font-family:inherit;font-size:10pt;">. The new standard establishes a right-of-use (ROU) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. Effective January 1, 2019, the Company adopted the new standard using the effective date as its date of initial application. The new standard provided a number of optional practical expedients in transition. The Company elected the “package of practical expedients”, which permits entities not to reassess under the new lease standard prior conclusions about lease identification, lease classification and initial direct costs. Upon adoption, the Company recognized operating lease liabilities on its balance sheet for </span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, with corresponding ROU assets of the same amount based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases. See Note 7 for additional information.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the SEC issued Release No. 33-10532 that amends and clarifies certain financial reporting requirements. The principal change to the Company’s financial reporting is the requirement to disclose in interim periods on Form 10-Q the changes in stockholder’s equity as prescribed by Rule 3-04 of Regulation S-X.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.</span></div> 4500000 REVENUE<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All revenue is recognized when the performance obligations under a contract are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from </span><span style="font-family:inherit;font-size:10pt;"><span>14 days</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;">, and their historical return rates, which range from </span><span style="font-family:inherit;font-size:10pt;"><span>1%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>5%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales.  Sales returns were </span><span style="font-family:inherit;font-size:10pt;"><span>2%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales for each of the </span><span style="font-family:inherit;font-size:10pt;">nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.  No material changes in estimates have been recognized during the periods presented. See Note 4 for additional information. </span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred Revenue</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are considered a contract liability and are recorded as deferred revenue. The decrease in deferred revenue for the three months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> is primarily due to </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of revenue recognized during the quarter that was included in deferred revenue as of June 30, 2019 offset by </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of cash payments received for unshipped product during the third quarter. See Note 4 for additional information. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Disaggregation of Revenue</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through an engagement of a third-party service provider. </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth revenue by market for the periods indicated (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:21%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Americas</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,445</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,970</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,353</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,361</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hong Kong</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,575</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,447</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,465</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133,681</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>525</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,698</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,510</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Taiwan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>649</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>935</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,340</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,933</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">South Korea</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>288</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>392</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Japan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>160</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Singapore</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>134</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Malaysia</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>216</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>170</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>316</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Russia and Kazakhstan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>244</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>184</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>662</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>626</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>343</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>357</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,017</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,207</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">India</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>162</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,023</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,043</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,779</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">United States, Canada, Mexico and Peru</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors” in this report and in our most recent Annual Report on Form 10-K.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s net sales by product and service are as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,732</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,434</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,258</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Freight and other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,468</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,365</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,713</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,550</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: sales returns</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(177</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(756</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,289</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,488</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,023</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,043</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,779</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">No single market other than Hong Kong had net sales greater than 10% of total net sales. Sales are made to the Company’s members and no single customer accounted for 10% or more of net sales for the three and </span><span style="font-family:inherit;font-size:10pt;">nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Arrangements with Multiple Performance Obligations</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Practical Expedients</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded in commissions expense. </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company does not provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of one year or less. <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All revenue is recognized when the performance obligations under a contract are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from </span><span style="font-family:inherit;font-size:10pt;"><span>14 days</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;">, and their historical return rates, which range from </span><span style="font-family:inherit;font-size:10pt;"><span>1%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>5%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales.  Sales returns were </span><span style="font-family:inherit;font-size:10pt;"><span>2%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales for each of the </span><span style="font-family:inherit;font-size:10pt;">nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.  No material changes in estimates have been recognized during the periods presented. See Note 4 for additional information. </span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred Revenue</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are considered a contract liability and are recorded as deferred revenue. The decrease in deferred revenue for the three months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> is primarily due to </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of revenue recognized during the quarter that was included in deferred revenue as of June 30, 2019 offset by </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of cash payments received for unshipped product during the third quarter. See Note 4 for additional information. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Disaggregation of Revenue</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through an engagement of a third-party service provider. </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Arrangements with Multiple Performance Obligations</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Practical Expedients</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded in commissions expense. </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company does not provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of one year or less. </span></div> P14D P1Y 0.01 0.05 0.02 1200000 1100000 <div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth revenue by market for the periods indicated (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:21%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Americas</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,445</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,970</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,353</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,361</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hong Kong</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,575</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,447</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,465</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133,681</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>525</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,698</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,510</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Taiwan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>649</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>935</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,340</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,933</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">South Korea</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>288</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>392</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Japan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>160</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Singapore</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>134</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Malaysia</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>216</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>170</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>316</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Russia and Kazakhstan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>244</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>184</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>662</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>626</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>343</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>357</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,017</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,207</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">India</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>162</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,023</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,043</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,779</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">United States, Canada, Mexico and Peru</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors” in this report and in our most recent Annual Report on Form 10-K.</span></div> 1445000 0.085 1970000 0.042 4353000 0.073 5361000 0.036 13575000 0.797 41447000 0.881 48465000 0.810 133681000 0.889 525000 0.031 1698000 0.036 2138000 0.036 5510000 0.037 649000 0.038 935000 0.020 2340000 0.039 2933000 0.019 98000 0.006 133000 0.003 288000 0.005 392000 0.003 47000 0.003 51000 0.001 141000 0.002 160000 0.001 13000 0.001 52000 0.001 43000 0.001 134000 0.001 51000 0.003 216000 0.005 170000 0.003 316000 0.002 244000 0.014 184000 0.004 662000 0.011 626000 0.004 343000 0.020 357000 0.007 1017000 0.017 1207000 0.008 33000 0.002 0 0 162000 0.003 0 0 17023000 1.000 47043000 1.000 59779000 1.000 150320000 1.000 <div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s net sales by product and service are as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,732</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,434</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,258</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Freight and other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,468</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,365</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,713</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,550</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: sales returns</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(177</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(756</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,289</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,488</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,023</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,043</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,779</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 15732000 44434000 56355000 142258000 1468000 3365000 4713000 10550000 177000 756000 1289000 2488000 17023000 47043000 59779000 150320000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">No single market other than Hong Kong had net sales greater than 10% of total net sales. Sales are made to the Company’s members and no single customer accounted for 10% or more of net sales for the three and </span><span style="font-family:inherit;font-size:10pt;">nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.</span></div> NET INCOME (LOSS) PER COMMON SHARE<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized, if any, is assumed to be used to repurchase shares.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables illustrate the computation of basic and diluted net income (loss) per common share for the periods indicated (in thousands, except per share data): </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss)</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss)</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income (loss) per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) available to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,243</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,623</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.12</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,629</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,309</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.67</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders plus assumed conversions</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,623</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.12</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,629</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,322</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.67</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income<br/>(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares<br/>(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income<br/>(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares<br/>(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income (loss) per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) available to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,769</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,010</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,476</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,298</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) available to common stockholders plus assumed conversions</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,769</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,010</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,476</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. As such, non-vested restricted stock totaling </span><span style="font-family:inherit;font-size:10pt;"><span>672,231</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>263,289</span></span><span style="font-family:inherit;font-size:10pt;"> shares were not included for the three and nine months ended September 30, 2019, respectively.</span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized, if any, is assumed to be used to repurchase shares.</span></div> <div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables illustrate the computation of basic and diluted net income (loss) per common share for the periods indicated (in thousands, except per share data): </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss)</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss)</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income (loss) per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) available to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,243</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,623</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.12</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,629</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,309</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.67</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders plus assumed conversions</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,623</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.12</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,629</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,322</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.67</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income<br/>(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares<br/>(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income<br/>(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares<br/>(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income (loss) per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) available to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,769</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,010</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,476</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,298</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) available to common stockholders plus assumed conversions</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,769</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,010</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,476</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -1243000 10623000 -0.12 7629000 11309000 0.67 0 13000 -1243000 10623000 -0.12 7629000 11322000 0.67 -2769000 11010000 -0.25 25476000 11298000 2.25 0 9000 -2769000 11010000 -0.25 25476000 11307000 2.25 672231 263289 BALANCE SHEET COMPONENTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of certain balance sheet amounts are as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,711</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,323</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83,402</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101,113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>132,653</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,881</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,998</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,994</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>135,651</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,817</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,171</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,104</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,145</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reserve for obsolescence</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(922</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(151</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,999</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,165</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>290</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>801</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee-related expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,998</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,051</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warehousing, inventory-related and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,104</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,269</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,392</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,121</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unshipped product</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,171</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,574</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Auto ship advances</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,983</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,876</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>148</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>345</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,302</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,795</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of certain balance sheet amounts are as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,711</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,323</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83,402</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101,113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>132,653</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,881</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,998</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,994</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>135,651</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,817</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,171</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,104</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,145</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reserve for obsolescence</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(922</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(151</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,999</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,165</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>290</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>801</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee-related expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,998</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,051</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warehousing, inventory-related and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,104</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,269</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,392</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,121</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unshipped product</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,171</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,574</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Auto ship advances</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,983</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,876</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>148</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>345</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,302</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,795</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 17711000 47323000 83402000 85330000 101113000 132653000 2881000 2998000 103994000 135651000 7817000 11171000 1104000 1145000 922000 151000 7999000 12165000 290000 801000 1998000 4051000 1104000 1269000 3392000 6121000 1171000 4574000 1983000 1876000 148000 345000 3302000 6795000 FAIR VALUE MEASUREMENTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, cash and cash equivalents include the Company’s investments in municipal and corporate debt securities, money market funds, and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with the FASB Accounting Standards Codification (“ASC”) 320, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investments - Debt and Equity Securities</span><span style="font-family:inherit;font-size:10pt;">. As such, the Company determined its investments in debt securities held at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amounts of the Company’s financial instruments, including cash and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. </span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investments by significant category included in cash equivalents at the end of each period were as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:31%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value Level</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,810</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,810</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,281</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,281</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Time deposits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,904</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,904</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,071</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,071</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal debt securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,432</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,433</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,149</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,142</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,266</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,255</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,862</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(26</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,836</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total investments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83,412</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83,402</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,363</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:19.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;">FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 1: Quoted market prices in active markets for identical assets or liabilities.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 3: Unobservable inputs that are not corroborated by market data.</span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, cash and cash equivalents include the Company’s investments in municipal and corporate debt securities, money market funds, and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with the FASB Accounting Standards Codification (“ASC”) 320, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investments - Debt and Equity Securities</span><span style="font-family:inherit;font-size:10pt;">. As such, the Company determined its investments in debt securities held at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs.</span></div> <div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investments by significant category included in cash equivalents at the end of each period were as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:31%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value Level</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,810</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,810</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,281</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,281</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Time deposits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,904</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,904</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,071</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,071</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal debt securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,432</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,433</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,149</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,142</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,266</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,255</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,862</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(26</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,836</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total investments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83,412</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83,402</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,363</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:19.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;">FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 1: Quoted market prices in active markets for identical assets or liabilities.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 3: Unobservable inputs that are not corroborated by market data.</span></div> 30810000 0 30810000 3281000 0 3281000 14904000 0 14904000 18071000 0 18071000 3432000 1000 3433000 12149000 -7000 12142000 34266000 -11000 34255000 51862000 -26000 51836000 83412000 -10000 83402000 85363000 -33000 85330000 <span style="font-family:inherit;font-size:10pt;font-style:italic;">FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:</span><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 1: Quoted market prices in active markets for identical assets or liabilities.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 3: Unobservable inputs that are not corroborated by market data.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amounts of the Company’s financial instruments, including cash and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. </span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> STOCKHOLDERS’ EQUITY<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Dividends</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company’s cash dividend activity for the </span><span style="font-family:inherit;font-size:10pt;">nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands, except per share data):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:19%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Record Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 27, 2019 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>912</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 5, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 15, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,824</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 5, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 15, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.24</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,736</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Repurchases</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from </span><span style="font-family:inherit;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 16, 2019, the Company’s Board of Directors authorized the Company to proceed with the purchase of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$8.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in shares of common stock under the foregoing stock repurchase program. In connection therewith, the Company was advised that George K. Broady, a director of the Company and beneficial owner of more than </span><span style="font-family:inherit;font-size:10pt;"><span>5%</span></span><span style="font-family:inherit;font-size:10pt;"> of its outstanding shares of common stock, would participate in the stock repurchase program on a basis roughly proportional to his family’s ownership interest. See Note 10.</span></div><div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During May 2019, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. The open market repurchases were completed on May 31, 2019. The stock repurchases, which included both open market purchases and the purchase of shares from Mr. Broady, resulted in the Company purchasing a total of </span><span style="font-family:inherit;font-size:10pt;"><span>612,729</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock for an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, plus transaction costs. </span></div><div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 6, 2019, the Company’s Board of Directors authorized the Company to proceed with purchases under the foregoing stock repurchase program in the open market in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. During August and September 2019, the Company purchased a total of </span><span style="font-family:inherit;font-size:10pt;"><span>383,127</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock in the open market for an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, plus transaction costs.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$22.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the </span><span style="font-family:inherit;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to </span><span style="font-family:inherit;font-size:10pt;"><span>2,500,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>1,219,583</span></span><span style="font-family:inherit;font-size:10pt;"> shares remained available for issuance under the 2016 Plan. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 1, 2019, the Company granted </span><span style="font-family:inherit;font-size:10pt;"><span>22,603</span></span><span style="font-family:inherit;font-size:10pt;"> shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interests with those of its stockholders and settling fiscal 2018 performance incentives totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$377,000</span></span><span style="font-family:inherit;font-size:10pt;">. The shares vest on a quarterly basis over the next </span><span style="font-family:inherit;font-size:10pt;"><span>three years</span></span><span style="font-family:inherit;font-size:10pt;"> and are subject to forfeiture in the event of their termination of service to the Company under specified circumstances.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 9, 2019, the Company granted </span><span style="font-family:inherit;font-size:10pt;"><span>1,117,485</span></span><span style="font-family:inherit;font-size:10pt;"> shares of restricted stock under the 2016 Plan to certain employees for the purpose of further aligning their interests with those of its stockholders and settling unpaid cash incentives of </span><span style="font-family:inherit;font-size:10pt;"><span>$7.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> under the 2014 Long-Term Incentive Plan with respect to performance periods that concluded on or prior to December 31, 2018.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company’s restricted stock activity under the 2016 Plan:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,486</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.61</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,140,088</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(125,405</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,060,169</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated Other Comprehensive Loss</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The changes in accumulated other comprehensive loss by component for the first </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months of 2019 were as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign Currency Translation Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized Gains/(Losses) on Available-For-Sale Investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,217</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(537</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(514</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,754</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,764</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company’s cash dividend activity for the </span><span style="font-family:inherit;font-size:10pt;">nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands, except per share data):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:19%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Record Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 27, 2019 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>912</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 5, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 15, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,824</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 5, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 15, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.24</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,736</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.08 912000 0.16 1824000 0.24 2736000 15000000.0 70000000.0 8000000.0 0.05 4700000 612729 6700000 383127 2900000 22400000 70000000.0 2500000 1219583 22603 377000 P3Y 1117485 7900000 <div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company’s restricted stock activity under the 2016 Plan:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,486</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.61</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,140,088</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(125,405</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,060,169</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 45486 21.61 1140088 7.27 125405 11.07 1060169 7.44 <div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The changes in accumulated other comprehensive loss by component for the first </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months of 2019 were as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign Currency Translation Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized Gains/(Losses) on Available-For-Sale Investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,217</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(537</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(514</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,754</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,764</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -1217000 -33000 -1250000 -537000 23000 -514000 -1754000 -10000 -1764000 LEASES<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company leases </span><span style="font-family:inherit;font-size:10pt;"><span>9,600</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of office space in Hong Kong with a term expiring in February 2021. The Company leases </span><span style="font-family:inherit;font-size:10pt;"><span>4,900</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of office space in Rolling Hills Estates, California with a term expiring in September 2025. To help further develop the market for its products in North America, the Company leases </span><span style="font-family:inherit;font-size:10pt;"><span>2,400</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>1,600</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>2,000</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of retail space in Monterey Park, California, Richmond, British Columbia, and Metuchen, New Jersey, respectively. The Monterey </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Park, Richmond and Metuchen locations have terms expiring in August 2020, February 2021, and November 2022, respectively.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company leases </span><span style="font-family:inherit;font-size:10pt;"><span>nine</span></span><span style="font-family:inherit;font-size:10pt;"> branch offices throughout China, and additional office space in Peru, Japan, Taiwan, South Korea, Singapore, Malaysia, Vietnam, Indonesia, Thailand, India, and the Cayman Islands. The Company also leases a multi-purpose facility and factory in Zhongshan, China and </span><span style="font-family:inherit;font-size:10pt;"><span>11</span></span><span style="font-family:inherit;font-size:10pt;"> service stations throughout the city of Guangzhou, China that serve or will in the future serve the needs of its Chinese consumers. The Company contracts with third parties for fulfillment and distribution operations in all of its international markets. None of the Company’s third party logistics contracts contain a lease as the Company does not have the right to access the warehouses or move its inventories at will.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of lease cost for the three months and </span><span style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.65625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>512</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,544</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>201</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>585</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,745</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of operating leases liabilities was </span><span style="font-family:inherit;font-size:10pt;"><span>$459,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months and </span><span style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted-average remaining lease term and discount rate related to operating leases as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:73%;"/><td style="width:26%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average remaining lease term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As most of our leases do not provide an implicit rate, the Company used its incremental borrowing rate, or the rate of each of its subsidiaries if available, based on the information available at the lease commencement date to determine the present value of lease payments.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The annual scheduled lease payments of our operating lease liabilities as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remainder of 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>473</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,717</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>730</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>427</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>245</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>400</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(400</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,592</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For all asset classes, the Company elected not to recognize assets or liabilities at the acquisition date for leases that, at the acquisition date, have a remaining lease term of 12 months or less. Additionally, for all asset classes, the Company choose not to separate nonlease components from lease components and instead account for the combined lease and nonlease components associated with that lease component as a single lease component.</span></div> 9600 4900 2400 1600 2000 9 11 <div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of lease cost for the three months and </span><span style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.65625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>512</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,544</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>201</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>585</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,745</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted-average remaining lease term and discount rate related to operating leases as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:73%;"/><td style="width:26%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average remaining lease term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 512000 1544000 73000 201000 585000 1745000 459000 1500000 P3Y2M12D 0.055 <div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The annual scheduled lease payments of our operating lease liabilities as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remainder of 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>473</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,717</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>730</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>427</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>245</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>400</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(400</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,592</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 473000 1717000 730000 427000 245000 400000 3992000 400000 3592000 INCOME TAXES<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effective income tax rate for the three and </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was impacted by recording the effect of the Tax Cuts and Jobs Act (the “Tax Act”) enacted on December 22, 2017 by the U.S. government, which makes broad and complex changes to the Internal Revenue Code of 1986, as amended.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 22, 2017, the Securities and Exchange Commission staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provided a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</span><span style="font-family:inherit;font-size:10pt;">. In accordance with the expiration of the SAB 118 measurement period, we completed the assessment of the income tax effect of the Tax Act for the year ended December 31, 2017 in the fourth quarter of tax year 2018. All adjustments recorded to the provisional amounts have been included as an adjustment to income tax expense.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the Tax Act, the Company could be subject to additional income tax expense due to the Global Intangible Low Taxed Income inclusion on current net income of greater than 10% owned controlled foreign corporations (“GILTI”). To determine the amount of GILTI inclusion, the Company must determine, in addition to other factors, the current earnings of controlled foreign corporations, as well as the amount of foreign taxes paid by the foreign entities. The law provides that corporate taxpayers may benefit from a 50% reduction in the GILTI inclusion which effectively reduces the 21% U.S. corporate tax rate on the foreign income to an effective rate of 10.5%. The 50% reduction, however, is limited if the U.S. shareholder has current domestic losses or is utilizing net operating losses. The GILTI inclusion further provides for a foreign tax credit in connection with the foreign taxes paid. The Company is not expected to have any GILTI inclusion for the year ended December 31, 2019.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company does not have a valuation allowance against its U.S. deferred tax assets. The Company analyzed all sources of available income and determined that they are more likely than not to realize the tax benefits of their deferred assets. As of September 30, 2019, any attributes generated from a U.S. federal net operating loss for the year ended December 31, 2019 are expected to be fully utilized.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company has a valuation allowance against certain foreign deferred tax assets. The Company is recording a valuation allowance in foreign jurisdictions with an overall net operating loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision. At December 31, 2018, the Company had foreign net operating loss carryforwards of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in various jurisdictions with various expirations.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of capital return activities, the Company determined that a portion of its current undistributed foreign earnings is no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. For state income tax purposes, the Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable state corporate income tax rate. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company has recorded a state deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods. Due to the Tax Act, repatriation from foreign subsidiaries will be offset with a dividends received deduction, resulting in little to no impact on federal tax expense. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. During 2019, a loan was issued by the Company to one of its controlled foreign corporations that exceeded 50% of current earnings. This transaction is tax-free for federal income tax purposes and the state tax impact is insignificant to the consolidated financial statements.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company and its subsidiaries file tax returns in the United States, California, New Jersey and Texas and various foreign jurisdictions. During the fourth quarter of 2018, the Company was notified that it was selected for audit of the 2016 tax year by the U.S. Internal Revenue Service. For purposes of this audit, fiscal years 2007 through 2016 are open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. No adjustments have been proposed at this time. The Company is no longer subject to state income tax examinations for years prior to 2014. No other jurisdictions are currently examining any income tax returns of the Company.</span></div> 1200000 COMMITMENTS AND CONTINGENCIES<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 8, 2019, the Company and its </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> executive officers were named in a putative securities class action filed in the United States District Court for the Central District of California, captioned </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kauffman v. Natural Health Trends Corp.</span><span style="font-family:inherit;font-size:10pt;">, Case No. 2:19-cv-00163. The complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between April 27, 2016 and January 5, 2019, inclusive, under (i) Section 10(b) of the Securities Exchange Act of 1934 (“Exchange Act”) and Rule 10b-5 promulgated thereunder against the Company and Chris T. Sharng and Timothy S. Davidson (together, the “Individual Defendants”), and (ii) Section 20(a) of the Exchange Act against the Individual Defendants. The complaint alleges, in part, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multilevel marketing business. The complaint seeks an indeterminate amount of damages, plus interest and costs. On May 3, 2019, the court issued an order appointing Xia Yang as lead plaintiff and appointing The Rosen Law Firm, P. A. as lead counsel. On June 3, 2019, lead plaintiff filed an amended complaint. On June 27, 2019, the parties filed a joint stipulation seeking to postpone briefing on defendants’ motion to dismiss to allow the parties to continue ongoing discussions, which stipulation was entered by the court on July 1, 2019.  On September 6, 2019, Defendants filed a motion to dismiss the amended complaint, which plaintiff opposed on October 16, 2019.  Defendants’ reply in support of their motion to dismiss was filed on November 4, 2019, and a hearing on the motion is currently set for November 18, 2019.  Defendants believe that these claims are without merit and intend to vigorously defend against them. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since August 2016, the SEC has been conducting a non-public investigation to determine whether there have been violations of the federal securities laws relating to the trading of the Company’s securities. The Company has fully cooperated with the SEC and has and continues to provide documents in response to subpoenas. The SEC has expressly stated that its document requests should not be construed as an indication that any violation of law has occurred, or as a reflection upon any person, entity, or security. The amount of time needed to resolve this matter is uncertain, and the Company cannot predict the outcome or whether it will face additional governmental inquiries or other actions.</span></div> 2 RELATED PARTY TRANSACTIONS<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2013, the Company entered into a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ReStor™</span><span style="font-family:inherit;font-size:10pt;">. George K. Broady, a director of the Company and beneficial owner of more than </span><span style="font-family:inherit;font-size:10pt;"><span>5%</span></span><span style="font-family:inherit;font-size:10pt;"> of its outstanding common stock, is owner of BHS. Under the agreement, the Company agreed to pay BHS a royalty based on a price per unit in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States. Such royalties were </span><span style="font-family:inherit;font-size:10pt;"><span>$19,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$72,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$75,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$248,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on </span><span style="font-family:inherit;font-size:10pt;"><span>120 days</span></span><span style="font-family:inherit;font-size:10pt;">’ notice or, under certain circumstances, with no notice. Otherwise, the agreement terminates March 31, 2020.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company procured in China and arranged for shipment to The Aberdeen Group, LLC (“Aberdeen”) </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> order of apparel products in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$7,100</span></span><span style="font-family:inherit;font-size:10pt;"> during the three months ended March 31, 2019.  Aberdeen is owned </span><span style="font-family:inherit;font-size:10pt;"><span>40%</span></span><span style="font-family:inherit;font-size:10pt;"> by Sharng Holdings, which is wholly-owned by the Company’s president, Chris T. Sharng, and his wife, </span><span style="font-family:inherit;font-size:10pt;"><span>40%</span></span><span style="font-family:inherit;font-size:10pt;"> by Mr. Broady, and </span><span style="font-family:inherit;font-size:10pt;"><span>20%</span></span><span style="font-family:inherit;font-size:10pt;"> by an unrelated third party.  Aberdeen promptly paid the Company for the product and shipping cost incurred. Given the Company’s provision of such product sourcing service to Aberdeen, Aberdeen also paid the Company a market-based fee consistent with the provision of such service of </span><span style="font-family:inherit;font-size:10pt;"><span>$420</span></span><span style="font-family:inherit;font-size:10pt;">. The Company analyzed the nature of the transaction with Aberdeen to determine whether it could be construed a violation under the guidelines of Section 402 of the Sarbanes-Oxley Act of 2002. The Company, through advice from its legal counsel, concluded that there is not a reasonable possibility that the transaction with Aberdeen would be deemed a violation of Section 402. This relationship between the Company and Aberdeen ceased following the completion of this transaction.</span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 17, 2019, the Company entered into a Stock Repurchase Agreement with The George K. Broady 2012 Irrevocable Trust (“Broady Trust”). Mr. Broady is the trustee and a beneficiary of the Broady Trust. The Stock Repurchase Agreement, which the Company and the Broady Trust entered into in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, provided for the Company’s purchase of common stock from the Broady Trust in off-the-market, private transactions at a rate of </span><span style="font-family:inherit;font-size:10pt;"><span>0.4105</span></span><span style="font-family:inherit;font-size:10pt;"> times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on May 16, 2019. The Company’s purchases from the Broady Trust concluded on May 31, 2019, were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.9 million</span></span><span style="font-family:inherit;font-size:10pt;">. See Note 6.</span></div> 0.05 19000 72000 75000 248000 P120D 1 7100 0.40 0.40 0.20 420 0.4105 1900000 SUBSEQUENT EVENT<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 29, 2019, the Board of Directors declared a special cash dividend of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.40</span></span><span style="font-family:inherit;font-size:10pt;"> on each share of common stock outstanding. Such dividends are payable on November 29, 2019 to stockholders of record on November 19, 2019. Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.40 XML 41 R14.htm IDEA: XBRL DOCUMENT v3.19.3
STOCKHOLDERS' EQUITY
9 Months Ended
Sep. 30, 2019
Equity [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
 
Dividends

The following table summarizes the Company’s cash dividend activity for the nine months ended September 30, 2019 (in thousands, except per share data):
Declaration Date
 
Per Share
 
Amount
 
Record Date
 
Payment Date
January 27, 2019 (special)
 
0.08

 
$
912

 
March 5, 2019
 
March 15, 2019
January 27, 2019
 
0.16

 
$
1,824

 
March 5, 2019
 
March 15, 2019
 
 
$
0.24

 
$
2,736

 
 
 
 


Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.

Stock Repurchases

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued.

On May 16, 2019, the Company’s Board of Directors authorized the Company to proceed with the purchase of up to $8.0 million in shares of common stock under the foregoing stock repurchase program. In connection therewith, the Company was advised that George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding shares of common stock, would participate in the stock repurchase program on a basis roughly proportional to his family’s ownership interest. See Note 10.

During May 2019, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of $4.7 million in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. The open market repurchases were completed on May 31, 2019. The stock repurchases, which included both open market purchases and the purchase of shares from Mr. Broady, resulted in the Company purchasing a total of 612,729 shares of its common stock for an aggregate purchase price of $6.7 million, plus transaction costs.

On August 6, 2019, the Company’s Board of Directors authorized the Company to proceed with purchases under the foregoing stock repurchase program in the open market in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. During August and September 2019, the Company purchased a total of 383,127 shares of common stock in the open market for an aggregate purchase price of $2.9 million, plus transaction costs.

As of September 30, 2019, $22.4 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.

Restricted Stock

At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At September 30, 2019, 1,219,583 shares remained available for issuance under the 2016 Plan.

On February 1, 2019, the Company granted 22,603 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interests with those of its stockholders and settling fiscal 2018 performance incentives totaling $377,000. The shares vest on a quarterly basis over the next three years and are subject to forfeiture in the event of their termination of service to the Company under specified circumstances.

On August 9, 2019, the Company granted 1,117,485 shares of restricted stock under the 2016 Plan to certain employees for the purpose of further aligning their interests with those of its stockholders and settling unpaid cash incentives of $7.9 million under the 2014 Long-Term Incentive Plan with respect to performance periods that concluded on or prior to December 31, 2018.

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2018
45,486

 
$
21.61

Granted
1,140,088

 
7.27

Vested
(125,405
)
 
11.07

Nonvested at September 30, 2019
1,060,169

 
7.44



Accumulated Other Comprehensive Loss
 
The changes in accumulated other comprehensive loss by component for the first nine months of 2019 were as follows (in thousands):
 
Foreign Currency Translation Adjustment
 
Unrealized Gains/(Losses) on Available-For-Sale Investments
 
Total
Balance, December 31, 2018
$
(1,217
)
 
$
(33
)
 
$
(1,250
)
Other comprehensive income (loss)
(537
)
 
23

 
(514
)
Balance, September 30, 2019
$
(1,754
)
 
$
(10
)
 
$
(1,764
)

XML 42 R10.htm IDEA: XBRL DOCUMENT v3.19.3
REVENUE
9 Months Ended
Sep. 30, 2019
Revenue Recognition [Abstract]  
REVENUE REVENUE

Revenue Recognition

All revenue is recognized when the performance obligations under a contract are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.
 
Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 5% of sales.  Sales returns were 2% of sales for each of the nine months ended September 30, 2019 and 2018, respectively.  No material changes in estimates have been recognized during the periods presented. See Note 4 for additional information.
 
The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.

Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.

Deferred Revenue

The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are considered a contract liability and are recorded as deferred revenue. The decrease in deferred revenue for the three months ended September 30, 2019 is primarily due to $1.2 million of revenue recognized during the quarter that was included in deferred revenue as of June 30, 2019 offset by $1.1 million of cash payments received for unshipped product during the third quarter. See Note 4 for additional information.

Disaggregation of Revenue

The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through an engagement of a third-party service provider.

The following table sets forth revenue by market for the periods indicated (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Americas1
$
1,445

 
8.5
%
 
$
1,970

 
4.2
%
 
$
4,353

 
7.3
%
 
$
5,361

 
3.6
%
Hong Kong2
13,575

 
79.7

 
41,447

 
88.1

 
48,465

 
81.0

 
133,681

 
88.9

China
525

 
3.1

 
1,698

 
3.6

 
2,138

 
3.6

 
5,510

 
3.7

Taiwan
649

 
3.8

 
935

 
2.0

 
2,340

 
3.9

 
2,933

 
1.9

South Korea
98

 
0.6

 
133

 
0.3

 
288

 
0.5

 
392

 
0.3

Japan
47

 
0.3

 
51

 
0.1

 
141

 
0.2

 
160

 
0.1

Singapore
13

 
0.1

 
52

 
0.1

 
43

 
0.1

 
134

 
0.1

Malaysia
51

 
0.3

 
216

 
0.5

 
170

 
0.3

 
316

 
0.2

Russia and Kazakhstan
244

 
1.4

 
184

 
0.4

 
662

 
1.1

 
626

 
0.4

Europe
343

 
2.0

 
357

 
0.7

 
1,017

 
1.7

 
1,207

 
0.8

India
33

 
0.2

 

 

 
162

 
0.3

 

 

Total
$
17,023

 
100.0
%
 
$
47,043

 
100.0
%
 
$
59,779

 
100.0
%
 
$
150,320

 
100.0
%

1 United States, Canada, Mexico and Peru
2 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors” in this report and in our most recent Annual Report on Form 10-K.

The Company’s net sales by product and service are as follows (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Product sales
$
15,732

 
$
44,434

 
$
56,355

 
$
142,258

Freight and other
1,468

 
3,365

 
4,713

 
10,550

Less: sales returns
(177
)
 
(756
)
 
(1,289
)
 
(2,488
)
Total net sales
$
17,023

 
$
47,043

 
$
59,779

 
$
150,320



Concentration

No single market other than Hong Kong had net sales greater than 10% of total net sales. Sales are made to the Company’s members and no single customer accounted for 10% or more of net sales for the three and nine months ended September 30, 2019 and 2018. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.

Arrangements with Multiple Performance Obligations

The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.

Practical Expedients

The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded in commissions expense.

The Company does not provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of one year or less.
XML 43 R3.htm IDEA: XBRL DOCUMENT v3.19.3
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Sep. 30, 2019
Dec. 31, 2018
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 50,000,000 50,000,000
Common stock, shares issued (in shares) 12,979,414 12,979,414
Treasury stock, shares (in shares) 1,459,090 1,603,322
XML 44 R7.htm IDEA: XBRL DOCUMENT v3.19.3
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) (Parenthetical) - $ / shares
3 Months Ended
Mar. 31, 2019
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Statement of Stockholders' Equity [Abstract]        
Dividends declared (in dollars per share) $ 0.24 $ 0.40 $ 1.90 $ 0.13
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.19.3
FAIR VALUE MEASUREMENTS - Available-for-Sale Investments Included in Cash Equivalents (Details) - Cash and Cash Equivalents - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Debt Securities, Available-for-sale [Line Items]    
Adjusted Cost $ 83,412 $ 85,363
Gross Unrealized Losses (10) (33)
Fair Value 83,402 85,330
Level 1 | Money market funds    
Debt Securities, Available-for-sale [Line Items]    
Adjusted Cost 30,810 3,281
Gross Unrealized Losses 0 0
Fair Value 30,810 3,281
Level 2 | Time deposits    
Debt Securities, Available-for-sale [Line Items]    
Adjusted Cost 14,904 18,071
Gross Unrealized Losses 0 0
Fair Value 14,904 18,071
Level 2 | Municipal debt securities    
Debt Securities, Available-for-sale [Line Items]    
Adjusted Cost 3,432 12,149
Gross Unrealized Losses 1 (7)
Fair Value 3,433 12,142
Level 2 | Corporate debt securities    
Debt Securities, Available-for-sale [Line Items]    
Adjusted Cost 34,266 51,862
Gross Unrealized Losses (11) (26)
Fair Value $ 34,255 $ 51,836
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.19.3
STOCKHOLDERS' EQUITY - Changes in Accumulated Other Comprehensive Loss (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2019
USD ($)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Balance, December 31, 2018 $ (1,250)
Other comprehensive income (loss) (514)
Balance, September 30, 2019 (1,764)
Foreign Currency Translation Adjustment  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Balance, December 31, 2018 (1,217)
Other comprehensive income (loss) (537)
Balance, September 30, 2019 (1,754)
Unrealized Gains/(Losses) on Available-For-Sale Investments  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Balance, December 31, 2018 (33)
Other comprehensive income (loss) 23
Balance, September 30, 2019 (10)
Total  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Balance, December 31, 2018 (1,250)
Balance, September 30, 2019 $ (1,764)
EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

I':V)I1:IY$G.2N"JMB)5U"E2DC(5Z;K*$YY@()MI0SS%J%-E9KX2QL03 #'2 UV!&2-F([*, M*2/F(24,1#+A.48B9ZV!1/R)AD3*\\\M,?JDBSZE?,L:C!@IPI,K,6*D#"CA M7C3 H>0%#$3"S'EV@4H*Q1]MJ$,2OOQB\DE &24](3!EI!Z17TP9B=8MO'B1 M2/$%&1))S=,;($IA=Q[^2DP^Z9)/*5]F,%QD,B*Y&"[27<& XITYM63TG"?7 M%2Z(JETS+,+5/.KNSF<&$:>1'CQ@%=AO*@X/+T*XT6!%8Q3NTBD.'B1 M*.9> D;B9( BG\?"R%,N\J[OXC"$QZ>-,&H*LT6%6#7E.B=.U!70" Z/-1#) MF9-;5Z3F'F(JC#L%T*(]#S6%T:)&%T:)"K!H2:;XO $5.$FNH(A["2CB4+@1:3@MSZ84,&O:PVR-N:)'F#6- MN:)#S)I&OHGGUM40]\% P^]1"OOR+,,T!IT&4"%?Y6.HZ!$&36.HZ!"#AD0N M$@)$ZQ!1>D,TW'#$H"-@T,CS+".,%1IAT ACA4(,&@&_Q/=O@$9>[:!VN04B MP??04B#R[L42)AT!JI!GJ4&8*C3"G)%G3SG$G"&1PULHXN8L)%(*19YM7<*D M(V#.R+/4( P6&F'."(.%0LP9 ;/$\[8"(C%SD@MLGN$_T""1;T.+,.P(@(4\ MU#88+&:$-3,8+";$FB$1\6T;*.)8@"*.W!N1AM/"L#/ FI&G^ TFBQEAS0PF MBPFQ9@:8)0<+2,3SM@8B$?.;F2*5C#U/-(-Y9P!;R+,0,YY?T4:X,X/98D+< M&1+Q'8,5$AG^BP\4<0L!19[GD<&\,\"=&0]U#6:+&>'.$LR6),2=):YA9'/6@UU_%' WG)\\K68X^_U"C:V6Q[^7"P+U7S-JG? M%]T)G.Y#E9_[TT71Y8C3\G]02P,$% @ /8AE3\!W;*>I @ + D !D M !X;"]W;W)K&ULC5;;CILP$/T5Q'L77X%$2:3- MI6JE5EIMU?;9FS@)6L"I[23;OZ]M6)88)\T+V,.9,W,&V^/)6=<1V]5 M6:MIO-?Z,$X2M=[SBJD'<>"U^;(5LF+:3.4N40?)V<8Y566" $B3BA5U/)LX MVY.<3<11ET7-GV2DCE7%Y-\Y+\5Y&L/XW?!<[/;:&I+9Y,!V_ ?7/P]/TLR2 MCF535+Q6A:@CR;?3^!&.5] Y.,2O@I]5;QQ9*2]"O-K)U\TT!C8C7O*UMA3, MO$Y\P&KC-Q,18BU*Y9[0^*BVJEL6D4K&WYEW4[GUNOF1YZQ9V M0*T#ZAQ,[%L.N'7 'P[DI@-I'V!'@?KW %:4D2$ < >EG *%7\ :3 M.DS=8#* L%>1(8ID@'BHY1!%1UGF56X5B$@!1B"LC :5T8$RG&:>L@9#>W$^ MP9 @OV/)Y .A MD&;8WT1#%"$$$Z^T0Q1-,:5>:0,1"4+T2FE&066C0&VO;$<(PN<7N+^Z\,H1 M".^H;PNZV"$D]4[!10"%<4K]LW*((AGT-NXJ%!%0ZF_)I'?25USN7-M5T5H< M:VWKTK-VK?T1V4[AV>=PO( !^])>!5QG^:!O[A'?F=P5M8I>A#;]R761K1": MF^S!@UD8>W-UZ28EWVH[S,Q8-OV[F6AQ:.\F27=!FOT#4$L#!!0 ( #V( M94]^#5^B$P, &0, 9 >&PO=V]R:W-H965TRJ)JENY9B'KN> 2AR"NSO')7"[WVR%<+=A%%7M%'[C27LLSXOS4MV&WI8O=UX4=^ M.@NUX*T6=7:B/ZGX53]R.?-ZED->TJK)6>5P>ERZ#WB^PZ$RT(C?.;TU@[&C MI#PQ]JPF7P]+%RF/:$'W0E%D\G&E&UH4BDGZ\;%P_,K^68N78IZR MAFY8\2<_B//235SG0(_9I1 _V.T+[02%KM.I_T:OM)!PY8G<8\^*1O\Z^TLC M6-FQ2%?*[*5]YI5^WCK^5S/8@'0&I#=H@S-IX'<&_IM!\*Y!T!D$]^X0=@:A ML8/7:M?!W&8B6RTXNSF\O0]UIJX=GH?RN/9J49^.?B?CVJ#\?(U M@3^*UX32 "0(-$$P(C"\7+>82&,JC?F$2> ;$;%1<43,D !4)(X,U,Y&D3"( M(UA7".H* 5V&Q^L6$PZVP2@B/D+&C=L 0.RCU )N(2#"R +N("!)DR%P)#(" M14: R, 0V6*28<31#)O7V4:A610;ZD J$AK2;!09@D:R8E!6#%SJ"8($)$B MN$1&7!+K!,Q3MQ'8OAO;#WEV-B*=/.<4U)," 8EA HS@[RH"0I*8'U9T5Z(# M,"#3(3(@U0'8.[F.)ZH&!M2EICI\;[I#2.P38A\^B 03'N9$\>1-P&!E>L#$ MEII8%9+P VG?<8KF;8!\1-E#,,US,9MW]M.!*N[GM[K_UBL_@-02P,$% @ /8AE3W1_Q8^V P #1$ M !D !X;"]W;W)K&ULE5C;CMLV$/T50>^-Q"$I MD@O;0.U-T0 )L$C1]EEKTVLANKB2=IW\?:G+&C)G&#@OEDB?&9X9<@Y)K2Y- M^ZT[6=M'WZNR[M;QJ>_/#TG2[4^VRKL/S=G6[I]CTU9Y[YKM2]*=6YL?1J.J M3"!-LZ3*BSK>K,:^IW:S:E[[LJCM4QMUKU65MS^VMFPNZYC%[QU?BY=3/W0D MF]4Y?[%_V?[O\U/K6LG5RZ&H;-T531VU]KB.?VNL5[-(3R MW#3?AL:GPSI.!T:VM/M^<)&[QYO=V;(_\U.X^N8@^'R_=W['V/P+ICG MO+.[IORW./2G=:SCZ&"/^6O9?VTN?]HY(!E'<_2?[9LM'7Q@XL;8-V4W_D;[ MUZYOJMF+HU+EWZ=G48_/R_1/]FY&&\!L %<#)GYJP&<#?J^!F W$O09R-I"> M03+%/B;S,>_SS:IM+E$[K8=S/BP[]B#==.V'SG%VQO]IP?)9$_"6C)4# M5""XC PN(U9- MP($B'2@B._Y$*12VTLQ+X0Z#W,I2C.:B22X:+6XU,4SJSQ,%$H%J-"05 M0U#QIGEKT"B_&?#EA0 Q&<@*2VF=2PDR?FG/H)M),L;X8H=1#%@62 T+Z"[# MB\X$Q('18L> " EI-Q"UG_H189!.0_FEA9-AY>1&^F0XSMQ2B&8V&"72X'33 MRLFP='*3^72P+A)U0*%@H<.W=&CY9%@_%6*#A9&C);HC4)E;?0$VM-XQ0O", M"KB@%8]AR5/^?L"PFG&>HH P*E,F5$RTYC%*] (*SFBM8N;^G M,8 E!N4$ M".U8"OR4$P(EI!(!-K3 "-R$EBU$#A-$<>I8$YH60 L"S@GE"IH_SQ%H;0* M'.Z 5@7 JB#2-.""KF20OY 3NOP@NR,G&8Y6^$))@'AHAP:ZC@'7L0@I/]#% M!_K^0S?0Q0?XI(".W8 / 4PIADH'PX3B$-A9.5W)'%>R6 C7K0NZ_#BQOP>O M(G3Y<;R_X\L(H/.OY@*)+ 633HP]/LGBUCA\*/B2MR]%W47/3>\NH.,U\=@T MO74NTP\NQ2>;'ZZ-TA[[X56Y]W:ZH$^-OCG/'Q^2ZQ>0S?]02P,$% @ M/8AE3T#5.Y0" P I T !D !X;"]W;W)K&UL ME5?1;ILP%/T5Q'L+UP9"JB32FFG:I$VJ.G5[=A,G007,P$FZOY]M""+V):,O MP3;G'I][;4[LQ5G4;\V!<^F]%WG9+/V#E-5#$#2; R]81Y^*\],&_ M##QG^X/4 \%J4;$]_\GE2_54JU[0LVRS@I=-)DJOYKNE_PD>UB36 0;Q*^/G M9M#V="JO0KSISK?MT@^U(I[SC=043#U.?,WS7#,I'7\Z4K^?4P<.VQ?V+R9Y MEOO$LH]KTN^^_\Q',%UTK4'!N1-^;7 MVQP;*8J.14DIV'O[S$KS/'?\ES \@'0!I ^ Z&8 [0*H%1"TRDRJGYEDJT4M MSE[=KE;%]*: !ZJ*N=&#IG;FG'JE(L()*$I #4%T11!;:;28Q&!*@TEI!'8J""JF"<7%1*B8 M"!&36&):3#R8Y@Y"2PJ"H2-"8E1(C B964)B9Q)5E="N"H***1U9XP05DR!B M4IQ@AA+,IF^2%"5()VR2U$F4AJFS,@B*I(!KF:-:YA/VR-R9Q=9Q"W$E D+\ MZP\G[) .]+^:8+#1HL"(&P&B9SY"@5L)?,!+ #<3F.(F'6B8+D3SP4Q=51!8 M&L[&RH(;"DQQ%'#MPEFB6Y!K(;BAP!1' =!L9QP6X$/ M^ K@Q@)3G 40TXBH\T_JHH"H\HWHP&UL?51]CYL@&/\JA@]0?*OM&FNR>KELR98TM^SV-]7' M:@[$ :VW;S] ZZSE]H_ X^_M023MN7B3-8#RWAEMY1[52G4[C&51 R-RQ3MH M]9N*"T:47HHSEIT 4EH2HSCT_00STK0H2VWM*+*47Q1M6C@*3UX8(^+/ 2CO M]RA M\)+ L[<@9?H#ZV1V%7N%)I6P8M++AK2>@VJ//P2Y/#-X"7AOH MY6SNF4Y.G+^9Q==RCWP3""@4RB@0/5PA!TJ-D([Q>]1$DZ4ASN6/SW^ *5,--$NU1<"KMTRLN4G$V MJN@HC+P/8]/:L1_U;S0W(1P)X40(XO\2HI$0+0AX2&9;?2**9*G@O2>&C]41 MY6ZNHUBX,PQ5N$2.UR"9+%= M+E 8NZ.LG5'6CB@+E\. 268NGX(/=C5QFB0.D\W")'DP";;A8NOS1U"XB9)% M%#P[M.82^4[$N6FE=^)*GW][2BO.%6A!?Z5[J_6]-2TH5,I,-WHNAK]W6"C> MC1<3GF['["]02P,$% @ /8AE3ZD1F-Q7 P ) \ !D !X;"]W;W)K M&ULE9?;$! I(X9FS/-#[$29.93#IM MKXDMVTP N8#M].TK0*:6M')(+F(.W[_[+UH6&)U8^5[M**VMCSPKJK&]J^O] MK>-4JQW-D^J&[6G!SVQ8F29Z4?^]HQDYC&]GG Z_I=EBJ;D(D M_.=(IS3+FDCB49;_3=;T;VY%MK>DF.63U M*SLMJ2C(MRU1_1,]THSCC1.>8\6RJOUOK0Y5S7(1A5O)DX_N-RW:WU-W)HR% M#!9@(<"] 'E7!40(R%"!)P3>?P&Y*O"%P!^:(1""8*@@%()PJ" 2@FBH(!:" M>*@ N>>511F^6F4!YU KE+U(Y2)R,QWB/%DY@EB?)EYAIB@9QR^S/U: M8WBM<1N!2!%". *!(Y V@B=%4+KEL6."EBE:)G+;/Z5FG0M="'S60>0KH.3= M@[U[@'=E/6>>ELH+ 4L+G<-1A#7N7N>"0.8DYS[LW->9$ [5 M N/B*:9R+X1'$!%]I0=+5&Q/Z5 M@I'I\86 9,ITG0OH,AG"*/;5FV@Q%%P. &7[AHF,,&#?-\0PS&1$OK!FAMF( M@.%( KGH.P%)12,4>I'RI)H"(,:!JUU$*![O^B@RF#>,1Z3/1X^$JGE??]Q M@V8*@"0,S8UIF)$(&I*1F@N"8D,BP\!"P,3R3&8-!#F9R/ M $20>L\X%R^OS??C; M(=\NN^^V;J=F>_%-ZO0?QI-_4$L#!!0 ( #V(94^2MAF$40( '$' 9 M >&PO=V]R:W-H965T@07I=]@;8\M[?TDE^D>M-'(4SP7E>- M7H9'8]H%0GI[%#77,]F*QG[92U5S8[OJ@'2K!-]Y4ETABG&":EXV89'[L6=5 MY/)DJK(1SRK0I[KFZO>3J.1E&9+P.O!2'H[&#: B;_E!?!?FM7U6MH=N*KNR M%HTN91,HL5^&'\EB33S!(WZ4XJ('[<"5LI'RS76^[)8A=HE$);;&27#[.HN5 MJ"JG9'/\ZD7#FZ%O,AFNQDM7/.RS +@YW8\U-E7N3EL^@+ MBL.@K_ZK.(O*PET2Z[&5E?;/8'O21M:]BHU2\_?N73;^?>GUKS280'L"O1$( M^R8OT[(IKQ%I6!4ZNG17=0(%HA M@<@+L#L!-LK886*/:3I,S+($MF&@#0-LXM&4LHD-(21EV0BWFN(H37 T"@VI M,8RS#(X=@[%C('8R,HHG1A\(C1F.8:,$-$H HW1DE$PKP@DFR1PV2D&C%%@P M#Z8D P4R(.EHX:\[3#;\0V26$-AF#MK,IS;Q>.]T&(('/NF,IK"-@T%['0-& M9+Q)\=2)D!E^9/7@6"& %1U;D&PO=V]R:W-H965TRJ*2*S=3JEYZGMQGK*3RB=>LTF^.7)14Z:DX M>;(6C!YL4%EXQ/=CKZ1YY::)7=N*-.%G5>05VPI'GLN2BC\;5O!FY8)[77C) M3YDR"UZ:U/3$OC/UH]X*/?-ZED->LDKFO'($.Z[<-2PWQ#OSM2M]FY4"^\^ #I D@?0-I:6B&;^4>J:)H(WCBBW?R:FC.&)=%[ MLS>+=BOL.YV\U*N7-(R"Q+L8H@ZS:3%D@($>X6GV7H)@$AOR$!Y&(4X0H#D& MEB"X(8AP@A E""U!>$,0WQ798F*+J2SF Y#(QV4B5"9"9&9W,BTF&LI$,+(; M,:H2(RKS.Y7X405F\8C,#)69(3(+G&".$LRGG]H")5A,.+4%4BB!&2X#/FX! M?\*Y=:#;@PO&A$:\!A..K@/=G=V880"UW!K(HU(\\E\&W'3P#M1,1G<>##%>8!9;VSG<>?!H_4@B$8-[KV3B9&]\Z>SYN;+MQF"U[RK6Q-Z; M_^!M2_*-BE->26?'E;Y][1UYY%PQG8W_I"O.=!?43PIV5&8XTV/1M@+M1/&Z M:W.\OM=*_P)02P,$% @ /8AE3]G$M.F_ @ :@L !D !X;"]W;W)K M&ULE59AKYHP%/TKA!_PH"V@O*B)NBQ;LB7F+=L^ M]VE5\H"RMNK;OU];D &]*N^+T'+NZ;E'C]S9A8LW>61,>>]%7LJY?U2J>@X" MN3VR@LHG7K%2/]ES45"EE^(0R$HPNK-%11[@,$R"@F:EOYC9O8U8S/A)Y5G) M-L*3IZ*@XN^*Y?PR]Y%_W7C)#D=E-H+%K*(']H.IG]5&Z%70LNRR@I4RXZ4G MV'[N+]'S&A-38!&_,G:1G7O/M/+*^9M9?-W-_= H8CG;*D-!]>7,UBS/#9/6 M\:/CNWI*5&_EL$%N"G ;4$4WRT@ M30$9% 2U,MOJ)ZKH8B;XQ1/UMU51\Z- ST2;N36;UCO[3'YY$25H%IP- M48-9U1CL 4R+"+2"5@:&9*RP4QXE>'#$?4SO$ +V2BP!Z1$0F" " M"2)+$/4(HH%9-2:QF++&Q.F@$Q>#XC"$E<2@DMA10G ,$R0@03+>BPE(, &\ MB =>U)BXTV>:=/JLS7@ ZDF9@E*F@)0$)DA!@G2\&2B$8Q2.L*,!=5N-4L>/ M1ZB^G!NI1H"2:\@#5EP.G%T'QG=Z@@&.' MX@^8 @H,"CA^:?L 4.( H'6-*ZOX&0M>4 M!ZC^RPA.,W;33,BM]QF<0(S&FX+A!&+LFC(9M+MJ0+V_S^%[\QZD+P3.,09R M/!D."=A-*$)#)7]+3^5=L+L[+:#Y!+;R><_O)Y"OU-Q MR$KIO7*EYR<[Y>PY5TQ+"9^TB*,>?-M%SO;*W$[TO:BGOWJA>-5,MD$[7B_^ M 5!+ P04 " ]B&5/]J3CY 4" " !0 &0 'AL+W=O6^,=C)'C5+]#F-9-<"(?. ]=/KD MQ 4C2IOBC&4O@-26Q"@.?3_%C+0=*C+K.X@BXQ=%VPX.PI,7QHCXLP?*AQP% MZ-WQTIX;91RXR'IRAN^@?O0'H2T\1ZE;!IUL>><)..7H,=B5J<%;P,\6!KG8 M>Z:2(^>OQOA2Y\@W@H!"I4P$HIVZEB.1 M4'+ZJZU5DZ,M\FHXD0M5+WSX#%,]"?*FXK_"%:B&&R4Z1\6IM%^ONDC%V11% M2V'D;5S;SJ[#>))^FFAN0C@1PIF@=D:5'2WJ4N /$S@"Q#1#?-"I:-6K$I!;364P2K.NX MQP1)'+N5)$XEB4-)O%(R8I)%EK78\AX2^O^YL]2I(W7H2%8ZTON.;%>8\AX3 M;.+UW>#%#\U G.W;EU[%+YV=.POO/%X>0_L@_L''V?2-B'/;2>_(E7Y6]N<_ M<:Y :_$?=#\:/0YG@\))F>U&[\4X%$9#\7Z:=W@>NL5?4$L#!!0 ( #V( M94\(G9\9I@$ +T# 9 >&PO=V]R:W-H965T;,M@"/O2G:VH*US_9XQ6[6@N+W3/72XTVBCN,/0G)GM#? ZD)1D M:9+<,\5%1\L\Y(ZFS/7%2='!T1![48J;CP-(/11T1;\2K^+<.I]@9=[S,_P" M][L_&HS8K%(+!9T5NB,&FH)^6^T/F<<'P!\!@UW\$]_)2>LW'_RH"YKX@D!" MY;P"Q^4*CR"E%\(R_DV:=+;TQ.7_E_ISZ!U[.7$+CUK^%;5K"[JCI(:&7Z1[ MU<-WF/K94#(U_Q.N(!'N*T&/2DL;OJ2Z6*?5I(*E*/X^KJ(+ZS#N;#<3+4Y( M)T(Z$]) 8*-1J/R).U[F1@_$C+/ON3_BU3[%V50^&481]K!XB]EKF6WO8AAUH[4#U$ON\+:T^);F0$+C_"^> M/3'CC1H#I_OIL;#YQ9:?4$L#!!0 ( #V(94^MA(:8'@( (T& 9 M>&PO=V]R:W-H965T9!+0&4]L)V[>O#RRBX-S@ __\WXR1AW)D_%4T -)[ZV@O*K^1 M;">$>D6O(K$@,'5 KO #Y,_AP-4*S2[GMH->M*SW M.%PJ_V.XVX]6+K^?*#W1&0.$DM051PQV>@5+MI/+X M,YGZ,U,'+N?O[I]-\:J8(Q'PS.CO]BR;RL]][PP72B4NG(FQW;WHRC?9.F4Y@[ $\!> [ MA8+,IE_ M(I+4)6>CQ^WA#T1_XW"'U=F<]*8Y"O-.)2_4[KV.\[!$=VTT:?96@Y>:))XU M2/G/$.R$8&,0+0QPE+@-(J=!9 SB_[+$JRRM)C6:WFJRR V)G9#8 8E6$*M) M%I P"S,W)7%2$@0; /! M\8,OGSLAN0.2K2#YMI+@P7$53DCA@.0K2+&!1$6!W90P<-^UP,$IUI&PO=V]R:W-H965T3+>)^9>$D9 B_WG_0?L7??RX%9>-#B+^_<4.,[C#KHV4FX%ST]P=S/ M#49S\[_@#,++0R4^1ZN%C5_4GJS3.:+M]Y[;LK[K"+G )HUNZ2A M5YI\T1#/7Y+0U20T LHK %T'%*N (@***T"Q#BA7 >5*!>67-I/F/FI4U.2; MKU62B[F&:_O,S)$KBP[:^5\4!]EK[<#SLHV_"X-_*8LAH'=A>^OW)MV79#@] MSD^!+.^Q^0]02P,$% @ /8AE3Z:V=F>D 0 F0, !D !X;"]W;W)K M&UL;9/;;N,@$(9?!?$ )2%.#Y%M:=/5JI5:*>IJ MVVMBCV-4#EX@*/6@OW MN05E^X(NZ;?C11[:$!VLS#MQ@+\0_G4[AQ:;*+748+RTACAH"OIKN=EF49\$ MKQ)Z?[8GL9.]M>_1>*P+NH@%@8(J1(+ Y03WH%0$81G_1R:=4L; \_TW_4_J M'7O9"P_W5KW).K0%O:6DAD8<57BQ_0.,_:PI&9M_@A,HE,=*,$=EE4]?4AU] ML'JD8"E:? RK-&GMAY-L/8;-!_ Q@$\!?)5Z&1*ERG^+(,K\ MW'"<316=:13I#(OWZ#V5V=TZ9Z<(&C7;0<,O-->3AB%_2L)GD_ $R"X -_. MU2Q@E0"K"\#M/"";!60S%=S]:'/0K)/&) W_D8*=337^M,_"':3Q9&\#7E : M8V-M *0MKA#4XCN9# 5-B-L;W+OA;QF,8+OQ(;#I-99?4$L#!!0 ( #V( M94^$D$Y9? , \1 9 >&PO=V]R:W-H965T@=&!E1_5AE)N?>9948WM#>?;6\>I%AN:)]4-V])"?+-B99YP<5JN MG6I;TF39D/+,P:X;.'F2%O9DU%Q[+29Z4_Z8T8X>QC>S3 MA;=TO>'U!6])16!)@F=*\"7!;PG(OT@@ MDD#.$=!%0B )@2DAE(3P3 @N$B))B$PCQ)(0FQ*0>ZJ<:TQIBWVN-O*:1CQV M2=-V=PE/)J.2':SR.#G;I!Y0="M80KR^VC1R\Z5HO4I%P H>K. U"GXW!V]0Z]D1$S28HL$$H5O_#>JDXG ,X.8J M+B:!K^">59P+K\V'U^:K:_,U"@16(.;[&\ * 9##8 9>5(R'-'T0PE%"18&X M :P0P0J1^4IC6"$&<@@'4QHK%46Q4ODNKW19T M1!=87#2T,@@4:P+IK!>I&DB7K,84T!=< 6EL 0&^,.S;>P#4;5QIS :@^150 M/V7-M"-UW E"&@W-O*,O##S23#Q2QYF@P4_:HP21[B1HPFA&'@$S/]S71PGJ M#0G2-K_&&E $1/*'O0"!R+ 7#$#S*Z!^RAHO0H 9H6 82/4&'VOV!FN, 0,S MCT*-AF;F,3)O.JR[$"T[T F_P%02P,$% @ M/8AE3_0"A[&F 0 FP, !D !X;"]W;W)K&UL M;9-M;YLP$,>_BN4/$!.'M%4$2$NG:9-6*6JU[;4#1[#J!V8[H?WV/1N*DHHW MV'?^W^\>L(O!NE?? 03RII7Q)>U"Z'>,^;H#+?S*]F#PI+5.BX"F.S'?.Q!- M"M**\2R[8UI(0ZLB^0ZN*NPY*&G@X(@_:RW<^QZ4'4JZII^.9WGJ0G2PJNC% M"5X@_.D/#BTV4QJIP7AI#7'0EO3;>K?/HSX)_DH8_-6>Q$Z.UKY&XU=3TBP6 M! KJ$ D"EPL\@E(1A&7\GYAT3AD#K_>?]!^I=^SE*#P\6O5/-J$KZ0,E#;3B MK,*S'7["U,^6DJGYWW !A?)8">:HK?+I2^JS#U9/%"Q%B[=QE2:MPWBRS:>P MY0 ^!? Y@*< -B9*E7\7052%LP-QX^Q[$7_Q>L=Q-G5TIE&D,RS>H_=2;?FF M8)<(FC3[4<-O-/FL8A0Y?RFPH:$/< MWN/>C?=E-(+MIZ? YO=8?0!02P,$% @ /8AE3WTIHW*L4P 2S0! !0 M !X;"]S:&%R9613=')I;F=S+GAM;.V]>W/CR)$O^O M%DF@GEE9^?AEYA_*]AN-^]^^*&_1!UN\,?UG&:_4[MLO3ON^0TWV7;__C=(!K_[H]_ M*-,__F'[Q]/\,2G4)KY/U+$J'^(B*?_PP_:/?_@!?^9'3M2G/-L^E&J:+9)% M_==9LNFH7C=043<\J?]XF3]V5#=L_M%VW:G_=);/=^LDVZK;YTU2_S'L'O_2 M^L(ON[C8)L7J6=TDF[S8UA_<%CNO0?/R=5*D^0+GJ<[BK?>&X[[7L[QZ MD]RGY18ZWZK+>.UU<#FY_7PSN5 ?IY.+VX_J]F9Z>393IU5V+#T7BTW,O@OW:/L1 +GGL';!Z@Z?X"38!^L_JS]Z6 MZ1H.\;; KS1N]W@0U;^ZR.?Q2ET_Y%D;(??"[NBX M.^YVO?&G6Z#^? E;=73W5LV2^:Z [GW.L5X#^<1J.F7.6P0<,GFDS4[FW@\ M25;\=%<4R!68%5#W<(YV'IO]J\]YS3$$CA;/M^EC@GPIUDWNX2!P1N&LWN?^ M!D_F\P1^AU\7_&1+*[-UO%JI][L2Z+9L&]ETG13W.*6?BOQI^P 4LM[$F=>G M;O(A@2;W/U/=VAE=2.IJMRVW<89[U_8:+$4T8SN^V\0&^]-9M[[TA;\LMU/C^+SUO M/^'5!;^^BKWE.;VZG%U=G)]-;J=GZOWD8G)Y.E6SC]/I[0SN^\^S,W7TYJUZ MH](,>%.^*V&1O3[/DCE<>WR)C]M6+R[+9%N^\WZ.RP<%C:HY_I'\?9?"287G MO4[.LT?X.B]2_Q1<;1^ GN>5CKR3G6]AY?8_!X<"@;7+9 98EW MDJXV>$*0L%=)7":J2.\?ML?Y\G@''YI;_RG/%T_IRN,J-PED;I[YMV\V]Z9U9I?)>N0!Q)_.T!9H#70 D\]#F^6WGT#K^# MO 0CAU.9EB7!W"(!1)C\F?@/@V3 MJF^,,[G]9+/GP2KM['D0Q:%U@CN5M*Y893]U6QXWNLBS^V-@ZFN8ZQQ%HD?_ MKJ)1[1D-@* M95(\)K_[H_*N/62_#_EJD13EO_VO<12.?J03LWWV2.BZT#,NF6?K2UC?RC^J M00#,%_\G"H:*=]L'..K_2!8_JBS7WP*!(0GA7/)VAB\71'MGW7V]A5%P,CH) M^F&_WNL6I(W--D%QQ:@S-!9@?_)M"PL$D8J$?=BN39PNCH%\Y_$FA>WS><$6 MM#$\)G&1P=R\/87SMEOO5G0YYTR_<%L6R0,<*KS]5[E_%=^":%;N0!J7)8&9 MS/-R"W,-^H.3H'O2I6F$P;#;"WI19);E\!D'<&S+34(2R,HC9J;4LI5D7J1L MZO3P]_?=:4?7,9[BAV0+.L;J+=QQ;]0/+7HMJ3-T/WFHKO] MY^0.M:GY]O]]D>:M"'H$N[_(5ZNX**T<6C^%?@,>J5)#_.W!;PLI?\6;SGG; M]WKU[+UVTM6W7S7CQE=?GF[]:,B+^SIR:6MV"_]\FEX"75U]4%?7TYO)[3D\ MH(X^7TX^GYW#,V\=*4H/RQ&E@A=$J][!IA6/Z\AE9(FXG5PODZTJ0>QJN$)* M(O[&'T&D![5U4^3+=(]\I"]\7_*S(H-^R)_?:@5M! HNK02E=^0#\6*=9F3& M('VG3:!@)I)[XVA9IB/DG&_5LLC7^J5662:E5QKEPFIK=\DR+Q)YGL6"=I$! M5_(QQ?5HVI[4;?C%!^B0S>5,(-5YJ_\^+M/Y@>?R+%WMMG*07G[ZSPG*PLGB M.'Z$902%.",5'\G('5&%I^P97LLY=,?T^J-Z>O7I^F;Z<7HY._]UJLXOX?-4 M'5UR;'#[X;MJN,8KFTF$A@T#D7@+]0$(++W/1#J= M/RLT[Y4K-I_%B[_M2I( ?<,7<+X5<=5[D#A@,^#IQSA=HE6S= M:!8NV\;[BGV8W5Z=_OSQZN)L>C/[=S7]Y?/Y[5^_:@/HM+=?9B2N[C,2[1'9 MKE%D.\_4Z0LBV_0 D8WWNKIV1Q=T8IE.6B^HQE%ZM_5=\PRE;W^AH;J&_T-337OLTA[&WK=(NUMZM!%VMO( MZQG'*XCIV]IZ->/X"I)J9!S?DZK^M,N^#U7M;>AU5+6WJ4.I:F\CWW8=?2M5 M[6WKFZZC;Z&JO>U\ T-O<)9_'4/W&OIZANXU]34,W6OD&QCZ-RW2WH:^GJ%_ M]2+M;>3;&/H+Z_1M;7T30S]PM5YDZ%X[-\EF5\P?4!9T%%,2U?;(:.UO?<<+ MXYNH=F]#7W]A?#75[I_8-VB&KS'D[J6$O5?:"\*%H_4WZQ"M6K\O[1]J)-UC MU9C,/JH/%U=_;C- [M>AG=<_W%Q]TO;,RY_4Y/3V_-?SV_/IS'<0&A-#J;:Y M*I)YGLT1H91Y-BGX&;\D1R_9NA8PZ;MG=;0K$_3IO76L=01F:'9)GB6@/,]3 ML7"@07"-L(E_T!>>90Q&@_VQ,[#%S&A<$[B#K+;M3J>]]OM/+UT_V MI2TYO_QU.GMI2ZZ%195(EIM&GW;K4&5T\/^/2?G*P7TXOYQPFS?GIWB4^2E[D>'>$<[C6YI+T%7:UM#L\_7U!7&/ MR84Z.Y^=7ES-/D,3Y,NX_3B]L0P%"._#UECMB]VBBK-PP:ID7 M*EEO5OES K+T\7M:0,M6#UVCNSS;\A<5CZ&Y*,I] M3IAO&2OB W<%;<&5\5[PE]#_QR1>;1\47/]X\$[S8M,)5 RZR0KW)%$.B%,= M/<&5BE9*6.DL)QZ^VM&MCE#)#;@[6U29+&84A MI2N%S2!IE]3V'"82J"?X+B/X(C8N8_O[+EX1)G()M+),9(S(&A>[.4QJE\&E M[4[F\N.M^FF5@QBCG[TKH+T.W)VF>W%!E^H)+OW5\W'^A+3JKH]ZB!\37 1! MYFT>GDN4513A*O# &5CKTMH('_"%5G'Q6^(DJ*O)[ L\#S,Y>DAG3_@2I1I MN26VCK\C>)5LV\CL@"#C+%[$^._S&CH]+U?L8/R4?$GG.5-H4NQ^5#_!&=VB M&?H!"+2I\8\Y#.7G'!UOMW'Z%#-YT^,_JEF^@\[CE657 M\:K,A07P;7RS*Z$'>O[G^!_Q;P_H5((%*O+=/4++@ G>Q_NAUHBE4CC+VOLMB. 1;XD:P=NF:9LSG'[YVJ-.VW^7 M)!EN^"9F 0.!4'FQ('[)HV&$%>[^IH##EFY6,"]Q>*Z>\7<$82PTL51V'<VD&? A(']B%"":?8#'%"+GZ;&;'8AP\*D;8A4PL!HA?!P,"70PEK7.7["\UI]5^%U M@]>*'F9*M+ @P/]CHH?7W")0Z1T+\21KZ=$M&17[G*"N!N,IDP.6O00M:+7 M]C @A@2\//O;+J,#84_)RPVQ ,CN/23WLD+:36N-JJ2:9!G<2H+Y1DE5G[^? MH1N\[,P0JL0[,QY9YI!:,+)H"G4TFYZ^Q28G<#A6*AJRWML!KF;."KFI70'F M]J#)RM0,Y1,DLTI2K)(!,.4HSYW9]2!M07%&I;$1).<"J>"90'207I!W7''$Z,Y:,,% M!4@Y_12F*01NYM@3GA+Z4V"AU-S&N3=H /C+Q'*KZR+/X.^Y+">PEP_)7;'# MTPI;-&26\F$R>Z] I8CO5BD,9*%N@?_,U;@?!>HB(<4N0%D(78K8Z&3V65WF M'6KAN!OI*[E -05Y+NQWF21&/8?U_@?O((&6>7USZ.M>CMF8)4H8*?R$C!NQZMRU,ZOQ M<1BB*%+<)SBN\S7>V(FPONIS713,%W;+W6=Q 6S?+"%6WL8XM LZ53!KCO>B MJ KD+E/@.HL4OT.VXP1P51IE?I@E3XJ0+:#O.!M)EZ:KZ!S=7'U^J];Y(EG! M^L9;NV6Q;%IUSV(%+[!ZQ,:'BOKSW+Q-= O 09.M% F(H,4K$/%(\ 4A*8Q@ M((@TZV@:(\7 4GVL+PD*\#(Z6, MUDY:3"HY;CT.:!-O40M@$'+U05+:R2BC MYTE?RW&L7%OV(N@H5OGQPOA3G-'Q$>->4&5%BYS$@&U]4W:E'EMB6D*VA[-$ MID5_(P/#\2#N;+-9R9 ;MMC8=V('ZP0]"^37T%"B:8CYC:&AJH";K/AZ<_21 M33S_#9%49,_Q6Q,E11]\6*@UBEHEO"(ILJ\0%QRSE9I-4(*A MLJ2FP3_KW5HAXR=0]S,S&%Y8$R@@W$\O;>4/DC/K46 M@^2P5A)*)[M[$/X$>HUC@RM?0TQN$EXU9&N]'K#$02]B]D+M*V!:L7+:!K%M\T5DF:>G.F(1;^P M.&:-L X<;??I,PP)JN@NWKU;.#^KHI1N;07 M*0EZR 6U,'L'C^$X#(0TA+7\C^Q-"IG>;EOT'00!N(KC-Y%3-07!* M^8;>DGELE: .4'],1J[Y?UJ*9W*%7%5'&^5X+.0^^="YZKP'?H-K1F)I#B>O MHVU=348NO1-6CE.+G&A?ZZ\DV?"=R9$@>+LC,X2#NN8 ,-#)B10,T+F4&!:2 M0#3&6Z12:*E(X QDCDY'Q,([9)5]T.2*K8Z54AG904&WF&]W=/GR+G-3EI:* M!8LT:,98L!5$^Z=HJK4K&3CVFM0O4FXHE$U,('A.://K/9G[!*\K_E)M0#N9 M:]7M >Z!O#!7.6PTK(U1J*G=5#=C*,9MB R:24S6-PK5U@3PR.9'PK*'?1!F MGHG ,=R:M!06?:&YM'!'(6T7;$X4)8*M[M32[[&1P>]-/ 0$%&%GO%3 HL; MV=_YNL/QR06:880[2YF*Y?R6^"+2D*LQ11VXSRP;=>X!NS<5=4USB\6N,&*H M;[TP-VY_[XWKTL(#4(T1T7)]3]#KI3Y/M+WPGU75<:7Y(9+>$BVPS!^P16)6 MBPH;0@);[E9+$&F(WZ (%50(4!M 2+BB96\<0+ILX=,2GB!V#CI<.SI2PJM1 M87]I2ODW;?\AU76\D3F6]\I$I/;!200 M61 0M,B6J>\*>Z:P0YH!!UAMGS6CY8%@+^:D4'@ ;=@=F.! YUVPG1!D-&BBUP(USG\-K*3J-"PK1Q*Z 'Y@[46TH%0<. M%'=41Q%+2VQ#W&5:>- \G%?8F%0=0<5.D_:T=ILL:D',S#E<+W+]"7.&MYCX MXT7FF);.]:;F>#?.?T-BQ1H?W&/E3>ZF,C_3SO@VV8, M^7*)!@A8>^@Y='MFL(-6AEY88V=,<&A@]V1D!S/EL[2,[T$:NS>6A";JP;-8 M5HZ1$>6 G)_RXC=>"M>C%,-;\1HM,"C-PQ'F"Y"=!$$5F<-6QL!FPW*W1K)TW5/6 UI@+,D*:79+YD6YIEM<7)5N7!Y@YM+L M!$/#/*_Y\29&:(CO"+NM>"71@(6Q0%NZO1I$/2&H>IUAO#).#U5I,)>,!@-U.BD,U)];&ZDQF.@]?XX MZ ^AZ;#3A6=ZP7 U'0Z^,#,*/@I-=3(?SEN$<5M-B%=J!;^+>GHC%^AOY.(OI, MSE,% \4/@Q#^@7'T\5^8SK!+GXUC%EJA+P81_=/G3V&O3_]JIRTW UV%0^HJ M''7IN& M\%_Z*^KB=V/V!"N:<$2J2QC]:/X-ASSQ^O<<]PG[/@JZ$2QCMPN]T-;#%WWW MB\%),!J=.%^$@V[0B[KFF[#-Q5YSJ0/%(&0!9H\F+S1CL_LCWQ4.6:6HM:=PRE1X:2C;E#;_ #W55YHXR"; M5$G^(X\3V^AHB&L4I@KQ5;2ZI9K!#T:&0UY@KD^,UA>>@C- TS$QD_)?PPVJ MJCWN:S#J14@"_: /1 Y;/P0^,,"?^E$0#<;J0T%1J^P+(9T4COT0CBYPB %P MC5&(E!,,!EUU ??".VE;JSY'X6BDWJJCT6"(_P )CT_PCRCHPSE]*T1I%\N0 MIR%+0XZ6#$]S2OTAN!Q0?]":N#+7BZ,Z6R)[B!=.-_>"]& +?Y=4LVUU*%J) M,U:/%H.>$3ZS!67DX*&XVCU*5G+;4U=(6(Q(L@.J2CO4UJMTP@Y,]0G.41$T M#O).DE&)3V4>9^))YEM]7EE0HZ;"C$MLDZS52Y" '#N1HREK<0%! -J(-%DA M,<,-:Y=$VXD.6A">!AF%Z%9&-YHTD(N,QA_= T>CF)/[VB",%C#^4GLSVLR+ M=A\(G^&8:,G;#M-Q[3ND@GV"']!CC'S.F/*N'%->$U.PEAJVP@N1H#1E@!]J MK5MN,1)VD/6H%4)YMG02A;O";I+-H;G9NEEFQ=H8F^A7:"'1 MX#20L^LL$ SKF*F8%E,0J6-K.2-; MI>>&+%M&IO5*V6@G+Q,;3F'Y=R3BWR7S&)V0Y,IW$-0:J/%D"8QL*L9Z!"-' MT=B:YG3U:6:?9S<^)DB)<8:R9%S MO^T#5+[8O-)9!!RP>CUS EL09+M=S^'35^0Y\,U1@0!Y'#S+ @=%-@(#;*[$ MISCP8U$P_1>R/#M&!'=202?K4&0T"UOS@>/>6R:3S=)Z-K2 0$S./=-H#D/#\G.R=738 ,U8\#,#2TM4HQ8" M"-J)Y:RPP3F\\HUZ#,A.J]6.[##:]+7>["QJ]XXR3S"XP2..ENP:AZH_1F,T MX1WH:8X/D8.L=%--,7)TB0IE#)+>6YT,\>@LR7*"Q>"7]J2P\>.;W^?4'"\O MRCOEIR4Q*298&[9$+8$S(/V@\ 3RT%L4MX8D(1V!4A(IC%X9P3<@L(=!KXN" M$NA#(V71_^88V*P5,(8]!Z&N.AC5HG<(8ZC,[\6);8#F#-W"!8GW-7''0V<< M17K&AXO$.@40[VL;);3]_,_>Z"@8#5%*#E'WZ_*T08/&:4>#H#\:XB\1Z+WP M&7_X)^STR:LW^M#Y[=OO@R;> R58)GZ>&<9"=S@.P?A%45%+A/5^U94$+ D% MLK+UDG%%A;1@ 8Z AD\:0HF*[['>%(('H]P6[+V%2 _!_H$O3 NZ0 #%J*#NQ6+^@1S=P "])GSH].(3I'3W+:NHH#%E-[0%O.JV_ M/.X%_6ZDQH.@UT/+21B$J"KWHF XZ*E:;E,5!>-QB 8N.M5AMP=_H3X>]@;P M?*B<)*_O,'Z&\8_W.9(^,L-QB(<"3DC0%[/7DQ-2N:,@!#V_.57INYJ?$T[E"9[:<3=44PEN M.M808(UF"VF._: +/?T9-@_WBGQ"J4SQV;SBVAQX#M$0!]4+T+CW1@V#, I5 M/4'J.Y#&ZC9UM';BRJ"=?I^K3=(*!8I^:SL@'A)O_2K"I,P?WWWY"6MI% M)H*Q)#Y="P4WY0RNX)/K6BF'-&H<,^B?6/3F[Q,MS6\@/8=E60)? "F#)K9*H6!+BK#(/48J/T^1>_&&J$+ MXE5=5AU"HG,Q^]=2[D*>M,ML:X--G%87! M;VGINVKH: C6,)!F!P<],Y"X"EKW2 R9D]FI#B13O0@V_MQ9M&,>-.%T&>_E M8.*=R\?5*1P%+MUZI%#;J(7>:=A RB(<:I%@,QA32TNSJ M6=@(UW(E<..\_J44:ER]="*18#,TLDZW:U+ M@_KF6XE\842UU#ZVXKZ85MV+/'0>+*+C6Z8>X()B(!^A<34MZZ2+=!%B#%A[ MRZ3UF:5F9(03-E$DUC3S]UV.4Y;3+48:,8$F7[;D13>B'B&I)9[QD4TZA._, MX4"*48T,CZ4"00CF9B/Z\!:"&XE:23-0-X5A(&U0Y)"^Y@\(S\&P+3&%V=A, MPQ+C6L+N -7[(O]"&!F7 +50QSUBC!#BJ!PFU#A" ^7),PUSK8D.;G^EVV&) MF:QA.'"1BXXOX8J6MDS K\H^T"Z+A,QN)N&1$M :;$U-GF MD!;*0)%!C'_($8=*7A8T;J!!''A'X]IS[R*Q"?4!KRBKIWPO<@CE6F=Y#"XX M6<%]0(2"#78JO._NN1(P,Y<2#O[B5)@VK[;$@FOC*-GXDN\@53HW_@6()BL5 MJHEF)90_EO/$.ADG+YC#.2^^^H5/WJ5L.G^#@QV37J75/.[-6*>])Y[_B;D> MI08,3GXVMX" 7XX%V MVC-*UL-DAO5??*O9#7E!Y$?!J=$'':D4C727:))(,7=1M]-%??@$3NYXC5@Q_/*#0H)_0H-66S:Y7J*K.A75'@ M1$?ZK[LIXBGEA,#M6CS9/&S'60#BRGT18]!\ 9, MU7@3#CI= WI#^-VHZWS1J4P"R<*$*^OH96#J#BY2A,RZ%\2&M&B/EQ9WCO/L M^$%B;/.G0(+Z>0_(@=\4+[\R(6QWE:S.:A4_:0.0CHJIR)62!^#N&"YZV4\3 M@2!^[\\Z^.,O-@F15/T/', )-*8,!(]6UNWRSBK,*[UO# M/&*=RT&/;W <-HW/1=&@X,3KOHSGR)/% 50F1J,6F;>50A:Y1-/)+5:9 X'! M^>M8T=%>HOG<6&#Y_/"&X7SOD*^5&^9(C -"&03I O^%^9.>A;+L#K'J<"(^ MP6OAL"'2<<_AA-ER8UCQ)G%!S-[G=;D/4/7:(.VUE C:B$!'E]SF+W\VK M2 %L,*],@D10>$YP"%620&QJO'A,Z0+'7?PIR0O8U9\[ZGV1QXMGS&"SD%DV MQ:#?)5D".X"".P:?TS-KQKL#E^ X!I3U7%MX\_0"T4(0+4DBWM9(#ZVD0H!I M!DL3!G-%\"@Y(# DC U+43^"Q;7;1P,E@YW6>QTX;-CMJ#/V'R,A-(2[VIVF M&,DB_PUWY86-MG-NO%LK2:QU.HPD'4]%G!X75"<(;&8"-KQ*ZUH4XN5VX3!^ >XVK#.=]$^%I6)&WR3U M=!'Z7=*%98&AE2'7 )_>D8N,%$.WI7)=[PR*RF3K"=\4J3H_AM\8VSJ 7BG!!+A!UNZ/F M=IBEF098=K1PS'LJ"0SS?I18)!U(31G[W!1PIE4F K:>E>SIQ0CE'7JV[->Z MK)((">E6?T>+8[)XNHE(R):F,7 \#M&.930M8KU.,P@]Y$NX]RD@%H=E\@]J M88'S)9&*JC\@!XZU68^D#F1BU2L1LQ=@YU$PJ):/.^3F/"IW=W]#] )*B29S MDTX8(';$>5K,=^N2@F3+MUI(E(#T2C0RKP1M&XJ&DT9?18">1.!%@W%/#[7E ME*4Z@Z/EPH96Z!8P66H:TVS(.%0480DY9UEDA9532>#T[9:P!Y(ZBNR8+F#4T'EI M<0IO>J,1;;O(!SQ+-+"QL/=W4UB(8ETE* MO$XXOX0E:NL\^Z\LBW/O\9-\^H@]_%/3'@^:M_#]L M#W<99I)E(Y"S;W@;CIS;L#+>OJ("F[<8-%[CN-2UP$5(7G'(0J-P)!Y?"X(< MZ$D^UWZCE+;BQ:S6L_#L-XOKS%MG!XSTE^Y(*!)++QJ1IO5P?8*:/;\_@*U'JU(4=H:A^LD211_8WGBL1AT06W[E%HY"1"QU!X1FZL#U M4VF\@2F%07?8#<+A"333[ZN7BB.AY9_]4$[ZY0-J8%)HJ(;7.)GBT,+CV@-A M76A8+WE"=)FM4UUFZ]8ILV5S8+M.BY_0K?G#$?LN.!^;<1)#<\<(*JDX=]AF M+R"CH&%G&"H8CLA$KTWU^-4 [?DOUA%31X,>OAOUX"\X F]M7PT;12V/!GWI MI*L[&PWAJ[IE]V(ZF4T]+(@DDFHW"/-K%2>9I*DZ@9L$+ECDJ;!M"=<_XWM= M4982) 0;]N)FM4J^;-*"A14WNQI0,/WFNYVS !:]UH9NMM$$969WD?KB.964A M3<8C\D*YV\JCN<0L;[+.4=,P:NM%3 "S^E)ZBB7[_3E<%K-=26Y<%@=-_'&= M+C#X+^#02YTJ-W"#-H/F7+B2_A9A+0M@4)7\N %'/9H4';5TO@VY<&5",4?4 M'.MK5HR<; M;DJR+?F+U_SS @8%['5-84]0J_AZ&1J(HMSK;IET-@LE+!N6? MX!*Y_P=\K=^GRY#Q=D"Y9(K6KC6+]$]$$DH6QF:AHZ5-4+2'H7*#B#A&G"QP M(E.XN3$$E0(7YMV.122;-51RJTJOU834XK[#Y")9TB;(VZZ!>O)[=-//W2 G MD\%5TI7%E0O=&HV9LA\D[Z(D#T%4%T%W!2.8E&SY?DP,4DD D7BAXNIV&K"C MDH9-AUA8A*Q<OBB M7)/.C.&],<5R!J/^@!&J)!$*CFGG .-D6UMG==.;D$[%C?E'%JBWU"E;.&L M;T(GU=RWK7<3I_)0W#;Q',^:%L4%8@G03XPAV]R?3]QF\:EM^#OEE6]M[!WI M@I29MZK7B?R7JB,;4"S^I.108XF,EI%)&BG)/4 .//3P +NA=ZN7'9>%X/WD MW0-2N$,_-@G6_()L2"%RK\Y 5$]?3P%%%EQ0B=:KI#(UJK*XZ#3IK=>))(7C M?)&8S$[C#%GCJ6<1Y#=UA@S>;3$^E7 -+G:8,:?ZD%ZM?3D1#]U<[S3?T-8N MV#@)-VBXX;3F2$LH=[+LWH$5YS MGVAW#EB0P-H2/L;.0LJ@3"36E"HQEB9M)&6K4UP$Y&+QOV0(+BEF\J.2LVO)= MGHDN_MI3G Q(0J%KOWF@$@G.O)W\Q=<=)#;I-O[BX,CWJ!)N6W2N;&)7:Q)F MGO"50>B4+(?2-S),$].R06L>_)>3MBQ>"94?'UA>C,HN-Z)PE MGY5)DW.:+^BPA2?C(6%N)?LRV8F\04B>T9?3CX, N5QJJ^6,/CB@S/>[U0K- M[)2>- 2E5F.^9Y/W^-D6$)%DMCK!XOTN9=].GKG).6DS82UY_4MW \A3(\VZ M.7K=NU^ D"S#,K8;SQBA,M"%_(R:B@E]-MDZI'G>-7L#+//"@DPE,HQ\C,(X MS*C9A#.9G:I1G^#MFM@)PG[>#*(G=:@2IJLGY\\(*Z$X'D[JGI+_ND4 G(/A MDR].3Y\4FCP?C+I58F1Q=*C2FOQ2.94KYS?9!C:I%CBPX>)"GR8K) +H1&RS MX>=&@),$9];D0@D^[41TL+E3HZ(VK1IGU0#CBH7>23E5;UKGW<)&N$@,'BTX M!03:OE-MN%R>F=3 3K0AC,U/TT')\IW*-TM=Y=T6ZBG-R?GI_.+V M7)\;,C%4Q1"+W*8G[8AJ&!S4K\V; >E-L@XD4I*]8JF=)G1OR&P,1HFG'^?T(GRQW$(JOAL] &B" ZY00C0;9\?&,U M@!6V63^%?&M+(]S'7"*4?0Y>$6-M%/Z>N7&E2Q$YL\J@-0'EE(7+7$I:.@V[ MG<'O>4*5<8%4H3.=I*B.K+FLR-)>!&2;9XLX0:I(=X /4UT$:J2I+;V-THG7XOK2!Z#,?RM[2JXZ>E<%L+D9.,)L_^8%[F M12=[/=OM.GGL8(?),\K%*RDN94MZ RVXR8Z'$V=9LF:. 8;Q3"A$+&PA42&Y MHV68:''4W6Q(D@;_/7,6'L0HK=+?D.:((]CT[2M=N0%'(%2MK[RTB"Q M7;OYP22N.)0EPN,V$H8&C#1-V^HKU>F?/EL>8LB>MX^1!:D.> M:RYJJ_DM8< :H]"P)0:^8"2E MTA,$YO$FW=ILQS:5;6O$(&-(77 K0:Z$W8(HIPV/SIUGKD1B<;K2Q@)3AR/J M*-5.,M2^EU@K 6>*-5VV)8$6F,-7JN50.J0M8P_M/K"UMS9XVCL-'14G)@B% M&)M %YG4@?!,LGKT%3,),JO=AN1;MKSH$9MYL D6VN0%POPMN@@5B2,LO%J< MLR->>>NE@Q-DJ3!R*\XX,[]=MIJ^3RRF5M^F680S9&N4>0BAW5"%0S MLJJ1?DUK=*TBOV_<=\T\)-^K>+AL2(#)[[JP,@L?,W'9P RWG" #3H M?*!O ME:JT#GU53Y([*XS&X!1I TYBYTN>&6D%;$N3',4%%R[+%N;V:3MXK08T@_23 M6Q,.,D($T!+ ^FTM^[+&KFM4YGX!GC89M\B7GPFJN+D4E+("]<_Y33(I;8:DHR+5?RTUD@@ M"Z/+NJ88SZ(R8Q\:\VJS!=0.$B2V&KCEZ@2RI]/T4D](MH3ZY&(QL4']8,]X MM4O:;#'\NE=;V]V*8HK8!5E=X+[O$C)%2(2<'',;2BX90?7,R4E64>#=^I8Y M3E4R<"-YINND0=37]Z"C:GLWFC-E%C-YL 9=@^@=&@HKI%4I@")$^ !1+CQL MBK/7/U?XN9!E#>#GEUK_].G\]I,IKWQZ=8FUMZ>7I^>^P9(L8%L;''Q*UR\( MUE3PX2 ;YM[^W(BH<6.Q*SF)VZ=5'$IL>E;" M9;@,86,%S;.4L4G0-QPYF_^:DFNN[,^PONX9!]$+6TXP7_!NN42W]F-G+S(6 M>824,HK>A2?'\\?C+AR2GO6!KD#HW_)9*R2_-PDB.)=T31?#7?(0KY9T:YJ" MP527T %F8P@)TM-36B8ZC&=!CI<*[3%B.C'&!1:56U!Q#-%84H-A[),XWAM@_)FZB)_4A[18!^H:A+F.>14MWG"UTDBXC( >2JUEYC:X M:%("TJR#?5>'O?(\#!:$WU1_RVG1MNE&E_?"!:3MA),.ZX%>*'4' LJ24/YL M([ TB]'(0/AB[@11%!T:Q%!0)ZYTR:G\6;N"&XV"5=#CO>.,I]IWX8X%90R* M<+1"(V^$CI4P)JPK%S5FXF[L23 3;A@L&51KZV<\*6:M\PW?UO#RU7R;8S^A M*1)[YBT*AA@0=*C<;3@MN#8X^2-XBO7X*&6U8++ZUNR$ W^ &UVV@+ 8N99J M[=5="A#.-!&._0%J XDY^ER*$-D^"@*HL:"ZA*@YG?"P),R*P@P0> &V&75,BG0'L! M"O4L+%/B6P*$4RU*5+-)(@C8O?!,S\JR"2#'27V#1KJ,]372RT%5(OI#\QQ5 M.25;>R;62 ?%I[U-H*(2VB5!F95^ A)E1U!AR"-EI!=Z6RJ6#.O[)6T/I924 M+?PL#$N!Y(8"@1>3V^F9NI[3T]OSJTM/BKT1#-$UH=UNW:K+ M[7)K>_/U"L>]FN5&&"(%?<=PE3R#"/BL)J;&'B[?!A<=$X[J*&SYJ@=)M;4PGY9V%XM3;W_.#-"5/7J!\%TAXXNE-8IU$!J M,\0FT1X:TA(L5S3;YIB;O3^.?E2=?TF( M#4@&\ Z>"EEX@X&*):00\U]@V!8?<3*8:F'?@!C=U3K*"^9JSI<+D 1UP9QT MC1<(IM7*K#?M^$#I!OQ"#IUQ5A:JE0%TB3 ]M\U!]7VO^V G@-GC,W%Y]- ML)#94AR[)G+03,G6LI10,R-DDB9/!BU*18#EH;M<1U +!6A$H<):P;X@-MG! M+)?GI=HJ:EE!;0BF[U)2E[ O(>I6)X[APSOF&0Y^62H$+$P9/HT,P%A^MW?HU0H2MC'?(5'W2WH"=HJ7-;'_'35Z%BI'DLYB(*Z6L=; MCF?L*5W"RDMW;A0Z4QU]'6>4F%# I!;\[ P. N*8+NE5)<;,1<'I8@1T@(>.]P<75=$O+ M1,J\E>2;L-D1O-YU9Y32(-(A@)[?E\XX%2#5W-XUVU+[9H2-=86A:C;C2K##XS]$0-? MYU+M$Z\=UEE%A0N<@#C<";][,- H@Z6J6MAMLI51DZ6M)K;4 MDQ;QUN)K?U)>RWDYU 1HR+[A9>2S!OF#F"BQ&SQ@4ZVS!2:=1 M37FA@7F586)JQN7R&+X_U@((B#6/Y AQ)5MR[VI 3K?3#[L#NOC$0UK+X.-8 M#5L8L21>85#,WT ;J*)BVO,GV*09+2TW9-K(JVF!FLMTV3P;S2M5B65UV$FL,_33W7U^/YO^\GEZ>:NP OJM]_ONKD1=%8[X]/&%%/#U MMI"W:+-+5(G#;MC=!>5I8T.U48/CMTT3O@UQ1%2ECOW\?#$6FC^3THNYY4%FMQ^OIFJJP_JZGIZ M,R$]-5#O)[/S&7YY?3.=P2[1]]H+,[NZ.#_C;XZNI8:W%P/[GJ/^ESJ:@>9_ MT$-T9'<9^0=U=$2Z?MD36_' 84A LFCBQ@[N&(X"-+)9&<@752NDRNQMOAX8 MJ\2=2H)O'IR;%=>)E"S2D2PG^XOHLCKN4N.W&).)1L^._5$ [ M@5$MZCTM\WR;X0%>.)GF,WQDM:KFQ&UBHQ\8E5 ':@95\Q'_+"XC&>MKS35Q M6TMYBH7>#*%*O >$>!S-IJ=O;4JD2,L>=6YW;8\.NH+-3!L8XYY'Q2WVTC*Y MM1],%O0&HYL3#%S1JJMH.P0D>345CN4DZAHM J]Q94E[WA.T06:2E,H9/^H7 MOME5EQ.8-ZY._7=U*BR181&$3+&AKC3E:AD9.ZPB<2H7L".+:DWCGP(]HN8V MS@75-%ZJ%FNYY'619_E.XB'+USY?MQ.+NX6R3]O,T@N=B;H?!4J22P2$FBS+ M'>5CFWUFK "T<-R-M#YCHUM9PGR7+F.F;Y>C*VUWHY8)./\R:N'I#"4IBC^0B,$$B MME'FVUGR9-+PUU*$TY(?Y\MC3 )^='/U^:U4;:VF"8]ETVKH3@4O2+PD%8ZH MQ(L^-V^3#K.4K713=@@NB0-P=+AF1],8H8HJY3Z8 9'/Q@"NM+6Z>E!CCOC0 M-1_)1\322^U!C%26 ".9IQN>4KE>[875D:)H>+&9E'J-X*!%OM&!8)5-L?4L M;6P*87T1XXB^.5&+$2J)#-;>/X;JI+YLK$U,948ES?5?2A-X) 32L$(:&N3X>@ ME,Y93B3;N]Z^0 >[UG:?G,Z\=L2W7UALM/FP'-W<9D.4!(XL2<^+]([O$M*Z>L?=?I/2 MQ1FD&/>Y>C80(5<5JES:BY1=]+A#(G0+(D/J"9A(%A/89?!8#B"\S9=!W,ZD M &V$(OMR!@-Q;RP'K3VBOJQ7[RB!SW_\CCHI'I/?-;U'$J#46M/!0G(JJ2X% M'8[FTM5"_;')$A]4 D,JFNM*[Y6,DJ9NN77(X4&IA/X1GUXR4Z?DQSP0TD^PR!@B M+Q!T3,B*IEU%?\5C4CP;K#F5QI)"Y]K&Z#\F(W?<86PDHI@0'5>!P$]]2WSH M7'7>H_-+_$[7" WKR.70:"#5.^'4/Y?$)%I[9G\WW83LE.6L?[I*MU@$.$V@ M]A^5@LL@N4*,!UK6Y&16HWUC;96X@!%<^: !XER@!-V6&?_=(2>4&JB_%PIX4[ M"FF[X. #40V(=7-+O\=&&'0A:U2M^TB6\,C^+M$[G%WFV]W[E[EEC@YWMWM3 MT>$TM_ *BE=L)^8>[>^]1^O(,*=*E9LKQ/AQ&1N6+2@IGHV@T_P028_2PC!_ MP!:)62TJ;(CJ!#DYO% P"BH$:/.3E'Q@F@>0+EOX]%VRS M=Y)L/UXZ.E/#J M9/'RE A"5CJ\!+:FP*VY2PD"5&.LKF7&.6RG-(-Z A4-5/!?U67ZY'7R,6A; M PM>SHQMV"\9BLST)<)>$LD6]ET]IU.]KLFC,33)-6">K8P,1XT"1T+I$ /# MTCA-'LJ"5%>=2M%+\=2.^E4">#@(7,ZYAE29.ZZVCG,,F]*95BJ*#*=_N-<+ M@G4)MTX]%7NFL$.:@03,/&M&RP,AKX<^*8QYP@V3V#%92K$X^S38J M\;^Y/>O-3%!'?Y%(08%ZSK'R1L>!?PQ,UV.00*@[BCP.W9[GG%KNV>0OV;?& M%4@08FAD9 O LEI5C9$0Y(.>GO/B-ET) OIP.$=Z*UU10 M%F171 _2!2C^58+TL;=4*JV8 M)SK[*-#LEFR.&EQP@\!Y1G+]'/\C_NT!%<5J-RX/,'-Q>\GNM;)!2$U:\V-. MVJC1.R+,PA9,7$&/>/$GC,P ^1-S>AJ9_LJ1Z9NDQEJ.2BT+ZY9; MM 6)[$:?K"M_UNPW*\J02M(($0&MMZ[EV-!L73Y;2; 7:> K%)6$B[-[O"H# M6.'30)3*UE?+NL& ON-K4A<%-@$]+J'J)/]FV3I-5L:R963Z@A%9;&Z\$U(E M6JTN@@FN6FL<&7$2).M3PHAD=J2!O7U0H.Q)8D4W\^?N@BI4 O&ET/E1]1 M2)7D;KJPK55P;#IF3/A@I)^&]$9+*8/B2$@SHPJ3;MIB3#$B J6HTT-Q=3"G M%C5U)57$)#K6RNWV3CHX 9R1W#LP5QYF.T27>.Z\LJ%$F M**T?Y1,!REC"/>5H\XX^HYDZ.HJUJC]98:#+_8.S)%J;/VA!>!JDNA/O1!>& M-)#+34.<-)K;1(;PDG(&!*836X/:_[VLJY: [;[?A6,[VE?0;6,-H-6 M5AR*:W.L53 NE?+%M\TO8'21)"[PZ@*0SK.TTK)CH;A3F T?< PO:.B);0-E7$7R:DEZT M6R;!)3B_)=_604BFY50H#752&05>!N0=L&6^F 4?X MEFN ;TFG-%4F![F:%<)$E7**833S\3;YI;?/:C6+JRXSORQU82S@>NNK[*H! MEF.6:<"A5_IT'XSTX-N+\74;)%NVC'/&CR=++%W$$_$ H)Y;+6S$ Z M0[=#"O7"S50\JKD4A@6(5%?*I L[AE4X)DU9*V-L,%U4JXSSTNQLY0F*9&2_ M**> 8\^#03KMK9YA$T"XF#\=]L%^!1VIS$:*^I3Q1+M,L")TDE1?3JBHG-==IL%CIJV7JE7R#AI;YM8"6E"(%VEO&B=JE9BN4 M Y I$BO]_KVI5'2US*O-!$>^:$E%_\A2,WG()&LVP+VWBO_7>C[_\I"WWR2,4L,V:S63;"I1@R?H20W^8&Y30T M2X#%@9O4S=T3=7HS',%F"-8IQ=-"&1Q KE-] M.[2\)M1TT]IS[Z)0"N.":Z:L7A![#?Q((,[R&*=\ CHG9;2E!AM"BG^=7GZ> MJJ-;W%X?#3V3?/:NW0I#SHCTZ@_?/C24QY+31M6XS/M.C1S7Y2'XSF3Q^H(5 M!]6J(+7/_B7@WE*%5':BWQ^H,94XP$\GHZ[J=R+ZU ]Z@YX:=7KT:1#TAJ'J M=8;PR2K+D0I[P6 T4*.3SDCUL;F1&H\[H>J/@_X0F@X[77BF%PS'(?YP(H&/ M@V@ C858\N=D3,U&0=CCOP;!(.S"7R,I2Z.&_1/X.%8GO8&*H+THZ/7Q 9A1 M<-+K*0R-<"K7*&BQ"^U M_!O3T5C_ S]G43TF6K>*!@H?AB$6(A>A7W\%Z8S M[-)G4_L&6J$O!A']T^=/8:]/_^JZ.-P,=!4.J:MPU*7//?H81ER$+X+_T5=?&[,1?>433A MB.-O,%(,:R+$':Q4BIM/7S1=[\8G 2CT8GS13CH!CTL MM"#?A'Y^M"Q>P/7X"0[E/*>98\4AH!B,/\&"E9S81A"MF*W(DI6Q$W+U\X)- MU3KZQ_>_V$+IY'RONK9TL"T;KW7V'S@E*IR ](5:P0?.#*V=['0,4RUZ"A"* MAD@U0"2Y6#M&V0_)<1@*F@388 0LX=J)-)4$;$W\I=T,<6?#I3D@G379^!LK MX7P-8ZF"-I!$@E$/:^+T^T$?S@M0T1!8"E6[Z4=!-!BK#P49+AB[2C< <) A M< %@-@-@0*,0B3 8#+I2A*.L.+6/PA'6A#L:#8;X#YR&\0G^$05]./)OA;[M M8AE*-Q1N*-M0M&?!F=XJJ<]P='$UF[U5U],;A=G.KB[5[./DYK!K!'=PMS5J M!(;2S&G:VNS3;"DZ96-+H\&HX>(I,5G3COR8VG5%HOM4U(H_.DBPG:#I^:8QIXCS\YO=Y M7UY>E'>T7]5GK'[$Q1.,E4R'GG&]PSZ6/@2B'A(='L$M$E%YPA%\ QPV#'I= M)$>XP$8"D"4]5=O5K +W#@M_M5K6ZKS>W 4]=8"EL3*_%R=&*;RT(6R.130+ M=BH<.N,HTC,^G/'(5LN^ME%"V\__[(V.@M'PA J+PF7=Y6E' YHV%AT=#?&7 MZ 3K8D;XPS]AIT]>O=&'SF_??A\T\1Y(+3QQ+\9PWUU M23DE#V&RMC*1K@X*FX[(XE-3"*B)BBT1E(+DQ#E\H6+M8%8_5*H:/$- M&FR*V:*N"+YCZS#=6Z,PY'NK!\?HM/[RN!=@]H0QB.D]E,JP##+"!FI_#_LT12*>.3J*(;FSHBSG!R0G= MP: $P,7/6%Y&4BV,L_1=#=(&!'2"!#;NAFHJ%9N/=:R9#D<(:8[]H L]_5G* M%!+\1QOD M M373]/)[//-]-/!Y\.U'F/&%L=4?LIFI6?DF\9&\))KHM:>:WJ?Z_8\FT.% MY-F((;'@&A% CNT7JK\==- <.Z"8RJ3<<;(@_!@FU2E+M^XQ%SQV7WSU"Y\\ M-XGI_ T.=DQ<43-IYZL>B*]A]2?ZYM;UKVCS')!+< )$:JYU_AB.@RX0GOF6 M/WXR+IZZN5NW!MP#1/60_NW1,025^PB%:_H[HI2VC7XAVT0?SLL0SC0>:?P MDOX "!QTSZ,(Y7/\T!N*4.YZ'MX0]Z+RF;I6L["S-\30ACVG9+3F<.J_C;[_ M=QI]/09W>W7Z\\>KB[/IS>S?U?27S^>W?SU8)0.E^M]+YG-G.BO%1&K5'Q1\ MT6C]VZT1!:CIP ->57)@"%S7)I\Z",YQH.;E)K,XP\/KR<$WG N#?Q3D)GW0 M$7DZ;ZTZDAP>;T%0[Z+8< (GEK.#2=IH^13JCUX3(/D/Z7(<1_W]KZ(V$*%$ M N(D\(S#MM&15*WV3<;AD?IM*]!:GRGU8X_;[%LS>,]@L/( M+".+BW=QB?$K9+:I_XGAA678YK7AA M*V:,1H';MO621Y> /7?/3I%.F]>@@ O9/2WY\K#*L1^D&L,I>5_FDBI4@LDF MMCB?<\W_A*[9'X[XMN?L <;1# ->M3NWM6UCT,-W01HZT&>ZVO(-$,'+ZME_5PLWU<)OFY!?__^H MM[U7RV>[^\P4G;;+RZ0E]UBCKO_?%:M?4['Z.Z>?.B,(/9#!L?H\.U-';Y - MI9@C11:IWA]($!W5E:0 /K;R:4]2#N -?&7)C64?DUPMZC\O\.RB(ZCT\IZ] MO$2>3]F$I7L OMEGG=2CS1%]K"X1/D]R>^LJ?>)@#J_]]EB+?3.4&,RJ0X4B M$^I/1IUNUSN09WOB9H*&,)>&$ME[XF[0T]<QC MX]JW!GX/?<[D?_EJ-/SO^QUAOZ7QHG=^L-W&3KB+?S.$7G1\&TC M?2(8P_^6/.6-7WZ78?>:QM=KF@I#/YJ__4Y#&3<-I6%-PJ8O';S)GI^^RTB[ M3736;:+(;A-!$]RE\TV'2*#J6G]X;L,2&-RVK[_+ITT GH.>NB[ M=!]V^DV+WO!EV+0]#"QJ_O8[$47#D0Z;ONPV'4-",S5^^9U&M_>V?0FA\Q67 M;P-ZQ1/ MA#Z.+9'R*B:5#D"+FNM<7>3FE0ZLNR+-#+J,/&L2^L-15A+^LV>;C C ;::<1F[.D^0)Y0_[T% MJ[%7(?>X70MZH_[WMKO&)EO7>:XOU.<-]1W5/FI?O0W+7;K]V M2Y5XZODNZQC'0M.+NF2*-YP-[&97:CO[2C^T&D8M/^Y6'15QI5(/=49R@$!! M3MU0>B<9C2X"II_3<(+)$^9_VFM?;"DJ$^B(.5M MG]B2*Z]]]>51&X'0R35@*L#4FS/H >(8#/MO$NHNZR5]G,H[%HNPP8;VB:]> M*Y7!IAJ=<'B+'OKBORP@XL7>[P76L*=]WNDRV6XI?8^4-7!3S:2D]\.Y]3:9 M*) *VV+B'Y(T/5JU%'IB*FS\B:F4\KB*7"C+RGCNUB MP]_V&F@\R-ZW+V!0]NS*3R]OG,:F["'&%U J>UX] &'S%9-]^1IRY_WRT\X2 MO/SP(:MQP#W9(DL<#N-!LP*\(Y,&3[=TG[;";9NUE#\ZFM6E_ M8[S+_S"8D:^+?#7JR!-!&KP)TQ/Y4$9[4VZXDGQYM"\^<\7 MW] QH[*1^.9+>ZOIJ@W_]16&ESI&RK^X:B"I9OG @J5:!_V5T#0[)^\.>B4* MJD7T4+IV!U;Q: (E[ =.U9\>-/D"S2)X(*HJ=.I@/N%AFGRQUH^I1913PW<> M/ :Q3]XV&QC4/@+8M$# FH%1GLV+'2FWD[],9_65:$7A.(;#<7IN3OC1OVQRRKB":)VLD7L7V".H?D4R=M^%E9C0^A4XO)K?3,W4]N0$)Z/9F MMI>HVHNZ[!$IV51J#5":XWW7;!O5W(AY\YKRP=XZI8CW+6?G4J_R.LN8#\P8 Y^3V8-"H]^J\4TZ^P$9K0G:*X41<>1 M<@7U^DNZ,/OW&[M6UUJG82HK-[<_T^77$6LK36;*.NZ/,UE#,XU[ M/;'9?^KEI+4%FU+^>C?C4P:MHNUY8Y7.N^?F.N<^"VW&IE4KB9>-YK%O6"OX M^5I7=*JDZJ3DQC'!N0<<*I;S"T$UUH3T^4Z_CV\KZKN;;CJF>N\>.4"LB M_-+O^^U_C39=4S[X)87WA[+<_O%_ U!+ P04 " ]B&5/X]YO/UL" !B M# #0 'AL+W-T>6QE52VC&61())DY M35H?>)O'?R^GLCU.4KX)ZS-[.9?W=Z.<5/;. 4 L?Q M*8MAL'P+O3\G/?/]AXE-<$*^>"+Y8]P3ZN73J!]AGA"?/T \[-%PC3N>IK\S MZ5YW<$F4"SZ>WQPZ0/,CAL$&T1A>(4K6DIBL'#%"MPX.#9 **B10NG%T_< @ M];T+!\XS/=7Q,,*%M+5=!?>Y[I9/ KUG!!)*!X$A=$ 254@I+/FU=NQB"_X2 M IV]VE9:82'1-@@7<$RP#UUD+62&Y5 F@#V41!3G1HXD16F>2E2>"2HEF#8R M@@K!D=709W2&IDTQI;?F"_E/ONC/'4_.MY%TVQ[U+ M&Q[$"RJR$>ICH[?#K6\Z#]](G)/6^FT^"-#LJ*KH]@,E!6?8;>:W!8,#"R81 MZNN 4DARK_E,JZ0:P!*"#9:*I+O(#XFJ%6Y5WTYM?JCF\ @U/_=[+C#'$M%= MT;KW7_);_L^*Y^=_+]G^JDP%/Z-&@>K((-N:!>01LK?)KZ_ ]J[(V+=] M47AB$5@Z7*[N68F/SUP\K3A_0O^4156/K:V4N[OAL,ZVM"3U;WQ'*W5ES45) MI#H5FV&]$Y3D]992619#9S2Z'9:$5=:GC^>^%F*HGW!),\EXI1J;AD=&G^O7 MZ\TI(NJ& TW):FR-+$3VDM^S0E(Q)9)^$7R_8]5F;-D66C-1RZ09N[VS9!4K MV7>:MV?UEC\_<,&^\TJ2(LD$+XKV5\V%]D=JA/JEY9$*R;+.C9*L8J)8Q];M M2'5X8#5;L8+);V.K_;N@EGJ*H?88;1S.QV,0[\3_"2-?KUE&ISS;E[22QS@* M6C2C5_66[6H+5:2D8VO"#U2@'=G0!EN-$N3'1Y J.*]<2-PQ=4$$N=TP&N2) MPB2:!5,_Q5/TV9_YX02CY 'C--$ '0#0Z0T0#19$@W0!2/Q0M<*Q!>@"DUQOD))HO-,@; /*F-\@DC28:Y"T >=LCY-^.!OD.@'S7W^OV MDP<-\CT ^=XL9.BGRQB?YXF?!@KZ5S7-DZ %U2 _ ) ?S$+&^!&'2ZP7[!%4 ML4>&8X93%(1JRF(TF$5)\@:IT#53>!Z%J/-B;5 LALW2J=5MA8G")@%U/L@K MMF&QW/M!C![]V1*C.?83E8;S'_$@H]B&E=)4N]\?HMD4Q\DO"/^Q#-*O.ALD M$MNP268J7K@3*<@8MF%EG.9"ZO_598($81LWQ'P>I,>"ZX=3E?YA&H1?<#@) MNI"0(&S#AHCQK)7#PH_3KRB-_3#Q)VT)U@DA.]B&]9 L/RP@EX8 M)[S<\4K=7".^1C-*:JK:=$Q(0:YA!;U@_DG99BMI_I8U)@1+59[XO:'X,J(X)*<@SK"!]F^)B2GJ0>3SCGUF #0LTT#$A M\WB&S7-]RZ(-J8X)?FDQ;9X?]BTNOV](.EXKG>'Y@V1.UZRB>:AZKU5[1HIL M(5!S..ZC>C?-?LAZ7Q03U195,T[:[XI-'^=OLY_^!5!+ P04 " ]B&5/ M9VT:EL ! "\&P &@ 'AL+U]R96QS+W=O713CD\:FJ0]G^LJZ:0Y[:K\W& MU?EREV^"T^%P[)KNC.SUI3MSL%C-LV:QDFSPF3>;D.:9.^[==]7L8A%"BNY\ MD:=V0?N74QW^L[Y:K[?+\%8MOPZA3%Y/N#/#UH MU!\TH@>-^X/&]*!)?]"$'C3M#YK2@V;]03-ZD R!C$-^$L*:K[4 KH7OM0"P MA2^V +*%;[8 M(6OM@"VA>^V +B%+[< NH5OMP"\A:^W KV5K[<"O?4!S]KH M89NOMP*]E:^W KV5K[<"O96OMP*]E:^W KV5K[<"O96OMP*]E:^W ;V-K[BPA*^W ;V-K[Z.WY>GN@M^?K[8'>_@%GW>BPFZ^W!WI[OMZ^HWUKW^ %!+ P04 M " ]B&5/-QE]R+@! #;&P $P %M#;VYT96YT7U1Y<&5S72YX;6S- MV=]N@C 4!O!7,=PN4MLR]R?JS;;;S61[@0X.0@3:M-7IVZ^@+IEAB8N:?#JHZU"R_YB-1NG8RRDX:' MUM?[8;^T77;?^U[X3]&Q[G#>6[]<#@&20X+D2$!RW(+D&(/DN /)<0^2XP$D M!Q^A!$$1E:.0RE%,Y2BHYK/N/[W9-U!+ 0(4 Q0 ( M #V(94\?(\\#P !," + " 0 !?D M !D;V-0&UL4$L! A0#% @ /8AE3V.6P1KN *P( M !$ ( !F0$ &1O8U!R;W!S+V-O&UL4$L! A0#% M @ /8AE3YEM!BRD$# "?#P & M @ 'W" >&PO=V]R:W-H965T&UL4$L! A0#% M @ /8AE3VMPD)1:! F14 !@ ( !;@P 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ /8AE3V9+T<&" @ M3P@ !@ ( !Q!< 'AL+W=O!YX D (- 8 " 7P: M !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ /8AE3SA9-H5.! ;10 !@ M ( !R"8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ /8AE3S[_[I&U 0 T@, M !D ( !"3$ 'AL+W=O&PO=V]R:W-H965T T !X;"]W;W)K&UL4$L! A0#% @ /8AE3_?-^%>T 0 T@, !D M ( !RC8 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ /8AE3YTWV^NU 0 T@, !D ( !BSP 'AL+W=O M&PO=V]R:W-H965T8^J-'P( 0' 9 " 6- M !X;"]W;W)K&UL4$L! A0#% @ /8AE3S&' M_5O% 0 -P0 !D ( !N4( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ /8AE3Q!%S["W 0 T@, !D M ( !C4@ 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ /8AE3_!/84/C 0 8@4 !D ( ! M?4X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ /8AE3\!W;*>I @ + D !D ( !,%D 'AL+W=O@! I!0 &0 M@ & 9@ >&PO=V]R:W-H965T&UL4$L! A0#% @ /8AE3Y*V&811 @ <0< !D M ( !+6P 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ /8AE3_:DX^0% @ @ 4 !D ( !7W0 M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M/8AE3XXUFY&E 0 FP, !D ( !S7H 'AL+W=O&PO&PO / " 7C: !X;"]W;W)K M8F]O:RYX;6Q02P$"% ,4 " ]B&5/9VT:EL ! "\&P &@ M @ '6W@ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M" ]B&5/-QE]R+@! #;&P $P @ '.X 6T-O;G1E;G1? @5'EP97-=+GAM;%!+!08 -@ V *P. "WX@ ! end XML 48 R26.htm IDEA: XBRL DOCUMENT v3.19.3
LEASES (Tables)
9 Months Ended
Sep. 30, 2019
Leases [Abstract]  
Schedule of Components of Lease Cost, Weighted-average Remaining Lease Term and Discount Rate
The components of lease cost for the three months and nine months ended September 30, 2019 were as follows (in thousands):
 
Three Months Ended September 30, 2019
 
Nine Months Ended September 30, 2019
Operating leases
$
512

 
$
1,544

Short-term leases
73

 
201

Total lease cost
$
585

 
$
1,745


The weighted-average remaining lease term and discount rate related to operating leases as of September 30, 2019 were as follows:
Weighted-average remaining lease term (in years)
3.2

Weighted-average discount rate
5.5
%

Schedule of Annual Scheduled Operating Lease Payments
The annual scheduled lease payments of our operating lease liabilities as of September 30, 2019 were as follows (in thousands):
Remainder of 2019
$
473

2020
1,717

2021
730

2022
427

2023
245

Thereafter
400

Total lease payments
$
3,992

Less: imputed interest
(400
)
Present value of lease liabilities
$
3,592


XML 49 R22.htm IDEA: XBRL DOCUMENT v3.19.3
NET INCOME (LOSS) PER COMMON SHARE (Tables)
9 Months Ended
Sep. 30, 2019
Earnings Per Share [Abstract]  
Schedule of Computation of Basic and Diluted Net Income (Loss) Per Common Share
The following tables illustrate the computation of basic and diluted net income (loss) per common share for the periods indicated (in thousands, except per share data): 
 
Three Months Ended September 30,
 
2019
 
2018
 
Income (loss)
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
 
Income (loss)
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
Basic net income (loss) per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income (loss) available to common stockholders
$
(1,243
)
 
10,623

 
$
(0.12
)
 
$
7,629

 
11,309

 
$
0.67

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Non-vested restricted stock

 

 
 

 

 
13

 
 

Diluted net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
(1,243
)
 
10,623

 
$
(0.12
)
 
$
7,629

 
11,322

 
$
0.67

 
 
 
 
 
 
 
 
 
 
 
 
 
Nine Months Ended September 30,
 
2019
 
2018
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
Basic net income (loss) per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income (loss) available to common stockholders
$
(2,769
)
 
11,010

 
$
(0.25
)
 
$
25,476

 
11,298

 
$
2.25

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Non-vested restricted stock

 

 
 

 

 
9

 
 

Diluted net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income (loss) available to common stockholders plus assumed conversions
$
(2,769
)
 
11,010

 
$
(0.25
)
 
$
25,476

 
11,307

 
$
2.25


XML 50 R43.htm IDEA: XBRL DOCUMENT v3.19.3
COMMITMENTS AND CONTINGENCIES (Details)
Jan. 08, 2019
defendant
Securities Class Action | Executive Officers  
Loss Contingencies [Line Items]  
Number of defendants 2
JSON 51 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nhtc20190930_10q.htm": { "axisCustom": 1, "axisStandard": 21, "contextCount": 251, "dts": { "calculationLink": { "local": [ "nhtc-20190930_cal.xml" ] }, "definitionLink": { "local": [ "nhtc-20190930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "nhtc20190930_10q.htm" ] }, "labelLink": { "local": [ "nhtc-20190930_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "nhtc-20190930_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml" ] }, "schema": { "local": [ "nhtc-20190930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 393, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 21, "http://www.naturalhealthtrendscorp.com/20190930": 1, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 27 }, "keyCustom": 23, "keyStandard": 263, "memberCustom": 19, "memberStandard": 40, "nsprefix": "nhtc", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover page", "role": "http://www.naturalhealthtrendscorp.com/role/CoverPage", "shortName": "Cover page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - REVENUE", "role": "http://www.naturalhealthtrendscorp.com/role/Revenue", "shortName": "REVENUE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE", "role": "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShare", "shortName": "NET INCOME (LOSS) PER COMMON SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - BALANCE SHEET COMPONENTS", "role": "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponents", "shortName": "BALANCE SHEET COMPONENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - FAIR VALUE MEASUREMENTS", "role": "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurements", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - STOCKHOLDERS' EQUITY", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - LEASES", "role": "http://www.naturalhealthtrendscorp.com/role/Leases", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - INCOME TAXES", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - SUBSEQUENT EVENT", "role": "http://www.naturalhealthtrendscorp.com/role/SubsequentEvent", "shortName": "SUBSEQUENT EVENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "nhtc:ScheduleofAdditionalBalanceSheetComponentsTableTextBlock", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FI2019Q3", "decimals": "-3", "lang": null, "name": "us-gaap:OtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION (Policies)", "role": "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationPolicies", "shortName": "NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302301 - Disclosure - REVENUE (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/RevenueTables", "shortName": "REVENUE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareTables", "shortName": "NET INCOME (LOSS) PER COMMON SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "nhtc:ScheduleofAdditionalBalanceSheetComponentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - BALANCE SHEET COMPONENTS (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsTables", "shortName": "BALANCE SHEET COMPONENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "nhtc:ScheduleofAdditionalBalanceSheetComponentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendsDeclaredTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityTables", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendsDeclaredTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - LEASES (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/LeasesTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401402 - Disclosure - NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationDetails", "shortName": "NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": "2", "first": true, "lang": null, "name": "nhtc:RevenueFromContractWithCustomersSalesReturnsPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402402 - Disclosure - REVENUE - Narrative (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/RevenueNarrativeDetails", "shortName": "REVENUE - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": "2", "first": true, "lang": null, "name": "nhtc:RevenueFromContractWithCustomersSalesReturnsPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402403 - Disclosure - REVENUE - Revenue by Market (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails", "shortName": "REVENUE - Revenue by Market (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember", "decimals": "3", "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1002501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402404 - Disclosure - REVENUE - Net Sales by Product and Service (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/RevenueNetSalesByProductAndServiceDetails", "shortName": "REVENUE - Net Sales by Product and Service (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "lang": null, "name": "nhtc:ContractwithCustomerRefundLiabilitySalesReturns", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareDetails", "shortName": "NET INCOME (LOSS) PER COMMON SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "nhtc:ScheduleofAdditionalBalanceSheetComponentsTableTextBlock", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - BALANCE SHEET COMPONENTS (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails", "shortName": "BALANCE SHEET COMPONENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "nhtc:ScheduleofAdditionalBalanceSheetComponentsTableTextBlock", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FI2019Q3", "decimals": "-3", "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:AvailableForSaleSecuritiesTextBlock", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FI2019Q3_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashAndCashEquivalentsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - FAIR VALUE MEASUREMENTS - Available-for-Sale Investments Included in Cash Equivalents (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails", "shortName": "FAIR VALUE MEASUREMENTS - Available-for-Sale Investments Included in Cash Equivalents (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:AvailableForSaleSecuritiesTextBlock", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FI2019Q3_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashAndCashEquivalentsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "D2019Q1Mar15-Mar15", "decimals": "2", "first": true, "lang": null, "name": "nhtc:CommonStockSpecialDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - STOCKHOLDERS' EQUITY - Cash Dividend Activity (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityCashDividendActivityDetails", "shortName": "STOCKHOLDERS' EQUITY - Cash Dividend Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "D2019Q1Mar15-Mar15", "decimals": "2", "first": true, "lang": null, "name": "nhtc:CommonStockSpecialDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "I2019Q2May16", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "shortName": "STOCKHOLDERS' EQUITY - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "I2019Q2May16", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406404 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails", "shortName": "STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406405 - Disclosure - STOCKHOLDERS' EQUITY - Changes in Accumulated Other Comprehensive Loss (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails", "shortName": "STOCKHOLDERS' EQUITY - Changes in Accumulated Other Comprehensive Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - LEASES - Narrative (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/LeasesNarrativeDetails", "shortName": "LEASES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - LEASES - Components of Lease Cost (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/LeasesComponentsOfLeaseCostDetails", "shortName": "LEASES - Components of Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FI2019Q3", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - LEASES - Weighted-average Remaining Lease Term and Discount Rate (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRateDetails", "shortName": "LEASES - Weighted-average Remaining Lease Term and Discount Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FI2019Q3", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407405 - Disclosure - LEASES - Annual Scheduled Lease Payments (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/LeasesAnnualScheduledLeasePaymentsDetails", "shortName": "LEASES - Annual Scheduled Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408401 - Disclosure - INCOME TAXES (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "D2019Q1Jan08-Jan08_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_nhtc_SecuritiesClassActionMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LossContingencyNumberOfDefendants", "reportCount": 1, "unique": true, "unitRef": "defendant", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409401 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "D2019Q1Jan08-Jan08_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_nhtc_SecuritiesClassActionMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LossContingencyNumberOfDefendants", "reportCount": 1, "unique": true, "unitRef": "defendant", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "D2019Q2May16-May31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsForRepurchaseOfCommonStock", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410401 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3QTD_srt_CounterpartyNameAxis_nhtc_BroadyHealthSciencesMember_srt_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionAxis_nhtc_RoyaltyAgreementandLicenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember", "decimals": "-3", "lang": null, "name": "us-gaap:RoyaltyExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "D2019Q4Oct29-Oct29_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "nhtc:CommonStockSpecialDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411401 - Disclosure - SUBSEQUENT EVENT (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/SubsequentEventDetails", "shortName": "SUBSEQUENT EVENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "D2019Q4Oct29-Oct29_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "nhtc:CommonStockSpecialDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossUnaudited", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2018Q1QTD", "decimals": "-3", "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1004501 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) (Parenthetical)", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": "-3", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION", "role": "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidation", "shortName": "NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc20190930_10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 60, "tag": { "country_CN": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CHINA", "terseLabel": "China" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails" ], "xbrltype": "domainItemType" }, "country_HK": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "HONG KONG", "terseLabel": "Hong Kong" } } }, "localname": "HK", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails" ], "xbrltype": "domainItemType" }, "country_IN": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "INDIA", "terseLabel": "India" } } }, "localname": "IN", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails" ], "xbrltype": "domainItemType" }, "country_JP": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "JAPAN", "terseLabel": "Japan" } } }, "localname": "JP", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails" ], "xbrltype": "domainItemType" }, "country_KR": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "KOREA, REPUBLIC OF", "terseLabel": "South Korea" } } }, "localname": "KR", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails" ], "xbrltype": "domainItemType" }, "country_MY": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "MALAYSIA", "terseLabel": "Malaysia" } } }, "localname": "MY", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails" ], "xbrltype": "domainItemType" }, "country_SG": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SINGAPORE", "terseLabel": "Singapore" } } }, "localname": "SG", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails" ], "xbrltype": "domainItemType" }, "country_TW": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "TAIWAN, PROVINCE OF CHINA", "terseLabel": "Taiwan" } } }, "localname": "TW", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r270" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r271" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "countryCodeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r272" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r272" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r272" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r273" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r272" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r272" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r272" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r272" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r268" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r269" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "nhtc_AccruedSalesReturns": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Sales Returns", "label": "Accrued Sales Returns", "terseLabel": "Sales returns" } } }, "localname": "AccruedSalesReturns", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_AccruedWarehousingAndInventoryRelatedExpense": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 3.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Warehousing And Inventory Related Expense", "label": "Accrued Warehousing And Inventory Related Expense", "terseLabel": "Warehousing, inventory-related and other" } } }, "localname": "AccruedWarehousingAndInventoryRelatedExpense", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_AutoShipAdvancesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents Auto Ship advances.", "label": "Auto Ship Advances [Member]", "terseLabel": "Auto ship advances" } } }, "localname": "AutoShipAdvancesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "domainItemType" }, "nhtc_BalanceSheetComponentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Balance Sheet Components [Abstract]", "label": "Balance Sheet Components [Abstract]" } } }, "localname": "BalanceSheetComponentsAbstract", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "xbrltype": "stringItemType" }, "nhtc_BroadyHealthSciencesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents Broady Health Sciences.", "label": "Broady Health Sciences [Member]", "terseLabel": "BHS" } } }, "localname": "BroadyHealthSciencesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "nhtc_CapitalizedContractCostsLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Capitalized Contract Costs, Liability, Current", "label": "Capitalized Contract Costs, Liability, Current", "terseLabel": "Amounts held in eWallets" } } }, "localname": "CapitalizedContractCostsLiabilityCurrent", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "nhtc_CommonStockPercentageofBeneficialStockOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Stock, Percentage of Beneficial Stock Outstanding", "label": "Common Stock, Percentage of Beneficial Stock Outstanding", "terseLabel": "Percentage of common stock outstanding (more than)" } } }, "localname": "CommonStockPercentageofBeneficialStockOutstanding", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "percentItemType" }, "nhtc_CommonStockSpecialDividendsPerShareCashPaid": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Stock, Special Dividends, Per Share, Cash Paid", "label": "Common Stock, Special Dividends, Per Share, Cash Paid", "terseLabel": "Special cash dividends paid, per share (in dollars per share)" } } }, "localname": "CommonStockSpecialDividendsPerShareCashPaid", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityCashDividendActivityDetails" ], "xbrltype": "perShareItemType" }, "nhtc_CommonStockSpecialDividendsPerShareDeclared": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Stock, Special Dividends, Per Share, Declared", "label": "Common Stock, Special Dividends, Per Share, Declared", "terseLabel": "Special cash dividend declared (in dollars per share)" } } }, "localname": "CommonStockSpecialDividendsPerShareDeclared", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventDetails" ], "xbrltype": "perShareItemType" }, "nhtc_ContractWithCustomerLiabilityIncreaseFromCashReceipts": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Liability, Increase From Cash Receipts", "label": "Contract With Customer, Liability, Increase From Cash Receipts", "terseLabel": "Increase in deferred revenue from cash payments received" } } }, "localname": "ContractWithCustomerLiabilityIncreaseFromCashReceipts", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_ContractwithCustomerArrangementTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract with Customer, Arrangement Type", "label": "Contract with Customer, Arrangement Type [Axis]", "terseLabel": "Contract with Customer, Arrangement Type [Axis]" } } }, "localname": "ContractwithCustomerArrangementTypeAxis", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "nhtc_ContractwithCustomerArrangementTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Contract with Customer, Arrangement Type", "label": "Contract with Customer, Arrangement Type [Domain]", "terseLabel": "Contract with Customer, Arrangement Type [Domain]" } } }, "localname": "ContractwithCustomerArrangementTypeDomain", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "domainItemType" }, "nhtc_ContractwithCustomerRefundLiabilitySalesReturns": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Contract with Customer, Refund Liability, Sales Returns", "label": "Contract with Customer, Refund Liability, Sales Returns", "negatedLabel": "Less: sales returns" } } }, "localname": "ContractwithCustomerRefundLiabilitySalesReturns", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueNetSalesByProductAndServiceDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_DeferredIncomeTaxExpenseBenefitExcludingEffectsofForeignExchange": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Income Tax Expense (Benefit), Excluding Effects of Foreign Exchange", "label": "Deferred Income Tax Expense (Benefit), Excluding Effects of Foreign Exchange", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefitExcludingEffectsofForeignExchange", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "nhtc_EquityIncentive2016PlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Incentive 2016 Plan", "label": "Equity Incentive 2016 Plan [Member]", "terseLabel": "2016 Plan" } } }, "localname": "EquityIncentive2016PlanMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "nhtc_IncreaseDecreaseinCapitalizedContractCostLiability": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) in Capitalized Contract Cost Liability", "label": "Increase (Decrease) in Capitalized Contract Cost Liability", "terseLabel": "Amounts held in eWallets" } } }, "localname": "IncreaseDecreaseinCapitalizedContractCostLiability", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "nhtc_IncreaseDecreaseinOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) in Operating Lease Liabilities", "label": "Increase (Decrease) in Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseinOperatingLeaseLiabilities", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "nhtc_LesseeLeasedArea": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Leased Area", "label": "Lessee, Leased Area", "terseLabel": "Leased area (sq ft)" } } }, "localname": "LesseeLeasedArea", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesNarrativeDetails" ], "xbrltype": "areaItemType" }, "nhtc_LesseeNonCashLeaseExpense": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Lessee, Non-Cash Lease Expense", "label": "Lessee, Non-Cash Lease Expense", "terseLabel": "Noncash lease expense" } } }, "localname": "LesseeNonCashLeaseExpense", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "nhtc_LesseeNumberofBranches": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Number of Branches", "label": "Lessee, Number of Branches", "terseLabel": "Number of leased branches" } } }, "localname": "LesseeNumberofBranches", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "nhtc_LesseeNumberofServiceStations": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Number of Service Stations", "label": "Lessee, Number of Service Stations", "terseLabel": "Number of leased service stations" } } }, "localname": "LesseeNumberofServiceStations", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "nhtc_MetuchenNewJerseyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Metuchen, New Jersey", "label": "Metuchen, New Jersey [Member]", "terseLabel": "Metuchen, New Jersey" } } }, "localname": "MetuchenNewJerseyMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_MontereyParkCaliforniaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Monterey Park, California", "label": "Monterey Park, California [Member]", "terseLabel": "Monterey Park, California" } } }, "localname": "MontereyParkCaliforniaMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_NumberOfDaysTerminationNotice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents number of days termination notice.", "label": "Number Of Days Termination Notice", "terseLabel": "Number of days for termination notice" } } }, "localname": "NumberOfDaysTerminationNotice", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "durationItemType" }, "nhtc_NumberofProductOrders": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Product Orders", "label": "Number of Product Orders", "terseLabel": "Number of product orders" } } }, "localname": "NumberofProductOrders", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "integerItemType" }, "nhtc_OtherRevenueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Revenue", "label": "Other Revenue [Member]", "terseLabel": "Other" } } }, "localname": "OtherRevenueMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "domainItemType" }, "nhtc_PresidentandHisWifeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "President and His Wife", "label": "President and His Wife [Member]", "terseLabel": "President and His Wife" } } }, "localname": "PresidentandHisWifeMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "nhtc_ReStoreMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents a product called ReStore\u2122.", "label": "ReStore [Member]", "terseLabel": "ReStor" } } }, "localname": "ReStoreMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "nhtc_RevenueFromContractWithCustomerSalesReturnsPolicyTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue From Contract With Customer, Sales Returns Policy Term", "label": "Revenue From Contract With Customer, Sales Returns Policy Term", "terseLabel": "Sales returns policy term" } } }, "localname": "RevenueFromContractWithCustomerSalesReturnsPolicyTerm", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueNarrativeDetails" ], "xbrltype": "durationItemType" }, "nhtc_RevenueFromContractWithCustomersHistoricalSalesReturnsPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue From Contract With Customers, Historical Sales Returns Percentage", "label": "Revenue From Contract With Customers, Historical Sales Returns Percentage", "terseLabel": "Historical sales returns rates" } } }, "localname": "RevenueFromContractWithCustomersHistoricalSalesReturnsPercentage", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueNarrativeDetails" ], "xbrltype": "percentItemType" }, "nhtc_RevenueFromContractWithCustomersSalesReturnsPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue From Contract With Customers, Sales Returns Percentage", "label": "Revenue From Contract With Customers, Sales Returns Percentage", "terseLabel": "Actual sales returns rates" } } }, "localname": "RevenueFromContractWithCustomersSalesReturnsPercentage", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueNarrativeDetails" ], "xbrltype": "percentItemType" }, "nhtc_RichmondBritishColumbiaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Richmond, British Columbia", "label": "Richmond, British Columbia [Member]", "terseLabel": "Richmond, British Columbia" } } }, "localname": "RichmondBritishColumbiaMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_RollingHillsEstatesCaliforniaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Rolling Hills Estates, California", "label": "Rolling Hills Estates, California [Member]", "terseLabel": "Rolling Hills Estates, California" } } }, "localname": "RollingHillsEstatesCaliforniaMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_RoyaltyAgreementandLicenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Royalty Agreement and License", "label": "Royalty Agreement and License [Member]", "terseLabel": "Royalty Agreement and License" } } }, "localname": "RoyaltyAgreementandLicenseMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "nhtc_RussiaandKazakhstanDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Russia and Kazakhstan [Domain]", "label": "Russia and Kazakhstan [Domain]", "terseLabel": "Russia and Kazakhstan" } } }, "localname": "RussiaandKazakhstanDomain", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails" ], "xbrltype": "domainItemType" }, "nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Additional Balance Sheet Components [Table Text Block]", "label": "Schedule of Additional Balance Sheet Components [Table Text Block]", "terseLabel": "Schedule of Additional Balance Sheet Components" } } }, "localname": "ScheduleofAdditionalBalanceSheetComponentsTableTextBlock", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "nhtc_SecuritiesClassActionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Securities Class Action [Member]", "label": "Securities Class Action [Member]", "terseLabel": "Securities Class Action" } } }, "localname": "SecuritiesClassActionMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "nhtc_SharngHoldingsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sharng Holdings", "label": "Sharng Holdings [Member]", "terseLabel": "Sharng Holdings" } } }, "localname": "SharngHoldingsMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "nhtc_ShipmentofApparelProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shipment of Apparel Products", "label": "Shipment of Apparel Products [Member]", "terseLabel": "Shipment of Apparel Products" } } }, "localname": "ShipmentofApparelProductsMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "nhtc_SpecialDividendsCommonStockCash": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Special Dividends, Common Stock, Cash", "label": "Special Dividends, Common Stock, Cash", "terseLabel": "Special cash dividend paid" } } }, "localname": "SpecialDividendsCommonStockCash", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityCashDividendActivityDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_StockRepurchaseAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Repurchase Agreement", "label": "Stock Repurchase Agreement [Member]", "terseLabel": "Stock Repurchase Agreement" } } }, "localname": "StockRepurchaseAgreementMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "nhtc_StockRepurchaseProgramRatioofNumberSharesAuthorizedToBeRepurchasedInPrivateTransaction": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Repurchase Program, Ratio of Number Shares Authorized To Be Repurchased In Private Transaction", "label": "Stock Repurchase Program, Ratio of Number Shares Authorized To Be Repurchased In Private Transaction", "terseLabel": "Ratio of number of common stock shares to be repurchased in off-the-market private transaction" } } }, "localname": "StockRepurchaseProgramRatioofNumberSharesAuthorizedToBeRepurchasedInPrivateTransaction", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "pureItemType" }, "nhtc_TheAberdeenGroupLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The Aberdeen Group, LLC", "label": "The Aberdeen Group, LLC [Member]", "terseLabel": "Aberdeen" } } }, "localname": "TheAberdeenGroupLLCMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "nhtc_TheGeorgeK.Broady2012IrrevocableTrustBroadyTrustMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The George K. Broady 2012 Irrevocable Trust (\u201cBroady Trust\u201d)", "label": "The George K. Broady 2012 Irrevocable Trust (\u201cBroady Trust\u201d) [Member]", "terseLabel": "Broady Trust" } } }, "localname": "TheGeorgeK.Broady2012IrrevocableTrustBroadyTrustMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "nhtc_UnshippedProductMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents unshipped product.", "label": "Unshipped Product [Member]", "terseLabel": "Unshipped product" } } }, "localname": "UnshippedProductMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20190930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "domainItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r152", "r209", "r211", "r267" ], "lang": { "en-US": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Entity" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_AmericasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Americas [Member]", "terseLabel": "Americas" } } }, "localname": "AmericasMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails" ], "xbrltype": "domainItemType" }, "srt_CondensedBalanceSheetStatementTable": { "auth_ref": [ "r81", "r171" ], "lang": { "en-US": { "role": { "label": "Condensed Balance Sheet Statement [Table]", "terseLabel": "Condensed Balance Sheet Statement [Table]" } } }, "localname": "CondensedBalanceSheetStatementTable", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "srt_CondensedBalanceSheetStatementsCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Condensed Balance Sheet Statements, Captions [Line Items]", "terseLabel": "Condensed Balance Sheet Statements, Captions [Line Items]" } } }, "localname": "CondensedBalanceSheetStatementsCaptionsLineItems", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r37", "r80" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_DirectorMember": { "auth_ref": [ "r110" ], "lang": { "en-US": { "role": { "label": "Director [Member]", "terseLabel": "Director" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails" ], "xbrltype": "domainItemType" }, "srt_ExecutiveOfficerMember": { "auth_ref": [ "r110" ], "lang": { "en-US": { "role": { "label": "Executive Officer [Member]", "terseLabel": "Executive Officers" } } }, "localname": "ExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r107", "r144", "r147", "r255", "r256" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails", "http://www.naturalhealthtrendscorp.com/role/RevenueNetSalesByProductAndServiceDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails", "http://www.naturalhealthtrendscorp.com/role/RevenueNetSalesByProductAndServiceDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r109", "r144", "r148", "r257", "r264", "r266" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r110", "r210" ], "lang": { "en-US": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesDetails", "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesDetails", "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r193" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "ASU 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r8", "r9", "r27" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Employee-related expense" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "auth_ref": [ "r15", "r235", "r247" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.", "label": "Accrued Income Taxes, Noncurrent", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accrued Liabilities and Other Liabilities [Abstract]", "terseLabel": "Other accrued expenses:" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "verboseLabel": "Accrued commissions" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r41", "r42", "r43", "r47", "r48" ], "lang": { "en-US": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "terseLabel": "Unrealized Gains/(Losses) on Available-For-Sale Investments" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r45", "r46", "r47" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "periodEndLabel": "Balance, September 30, 2019", "periodStartLabel": "Balance, December 31, 2018", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r44", "r47", "r48", "r178" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Total", "verboseLabel": "Accumulated Other Comprehensive (Loss) Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r39", "r47", "r48", "r178" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation Adjustment" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r18" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r84" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r95" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive shares excluded from calculation of earnings per share in periods when losses are reported (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r95" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r95" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r106", "r234", "r246" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r36" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available-for-sale Securities", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax", "terseLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available-for-sale Securities, Amortized Cost Basis", "totalLabel": "Adjusted Cost" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Available-for-sale Securities [Table Text Block]", "terseLabel": "Schedule of Investments by Significant Category Included in Cash Equivalents" } } }, "localname": "AvailableForSaleSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r155", "r163" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r241" ], "lang": { "en-US": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]", "terseLabel": "Time deposits" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r1", "r83", "r104" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r23", "r70" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r11", "r71", "r76" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r65", "r70", "r75" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period", "periodStartLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period", "totalLabel": "Cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]", "terseLabel": "Cash, cash equivalents and restricted cash:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r65", "r188" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]", "terseLabel": "Cash" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r29", "r126", "r237", "r251" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 9)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r125", "r133" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Cash dividends paid, per share (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityCashDividendActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends declared (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Common stock, ending balance (in shares)", "periodStartLabel": "Common stock, beginning balance (in shares)", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r17" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at September 30, 2019 and December 31, 2018" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r51", "r53", "r54" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss), net of tax:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r102", "r103", "r186", "r187" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r102", "r103", "r186", "r187", "r259" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r102", "r103", "r186", "r187", "r259" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r100", "r245" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r102", "r103", "r186", "r187" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r102", "r103", "r186", "r187" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r76", "r176", "r180", "r181" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Contract with Customer, Liability [Abstract]", "terseLabel": "Deferred revenue:" } } }, "localname": "ContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r141", "r142", "r145" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue", "verboseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r146" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Decrease in deferred revenue, revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r150", "r153", "r258" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r59" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for deferred compensation arrangements payable after one year (or the normal operating cycle, if longer). Represents currently earned compensation under cash arrangements (such as a profit-sharing plan, rabbi trust, and employee contract--excluding equity-based arrangements) that is not actually paid until a later date.", "label": "Deferred Compensation Cash-based Arrangements, Liability, Classified, Noncurrent", "verboseLabel": "Long-term incentive" } } }, "localname": "DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r166" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax asset" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r164", "r166" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r68", "r123" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation and amortization" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/RevenueNetSalesByProductAndServiceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/RevenueNetSalesByProductAndServiceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r137", "r244" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "negatedLabel": "Dividends declared" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsCash": { "auth_ref": [ "r137", "r244" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.", "label": "Dividends, Cash", "terseLabel": "Cash dividend paid" } } }, "localname": "DividendsCash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityCashDividendActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsDeclaredTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.", "label": "Dividends Declared [Table Text Block]", "terseLabel": "Schedule of Company's Cash Dividend Activity" } } }, "localname": "DividendsDeclaredTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income (loss) per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r57", "r85", "r90", "r92", "r93", "r94", "r98", "r240", "r253" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Net income (loss) available to common stockholders, Per Share Amount (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic net income (loss) per common share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "terseLabel": "Weighted-average number of common shares outstanding:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r57", "r85", "r90", "r92", "r93", "r94", "r98", "r240", "r253" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Net income (loss) available to common stockholders plus assumed conversions, Per Share Amount (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted net income per common share:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r76", "r95", "r96", "r97" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r99" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET INCOME (LOSS) PER COMMON SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r188" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rates on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r150", "r151", "r153", "r182", "r218" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r150", "r151", "r153", "r182", "r219" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r150", "r151", "r153", "r182", "r220" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r76", "r184", "r185" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign Tax Authority" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r101" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Concentration Risk" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r121", "r122" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r58" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r55", "r85", "r233", "r238", "r254" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r170" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r78", "r105", "r169" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r67" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r67" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r67" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued commissions" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r67" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r67" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase (Decrease) in Deferred Compensation", "terseLabel": "Long-term incentive" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r67" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r67" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accrued Liabilities", "terseLabel": "Other accrued expenses" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r67" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r67" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase (Decrease) in Other Current Liabilities", "terseLabel": "Other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r67" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r91", "r96" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Non-vested restricted stock, Shares (Denominator) (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r32" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r34", "r119" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventories:" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r33" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Inventory, Raw Materials and Supplies, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r34", "r82", "r119", "r120" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "negatedTerseLabel": "Reserve for obsolescence" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r260", "r261", "r262", "r263" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r260", "r261", "r262", "r263" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r204", "r206" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/LeasesComponentsOfLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesComponentsOfLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r204" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Components of Lease Cost, Weighted-average Remaining Lease Term and Discount Rate" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r205" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Annual Scheduled Operating Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r205" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/LeasesAnnualScheduledLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.naturalhealthtrendscorp.com/role/LeasesAnnualScheduledLeasePaymentsDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesAnnualScheduledLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r205" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/LeasesAnnualScheduledLeasePaymentsDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesAnnualScheduledLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r205" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/LeasesAnnualScheduledLeasePaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesAnnualScheduledLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r205" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/LeasesAnnualScheduledLeasePaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesAnnualScheduledLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r205" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/LeasesAnnualScheduledLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesAnnualScheduledLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r205" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/LeasesAnnualScheduledLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesAnnualScheduledLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r205" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/LeasesAnnualScheduledLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "Remainder of 2019" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesAnnualScheduledLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r205" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/LeasesAnnualScheduledLeasePaymentsDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesAnnualScheduledLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r26" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r22", "r236", "r249" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r134", "r135" ], "lang": { "en-US": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r134", "r135" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r134", "r135" ], "lang": { "en-US": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyNumberOfDefendants": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of defendants named in a legal action.", "label": "Loss Contingency, Number of Defendants", "terseLabel": "Number of defendants" } } }, "localname": "LossContingencyNumberOfDefendants", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Ownership percentage by unrelated third party" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Ownership percentage by parent" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MunicipalBondsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds [Member]", "terseLabel": "Municipal debt securities" } } }, "localname": "MunicipalBondsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r65" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r65" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r65", "r66", "r69" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r49", "r52", "r56", "r69", "r96", "r239", "r252" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossUnaudited", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r85", "r88" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net income (loss) available to common stockholders, Income (loss) (Numerator)" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r88", "r89" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net income (loss) available to common stockholders plus assumed conversions, Income (loss) (Numerator)" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r84", "r86" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Schedule of Company's Restricted Stock Activity" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r198", "r206" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/LeasesComponentsOfLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesComponentsOfLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r195" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/LeasesAnnualScheduledLeasePaymentsDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesAnnualScheduledLeasePaymentsDetails", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r195" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r195" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r196", "r200" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid for amounts included in the measurement of operating leases liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r194" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets", "verboseLabel": "ROU assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r203", "r206" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r202", "r206" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRateDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r167" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r8", "r9", "r10", "r27" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "totalLabel": "Other accrued expenses", "verboseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r24" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r40", "r45", "r189", "r190", "r191", "r192" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossUnaudited", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r50", "r53", "r174", "r175", "r177" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "verboseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r41", "r45" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax", "terseLabel": "Unrealized gains on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossUnaudited", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r27" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "verboseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r62" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r64" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchase of common stock", "terseLabel": "Aggregate price of common stock repurchased" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited", "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r64" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r63" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r155", "r163" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Preferred stock, ending balance (in shares)", "periodStartLabel": "Preferred stock, beginning balance (in shares)", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r16" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.", "label": "Reclassification, Policy [Policy Text Block]", "terseLabel": "Reclassification" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r147" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product sales" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueNetSalesByProductAndServiceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r124", "r250" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r208", "r211", "r212" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Amount of transaction with related party" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r152", "r209", "r211" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.", "label": "Related Party Transaction, Other Revenues from Transactions with Related Party", "terseLabel": "Market-based fees paid" } } }, "localname": "RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r152", "r209", "r211", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r6", "r14", "r75", "r265" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r95" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r19", "r137", "r248" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r143", "r144" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales", "verboseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "http://www.naturalhealthtrendscorp.com/role/RevenueNetSalesByProductAndServiceDetails", "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r77", "r149" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "verboseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "REVENUE" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r108" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Schedule of Revenue by Market" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue Recognition [Abstract]" } } }, "localname": "RevenueRecognitionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r201", "r206" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesCommissionsAndFees": { "auth_ref": [ "r61" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).", "label": "Sales Commissions and Fees", "terseLabel": "Commissions expense" } } }, "localname": "SalesCommissionsAndFees", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r102" ], "lang": { "en-US": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Sales Revenue, Net" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r47" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Changes in Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r95" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r112", "r113", "r114", "r115", "r116", "r117", "r242", "r243" ], "lang": { "en-US": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r96" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Computation of Basic and Diluted Net Income (Loss) Per Common Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r107" ], "lang": { "en-US": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]", "terseLabel": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r107" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Schedule of Net Sales by Product and Service" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r79", "r209", "r211", "r212", "r213", "r214" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r155", "r163" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r61", "r118" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r161" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Number of shares granted (in shares)", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r161" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r160" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested at September 30, 2019 (in shares)", "periodStartLabel": "Nonvested at December 31, 2018 (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r160" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested at September 30, 2019 (in dollars per share)", "periodStartLabel": "Nonvested at December 31, 2018 (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Wtd. Avg. Price at Date of Issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized under the plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for issuance under the plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r154", "r158" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShippingAndHandlingMember": { "auth_ref": [ "r147" ], "lang": { "en-US": { "role": { "documentation": "Packing and transport of product.", "label": "Shipping and Handling [Member]", "terseLabel": "Freight and other" } } }, "localname": "ShippingAndHandlingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueNetSalesByProductAndServiceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r199", "r206" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/LeasesComponentsOfLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term leases" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/LeasesComponentsOfLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r31", "r136" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r72", "r73", "r74" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Issuance of treasury stock for employee awards, net" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture", "terseLabel": "Common stock issued (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r16", "r17", "r136", "r137" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Total settling fiscal performance incentive" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture", "terseLabel": "Common stock issued" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock repurchase program, amount authorized" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Stock repurchase program, amount available for future purchases" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r20", "r21", "r111" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r172", "r173", "r179" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Stockholders' equity, ending balance", "periodStartLabel": "Stockholders' equity, beginning balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r140" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r216" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r216" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r216" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r217" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENT" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEvent" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r38" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "BALANCE SHEET COMPONENTS" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_TaxCreditCarryforwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Tax Credit Carryforward [Line Items]", "terseLabel": "Tax Credit Carryforward [Line Items]" } } }, "localname": "TaxCreditCarryforwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardTable": { "auth_ref": [ "r168" ], "lang": { "en-US": { "role": { "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.", "label": "Tax Credit Carryforward [Table]", "terseLabel": "Tax Credit Carryforward [Table]" } } }, "localname": "TaxCreditCarryforwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r30", "r138" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r30", "r138" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "negatedPeriodEndLabel": "Treasury stock, ending balance (in shares)", "negatedPeriodStartLabel": "Treasury stock, beginning balance (in shares)", "terseLabel": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r17", "r136", "r137" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "negatedTerseLabel": "Repurchase of common stock (in shares)", "terseLabel": "Repurchase of common stock (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r30", "r138", "r139" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost; 1,459,090 and 1,603,322 shares at September 30, 2019 and December 31, 2018, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r136", "r137", "r138" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Repurchase of common stock", "terseLabel": "Total purchase price of common stock repurchased" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]", "terseLabel": "Effect of dilutive securities:" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r89", "r94" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Net income (loss) available to common stockholders plus assumed conversions, Shares (Denominator) (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r87", "r94" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Net income (loss) available to common stockholders, Shares (Denominator) (in shares)", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r149": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=d3e5283-111683" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32157-110900" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r207": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6477933&loc=d3e60009-112784" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(2)(i))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C(1)(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r268": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r269": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r271": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r272": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r273": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4),(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r38": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r83": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r99": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" } }, "version": "2.1" } XML 52 R27.htm IDEA: XBRL DOCUMENT v3.19.3
NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION (Details) - USD ($)
$ in Thousands
Sep. 30, 2019
Jan. 01, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Present value of lease liabilities $ 3,592  
ROU assets $ 3,515  
ASU 2016-02    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Present value of lease liabilities   $ 4,500
ROU assets   $ 4,500
XML 53 R23.htm IDEA: XBRL DOCUMENT v3.19.3
BALANCE SHEET COMPONENTS (Tables)
9 Months Ended
Sep. 30, 2019
Balance Sheet Components [Abstract]  
Schedule of Additional Balance Sheet Components

The components of certain balance sheet amounts are as follows (in thousands):
 
September 30, 2019
 
December 31, 2018
Cash, cash equivalents and restricted cash:
 
 
 
Cash
$
17,711

 
$
47,323

Cash equivalents
83,402

 
85,330

 
101,113

 
132,653

Restricted cash
2,881

 
2,998

 
$
103,994

 
$
135,651

Inventories:
 
 
 
Finished goods
$
7,817

 
$
11,171

Raw materials
1,104

 
1,145

Reserve for obsolescence
(922
)
 
(151
)
 
$
7,999

 
$
12,165

Other accrued expenses:
 
 
 
Sales returns
$
290

 
$
801

Employee-related expense
1,998

 
4,051

Warehousing, inventory-related and other
1,104

 
1,269

 
$
3,392

 
$
6,121

Deferred revenue:
 
 
 
Unshipped product
$
1,171

 
$
4,574

Auto ship advances
1,983

 
1,876

Other
148

 
345

 
$
3,302

 
$
6,795


XML 54 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 55 R42.htm IDEA: XBRL DOCUMENT v3.19.3
INCOME TAXES (Details)
$ in Millions
Dec. 31, 2018
USD ($)
Foreign Tax Authority  
Tax Credit Carryforward [Line Items]  
Net operating loss carryforwards $ 1.2
XML 56 R15.htm IDEA: XBRL DOCUMENT v3.19.3
LEASES
9 Months Ended
Sep. 30, 2019
Leases [Abstract]  
LEASES LEASES

The Company leases 9,600 square feet of office space in Hong Kong with a term expiring in February 2021. The Company leases 4,900 square feet of office space in Rolling Hills Estates, California with a term expiring in September 2025. To help further develop the market for its products in North America, the Company leases 2,400, 1,600 and 2,000 square feet of retail space in Monterey Park, California, Richmond, British Columbia, and Metuchen, New Jersey, respectively. The Monterey
Park, Richmond and Metuchen locations have terms expiring in August 2020, February 2021, and November 2022, respectively.

The Company leases nine branch offices throughout China, and additional office space in Peru, Japan, Taiwan, South Korea, Singapore, Malaysia, Vietnam, Indonesia, Thailand, India, and the Cayman Islands. The Company also leases a multi-purpose facility and factory in Zhongshan, China and 11 service stations throughout the city of Guangzhou, China that serve or will in the future serve the needs of its Chinese consumers. The Company contracts with third parties for fulfillment and distribution operations in all of its international markets. None of the Company’s third party logistics contracts contain a lease as the Company does not have the right to access the warehouses or move its inventories at will.

The components of lease cost for the three months and nine months ended September 30, 2019 were as follows (in thousands):
 
Three Months Ended September 30, 2019
 
Nine Months Ended September 30, 2019
Operating leases
$
512

 
$
1,544

Short-term leases
73

 
201

Total lease cost
$
585

 
$
1,745



Cash paid for amounts included in the measurement of operating leases liabilities was $459,000 and $1.5 million for the three months and nine months ended September 30, 2019, respectively.

The weighted-average remaining lease term and discount rate related to operating leases as of September 30, 2019 were as follows:
Weighted-average remaining lease term (in years)
3.2

Weighted-average discount rate
5.5
%


As most of our leases do not provide an implicit rate, the Company used its incremental borrowing rate, or the rate of each of its subsidiaries if available, based on the information available at the lease commencement date to determine the present value of lease payments.

The annual scheduled lease payments of our operating lease liabilities as of September 30, 2019 were as follows (in thousands):
Remainder of 2019
$
473

2020
1,717

2021
730

2022
427

2023
245

Thereafter
400

Total lease payments
$
3,992

Less: imputed interest
(400
)
Present value of lease liabilities
$
3,592



For all asset classes, the Company elected not to recognize assets or liabilities at the acquisition date for leases that, at the acquisition date, have a remaining lease term of 12 months or less. Additionally, for all asset classes, the Company choose not to separate nonlease components from lease components and instead account for the combined lease and nonlease components associated with that lease component as a single lease component.
XML 57 R11.htm IDEA: XBRL DOCUMENT v3.19.3
NET INCOME (LOSS) PER COMMON SHARE
9 Months Ended
Sep. 30, 2019
Earnings Per Share [Abstract]  
NET INCOME (LOSS) PER COMMON SHARE NET INCOME (LOSS) PER COMMON SHARE

Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized, if any, is assumed to be used to repurchase shares.

The following tables illustrate the computation of basic and diluted net income (loss) per common share for the periods indicated (in thousands, except per share data): 
 
Three Months Ended September 30,
 
2019
 
2018
 
Income (loss)
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
 
Income (loss)
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
Basic net income (loss) per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income (loss) available to common stockholders
$
(1,243
)
 
10,623

 
$
(0.12
)
 
$
7,629

 
11,309

 
$
0.67

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Non-vested restricted stock

 

 
 

 

 
13

 
 

Diluted net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
(1,243
)
 
10,623

 
$
(0.12
)
 
$
7,629

 
11,322

 
$
0.67

 
 
 
 
 
 
 
 
 
 
 
 
 
Nine Months Ended September 30,
 
2019
 
2018
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
Basic net income (loss) per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income (loss) available to common stockholders
$
(2,769
)
 
11,010

 
$
(0.25
)
 
$
25,476

 
11,298

 
$
2.25

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Non-vested restricted stock

 

 
 

 

 
9

 
 

Diluted net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income (loss) available to common stockholders plus assumed conversions
$
(2,769
)
 
11,010

 
$
(0.25
)
 
$
25,476

 
11,307

 
$
2.25



In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. As such, non-vested restricted stock totaling 672,231 and 263,289 shares were not included for the three and nine months ended September 30, 2019, respectively.
XML 58 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 251 286 1 false 60 0 false 10 false false R1.htm 0001000 - Document - Cover page Sheet http://www.naturalhealthtrendscorp.com/role/CoverPage Cover page Cover 1 false false R2.htm 1002000 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1002501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1003000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 1004000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossUnaudited CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) Statements 5 false false R6.htm 1004000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) Statements 6 false false R7.htm 1004501 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) (Parenthetical) Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) (Parenthetical) Statements 7 false false R8.htm 1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 8 false false R9.htm 2101100 - Disclosure - NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION Sheet http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidation NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION Notes 9 false false R10.htm 2102100 - Disclosure - REVENUE Sheet http://www.naturalhealthtrendscorp.com/role/Revenue REVENUE Notes 10 false false R11.htm 2103100 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE Sheet http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShare NET INCOME (LOSS) PER COMMON SHARE Notes 11 false false R12.htm 2104100 - Disclosure - BALANCE SHEET COMPONENTS Sheet http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponents BALANCE SHEET COMPONENTS Notes 12 false false R13.htm 2105100 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.naturalhealthtrendscorp.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS Notes 13 false false R14.htm 2106100 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 14 false false R15.htm 2107100 - Disclosure - LEASES Sheet http://www.naturalhealthtrendscorp.com/role/Leases LEASES Notes 15 false false R16.htm 2108100 - Disclosure - INCOME TAXES Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxes INCOME TAXES Notes 16 false false R17.htm 2109100 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 17 false false R18.htm 2110100 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 18 false false R19.htm 2111100 - Disclosure - SUBSEQUENT EVENT Sheet http://www.naturalhealthtrendscorp.com/role/SubsequentEvent SUBSEQUENT EVENT Notes 19 false false R20.htm 2201201 - Disclosure - NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION (Policies) Sheet http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationPolicies NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION (Policies) Policies 20 false false R21.htm 2302301 - Disclosure - REVENUE (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/RevenueTables REVENUE (Tables) Tables http://www.naturalhealthtrendscorp.com/role/Revenue 21 false false R22.htm 2303301 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareTables NET INCOME (LOSS) PER COMMON SHARE (Tables) Tables http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShare 22 false false R23.htm 2304301 - Disclosure - BALANCE SHEET COMPONENTS (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsTables BALANCE SHEET COMPONENTS (Tables) Tables http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponents 23 false false R24.htm 2305301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.naturalhealthtrendscorp.com/role/FairValueMeasurements 24 false false R25.htm 2306301 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.naturalhealthtrendscorp.com/role/StockholdersEquity 25 false false R26.htm 2307301 - Disclosure - LEASES (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/LeasesTables LEASES (Tables) Tables http://www.naturalhealthtrendscorp.com/role/Leases 26 false false R27.htm 2401402 - Disclosure - NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION (Details) Sheet http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationDetails NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION (Details) Details http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationPolicies 27 false false R28.htm 2402402 - Disclosure - REVENUE - Narrative (Details) Sheet http://www.naturalhealthtrendscorp.com/role/RevenueNarrativeDetails REVENUE - Narrative (Details) Details 28 false false R29.htm 2402403 - Disclosure - REVENUE - Revenue by Market (Details) Sheet http://www.naturalhealthtrendscorp.com/role/RevenueRevenueByMarketDetails REVENUE - Revenue by Market (Details) Details 29 false false R30.htm 2402404 - Disclosure - REVENUE - Net Sales by Product and Service (Details) Sheet http://www.naturalhealthtrendscorp.com/role/RevenueNetSalesByProductAndServiceDetails REVENUE - Net Sales by Product and Service (Details) Details 30 false false R31.htm 2403402 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE (Details) Sheet http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareDetails NET INCOME (LOSS) PER COMMON SHARE (Details) Details http://www.naturalhealthtrendscorp.com/role/NetIncomeLossPerCommonShareTables 31 false false R32.htm 2404402 - Disclosure - BALANCE SHEET COMPONENTS (Details) Sheet http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails BALANCE SHEET COMPONENTS (Details) Details http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsTables 32 false false R33.htm 2405402 - Disclosure - FAIR VALUE MEASUREMENTS - Available-for-Sale Investments Included in Cash Equivalents (Details) Sheet http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails FAIR VALUE MEASUREMENTS - Available-for-Sale Investments Included in Cash Equivalents (Details) Details 33 false false R34.htm 2406402 - Disclosure - STOCKHOLDERS' EQUITY - Cash Dividend Activity (Details) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityCashDividendActivityDetails STOCKHOLDERS' EQUITY - Cash Dividend Activity (Details) Details 34 false false R35.htm 2406403 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails STOCKHOLDERS' EQUITY - Narrative (Details) Details 35 false false R36.htm 2406404 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details) Details 36 false false R37.htm 2406405 - Disclosure - STOCKHOLDERS' EQUITY - Changes in Accumulated Other Comprehensive Loss (Details) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails STOCKHOLDERS' EQUITY - Changes in Accumulated Other Comprehensive Loss (Details) Details 37 false false R38.htm 2407402 - Disclosure - LEASES - Narrative (Details) Sheet http://www.naturalhealthtrendscorp.com/role/LeasesNarrativeDetails LEASES - Narrative (Details) Details 38 false false R39.htm 2407403 - Disclosure - LEASES - Components of Lease Cost (Details) Sheet http://www.naturalhealthtrendscorp.com/role/LeasesComponentsOfLeaseCostDetails LEASES - Components of Lease Cost (Details) Details 39 false false R40.htm 2407404 - Disclosure - LEASES - Weighted-average Remaining Lease Term and Discount Rate (Details) Sheet http://www.naturalhealthtrendscorp.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRateDetails LEASES - Weighted-average Remaining Lease Term and Discount Rate (Details) Details 40 false false R41.htm 2407405 - Disclosure - LEASES - Annual Scheduled Lease Payments (Details) Sheet http://www.naturalhealthtrendscorp.com/role/LeasesAnnualScheduledLeasePaymentsDetails LEASES - Annual Scheduled Lease Payments (Details) Details 41 false false R42.htm 2408401 - Disclosure - INCOME TAXES (Details) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDetails INCOME TAXES (Details) Details http://www.naturalhealthtrendscorp.com/role/IncomeTaxes 42 false false R43.htm 2409401 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies 43 false false R44.htm 2410401 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails RELATED PARTY TRANSACTIONS (Details) Details http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions 44 false false R45.htm 2411401 - Disclosure - SUBSEQUENT EVENT (Details) Sheet http://www.naturalhealthtrendscorp.com/role/SubsequentEventDetails SUBSEQUENT EVENT (Details) Details http://www.naturalhealthtrendscorp.com/role/SubsequentEvent 45 false false All Reports Book All Reports nhtc20190930_10q.htm ex31-1.htm ex31-2.htm ex32-1.htm nhtc-20190930.xsd nhtc-20190930_cal.xml nhtc-20190930_def.xml nhtc-20190930_lab.xml nhtc-20190930_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true XML 59 R19.htm IDEA: XBRL DOCUMENT v3.19.3
SUBSEQUENT EVENT
9 Months Ended
Sep. 30, 2019
Subsequent Events [Abstract]  
SUBSEQUENT EVENT SUBSEQUENT EVENT

On October 29, 2019, the Board of Directors declared a special cash dividend of $0.40 on each share of common stock outstanding. Such dividends are payable on November 29, 2019 to stockholders of record on November 19, 2019. Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.

XML 60 R32.htm IDEA: XBRL DOCUMENT v3.19.3
BALANCE SHEET COMPONENTS (Details) - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
Cash, cash equivalents and restricted cash:        
Cash and cash equivalents $ 101,113 $ 132,653    
Restricted cash 2,881 2,998    
Cash, cash equivalents and restricted cash 103,994 135,651 $ 135,209 $ 138,478
Inventories:        
Finished goods 7,817 11,171    
Raw materials 1,104 1,145    
Reserve for obsolescence (922) (151)    
Inventories, net 7,999 12,165    
Other accrued expenses:        
Sales returns 290 801    
Employee-related expense 1,998 4,051    
Warehousing, inventory-related and other 1,104 1,269    
Other accrued expenses 3,392 6,121    
Deferred revenue:        
Deferred revenue 3,302 6,795    
Unshipped product        
Deferred revenue:        
Deferred revenue 1,171 4,574    
Auto ship advances        
Deferred revenue:        
Deferred revenue 1,983 1,876    
Other        
Deferred revenue:        
Deferred revenue 148 345    
Cash        
Cash, cash equivalents and restricted cash:        
Cash and cash equivalents 17,711 47,323    
Cash equivalents        
Cash, cash equivalents and restricted cash:        
Cash and cash equivalents $ 83,402 $ 85,330    
XML 61 R36.htm IDEA: XBRL DOCUMENT v3.19.3
STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details) - Restricted Stock - 2016 Plan - $ / shares
9 Months Ended
Aug. 09, 2019
Feb. 01, 2019
Sep. 30, 2019
Shares      
Nonvested at December 31, 2018 (in shares)     45,486
Granted (in shares) 1,117,485 22,603 1,140,088
Vested (in shares)     (125,405)
Nonvested at September 30, 2019 (in shares)     1,060,169
Wtd. Avg. Price at Date of Issuance      
Nonvested at December 31, 2018 (in dollars per share)     $ 21.61
Granted (in dollars per share)     7.27
Vested (in dollars per share)     11.07
Nonvested at September 30, 2019 (in dollars per share)     $ 7.44
XML 62 R2.htm IDEA: XBRL DOCUMENT v3.19.3
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 101,113 $ 132,653
Inventories 7,999 12,165
Other current assets 6,997 5,369
Total current assets 116,109 150,187
Property and equipment, net 821 934
Operating lease right-of-use assets 3,515  
Goodwill 1,764 1,764
Restricted cash 2,881 2,998
Deferred tax asset 1,210 1,207
Other assets 807 831
Total assets 127,107 157,921
Current liabilities:    
Accounts payable 627 1,631
Accrued commissions 3,798 12,502
Other accrued expenses 3,392 6,121
Deferred revenue 3,302 6,795
Amounts held in eWallets 13,090 14,611
Operating lease liabilities 1,689  
Other current liabilities 1,188 1,424
Total current liabilities 27,086 43,084
Income taxes payable 15,365 16,982
Deferred tax liability 186 186
Long-term incentive 0 7,808
Operating lease liabilities 1,903  
Total liabilities 44,540 68,060
Commitments and contingencies (Note 9)
Stockholders’ equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding 0 0
Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at September 30, 2019 and December 31, 2018 13 13
Additional paid-in capital 86,102 86,415
Retained earnings 23,567 44,431
Accumulated other comprehensive loss (1,764) (1,250)
Treasury stock, at cost; 1,459,090 and 1,603,322 shares at September 30, 2019 and December 31, 2018, respectively (25,351) (39,748)
Total stockholders’ equity 82,567 89,861
Total liabilities and stockholders’ equity $ 127,107 $ 157,921
XML 63 R6.htm IDEA: XBRL DOCUMENT v3.19.3
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)
$ in Thousands
Total
Preferred Stock
Common Stock
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive (Loss) Income
Treasury Stock
Preferred stock, beginning balance (in shares) at Dec. 31, 2017   0          
Common stock, beginning balance (in shares) at Dec. 31, 2017     12,979,414        
Treasury stock, beginning balance (in shares) at Dec. 31, 2017             (1,637,524)
Stockholders' equity, beginning balance at Dec. 31, 2017 $ 90,621 $ 0 $ 13 $ 86,683 $ 44,908 $ (413) $ (40,570)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) 8,824       8,824    
Common stock issued 554     (268)     $ 822
Common stock issued (in shares)             34,202
Dividends declared (1,479)       (1,479)    
Foreign currency translation adjustment 397         397  
Unrealized gains on available-for-sale securities (11)         (11)  
Preferred stock, ending balance (in shares) at Mar. 31, 2018   0          
Common stock, ending balance (in shares) at Mar. 31, 2018     12,979,414        
Treasury stock, ending balance (in shares) at Mar. 31, 2018             (1,603,322)
Stockholders' equity, ending balance at Mar. 31, 2018 98,906 $ 0 $ 13 86,415 52,253 (27) $ (39,748)
Preferred stock, beginning balance (in shares) at Dec. 31, 2017   0          
Common stock, beginning balance (in shares) at Dec. 31, 2017     12,979,414        
Treasury stock, beginning balance (in shares) at Dec. 31, 2017             (1,637,524)
Stockholders' equity, beginning balance at Dec. 31, 2017 90,621 $ 0 $ 13 86,683 44,908 (413) $ (40,570)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) 25,476            
Foreign currency translation adjustment (798)            
Unrealized gains on available-for-sale securities 9            
Preferred stock, ending balance (in shares) at Sep. 30, 2018   0          
Common stock, ending balance (in shares) at Sep. 30, 2018     12,979,414        
Treasury stock, ending balance (in shares) at Sep. 30, 2018             (1,603,322)
Stockholders' equity, ending balance at Sep. 30, 2018 88,218 $ 0 $ 13 86,415 42,740 (1,202) $ (39,748)
Preferred stock, beginning balance (in shares) at Mar. 31, 2018   0          
Common stock, beginning balance (in shares) at Mar. 31, 2018     12,979,414        
Treasury stock, beginning balance (in shares) at Mar. 31, 2018             (1,603,322)
Stockholders' equity, beginning balance at Mar. 31, 2018 98,906 $ 0 $ 13 86,415 52,253 (27) $ (39,748)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) 9,023       9,023    
Dividends declared (21,614)       (21,614)    
Foreign currency translation adjustment (762)         (762)  
Unrealized gains on available-for-sale securities 15         15  
Preferred stock, ending balance (in shares) at Jun. 30, 2018   0          
Common stock, ending balance (in shares) at Jun. 30, 2018     12,979,414        
Treasury stock, ending balance (in shares) at Jun. 30, 2018             (1,603,322)
Stockholders' equity, ending balance at Jun. 30, 2018 85,568 $ 0 $ 13 86,415 39,662 (774) $ (39,748)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) 7,629       7,629    
Dividends declared (4,551)       (4,551)    
Foreign currency translation adjustment (433)         (433)  
Unrealized gains on available-for-sale securities 5         5  
Preferred stock, ending balance (in shares) at Sep. 30, 2018   0          
Common stock, ending balance (in shares) at Sep. 30, 2018     12,979,414        
Treasury stock, ending balance (in shares) at Sep. 30, 2018             (1,603,322)
Stockholders' equity, ending balance at Sep. 30, 2018 $ 88,218 $ 0 $ 13 86,415 42,740 (1,202) $ (39,748)
Preferred stock, beginning balance (in shares) at Dec. 31, 2018 0 0          
Common stock, beginning balance (in shares) at Dec. 31, 2018 12,979,414   12,979,414        
Treasury stock, beginning balance (in shares) at Dec. 31, 2018 (1,603,322)           (1,603,322)
Stockholders' equity, beginning balance at Dec. 31, 2018 $ 89,861 $ 0 $ 13 86,415 44,431 (1,250) $ (39,748)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) (1,923)       (1,923)    
Common stock issued 377     (166)     $ 543
Common stock issued (in shares)             22,603
Dividends declared (2,736)       (2,736)    
Foreign currency translation adjustment 259         259  
Unrealized gains on available-for-sale securities 17         17  
Preferred stock, ending balance (in shares) at Mar. 31, 2019   0          
Common stock, ending balance (in shares) at Mar. 31, 2019     12,979,414        
Treasury stock, ending balance (in shares) at Mar. 31, 2019             (1,580,719)
Stockholders' equity, ending balance at Mar. 31, 2019 $ 85,855 $ 0 $ 13 86,249 39,772 (974) $ (39,205)
Preferred stock, beginning balance (in shares) at Dec. 31, 2018 0 0          
Common stock, beginning balance (in shares) at Dec. 31, 2018 12,979,414   12,979,414        
Treasury stock, beginning balance (in shares) at Dec. 31, 2018 (1,603,322)           (1,603,322)
Stockholders' equity, beginning balance at Dec. 31, 2018 $ 89,861 $ 0 $ 13 86,415 44,431 (1,250) $ (39,748)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) (2,769)            
Foreign currency translation adjustment (537)            
Unrealized gains on available-for-sale securities $ 23            
Preferred stock, ending balance (in shares) at Sep. 30, 2019 0 0          
Common stock, ending balance (in shares) at Sep. 30, 2019 12,979,414   12,979,414        
Treasury stock, ending balance (in shares) at Sep. 30, 2019 (1,459,090)           (1,459,090)
Stockholders' equity, ending balance at Sep. 30, 2019 $ 82,567 $ 0 $ 13 86,102 23,567 (1,764) $ (25,351)
Preferred stock, beginning balance (in shares) at Mar. 31, 2019   0          
Common stock, beginning balance (in shares) at Mar. 31, 2019     12,979,414        
Treasury stock, beginning balance (in shares) at Mar. 31, 2019             (1,580,719)
Stockholders' equity, beginning balance at Mar. 31, 2019 85,855 $ 0 $ 13 86,249 39,772 (974) $ (39,205)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) 397       397    
Repurchase of common stock (in shares)             (612,729)
Repurchase of common stock (6,682)           $ (6,682)
Foreign currency translation adjustment (212)         (212)  
Unrealized gains on available-for-sale securities (6)         (6)  
Preferred stock, ending balance (in shares) at Jun. 30, 2019   0          
Common stock, ending balance (in shares) at Jun. 30, 2019     12,979,414        
Treasury stock, ending balance (in shares) at Jun. 30, 2019             (2,193,448)
Stockholders' equity, ending balance at Jun. 30, 2019 79,352 $ 0 $ 13 86,249 40,169 (1,192) $ (45,887)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) (1,243)       (1,243)    
Common stock issued 7,912     (147) (15,359)   $ 23,418
Common stock issued (in shares)             1,117,485
Repurchase of common stock (in shares)             (383,127)
Repurchase of common stock (2,882)           $ (2,882)
Foreign currency translation adjustment (584)         (584)  
Unrealized gains on available-for-sale securities $ 12         12  
Preferred stock, ending balance (in shares) at Sep. 30, 2019 0 0          
Common stock, ending balance (in shares) at Sep. 30, 2019 12,979,414   12,979,414        
Treasury stock, ending balance (in shares) at Sep. 30, 2019 (1,459,090)           (1,459,090)
Stockholders' equity, ending balance at Sep. 30, 2019 $ 82,567 $ 0 $ 13 $ 86,102 $ 23,567 $ (1,764) $ (25,351)